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Atopic Dermatitis Severity - Risk Factors and Impact on Quality of Life 
Atopic dermatitis (AD) is a chronic relapsing inflammation of the skin, which 
occurs in genetically predisposed individuals, with unknown aetioiogy and no 
cure. The prevalence has increased over the last three decades and shown 
to be higher in an urban area. But there is little known about factors that may 
affect disease severity. Comparing rural and urban populations may help in 
identifying those factors that may have an effect on disease severity. There is 
also scarce information about the impact of AD on children and family's 
quality of life (QOL), especially from a community-based study. The absence 
of any standard severity and QOL assessment system has hampered 
performing such studies. It is only in the last 10 years that dermatologists 
have tried to measure eczema severity and its impact in a systematic way. 
The association between increased disease severity and impaired QOL 
strengthens claims for more research into this disease. 
A longitudinal study design was implemented in evaluation of risk factors for 
atopic dermatitis severity and its impact on QOL, which was a comparison of 
two populations recruited through general practices in South London and mid 
Wales. In children aged 5 to 10 years. GPs were asked to create a list of 
patients under a code of eczema or dermatitis from their database. Repeat 
prescriptions for emollients and/or topical steroids were also used by some of 
the GPs to create a list of potential patients. Parents were contacted by post 
and the diagnosis in their children was verified by the UK diagnostic criteria 
for AD. Parents filled in a locally constructed and piloted questionnaire to 
gather information about potential risk factors and confounders. AD severity 
was assessed using the SCORAD Index. The Dermatitis Family Impact (DFI) 
and Children Dermatology Life Quality Index (CDLQI) were used to measure 
family's QOL and children's QOL respectively on two occasions six months 
apart. 
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The aim was to determine those factors that might have an effect on the 
severity of AD, to document the impact of eczema on the family and 
children's QOL, and to investigate the relationships between OOL and 
disease severity. The ultimate goal was to improve the management and 
help in prevention of AD. 
One hundred and thirty-seven children (52.6% females) with atopic dermatitis 
were recruited from a community setting, 82 (60%) urban and 55 (40%) rural. 
These children were examined up to four times and 120 (88%) attended the 
final visit. The study has demonstrated that eczema was mild in most cases 
(80%) and requires GlPs care only. From this sample it has been shown that 
the following factors have been associated with increased risk of severe 
disease: living in an urban area, early onset of eczema, and child's asthma 
and or hay fever (atopy). It also showed that black children were at higher 
risk of severe AD than their white counterparts, a risk that can be masked by 
reliance on erythema scores. These findings may improve our understanding 
and may help in prevention of this disease. 
Childhood atopic dermatitis had affected the children's QOL in more than 
two-thirds of children and has affected the families' QOL in more than one- 
thirds of the children. QOL scores both by children and families were 
significantly correlated with disease severity at single points of time and 
longitudinally. This shows the importance of considering patients' and their 
families' perceptions of the disease in understanding impact. It also reflects 
the construct validity of the CDLOI and DFI and that therefore, they can be 
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1 CHAPTER 1 INTRODUCTION 
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1.1 Section 1: History, nomenclature, 
definitions, and prevalence 
1.1.1 History 
Atopic dermatitis (AD) is a chronic relapsing intensely pruritic disease, which 
occurs in genetically predisposed individuals. It usually starts at an early 
stage of life, but at times its onset may be delayed until adolescence. It is 
common in individuals with bronchial asthma, hay fever, or urticaria (Rajka., 
1989a). Pharaoh Menes of Memphis, who may have had anaphylaxis 
following an insect sting in 2900 BC, was probably the earliest allergic 
subject and may be the first documented case of atopic dermatitis (Avenberg 
and Harper., 1980). The Roman historian Suetonius (born about AD 69) 
precisely described the signs and symptoms of atopy in Emperor Augustus 
Caesar (63BC to 14A. D) who was suffering from intensely itchy lichenified 
skin, bronchial asthma and rhinitis (Mali., 1975). 
Nomenclature 
The name "atopic dermatitis" was first proposed by Wise and Sulzberger 
(1933) but before this, the medical literature had many synonyms for the 
disease. In 1884, Ferdinand von Hebra uses the term "prurigo" to describe an 
itchy papular eruption that began in early childhood, localised in flexures, and 
persisted throughout life (Hebra., 1884, cited in: Sehgal and Jain., 1993). 
Jean Louis Brocq (1856-1928) and Lucien Jacquet (1860-1914) named the 
disease "neurodermatitis" because of nervous system involvement in its 
dominating pruritic symptoms (Brocq and Jacquet 1891). In 1892 Ernest 
Besnier used the term "prurigo diathesiquell to describe an itchy 
papulovesicular eruption which changed in morphology after a few years to 
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thickened and lichenified lesions that was associated with bronchial asthma 
and hay fever, and was accepted as a distinct entity after this report 
(Besnier., 1892). Thereafter "Besnier's prurigo" was proposed as an 
acceptable name by Rasch in 1913 who confirmed Besnier's description of 
prurigo diathesique (Rasch., 1925). In the early 1930s this disease entity was 
named atopic dermatitis (Wise and Sulzberger., 1933). After that, Hill and 
Sulzberger classified atopic dermatitis into infantile, childhood, and 
adolescent/adult phases. They suggested that in order to maintain this 
dermatological manifestation as an entity, from other nonatopic eczemas, it is 
best named atopic dermatitis of the infant, of the child, and of the adult (Hill 
and Sulzberger., 1935). 
However, the nomenclature of atopic dermatitis varies from one speciality to 
another and from one country to another with the most used synonyms for 
atopic dermatitis being atopic eczema and infantile eczema. Despite the 
advance in naming the disease, the nomenclature of atopic dermatitis does 
not specifically reflect the dry, scaly and itchy features of the disease (Sehgal 
and Jain., 1993). Atopic dermatitis or atopic eczema is a name that is 
accepted world wide to describe the disease entity. Until a better 
understanding of the disease is achieved, atopic dermatitis or atopic eczema 
serves the purpose of indication of this entity and makes communication 
universal (Williams., 2000a). 
1.1.3 Atopy 
Atopy is a Greek word meaning without place or strange and was suggested 
by Professor Edward D Perry of Columbia University and applied by Coca 
and Cooke to describe this syndrome (Coca and Cooke., 1923). The first 
description of atopic hypersensitiveness was in 1923 by Coca and Cooke as 
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an individual propensity to develop what were subsequently found to be IgE- 
dependent reactions against environmental allergens (Coca and Cooke., 
1923). 
It is nearly 8 decades since the first description of atopy by Coca and Cooke. 
Atopy may be redefined taking into consideration modern immunological 
knowledge. The recent definition should include the respiratory syndrome of 
asthma and rhinitis, atopic skin manifestations which share genetic 
predisposition, hyperreactivity of the target organ to pharmacological agents 
(cholinergic hyperreactivity and beta-adrenergic hype rresponsiven ess) or 
irritants, and an immunological Th2-Cell response to allergens (exogeneous 
or endogeneous) with facultative specific IgE production, and eosinophil 
activation (Wutchirch., 1999). 
1.1.4 Atopic dermatitis definitions 
1.1.4.1 Hanifin and Rajka criteria for atopic dermatitis 
The last two decades have witnessed the development of a standard 
definition for this mysterious disease. Hanifin and Lobitz (1 977b) proposed a 
list of clinical features to form the diagnostic criteria for atopic dermatitis. In 
1980, Hanifin and Rajka have made revisions of the previous criteria that 
were based on practical experience, proposal and discussion by various 
individuals. They described the Hanifin and Rajka criteria for atopic 
dermatitis, which are based on a list of clinical signs and sYmptoms of AD. 
These comprise 4 major and 23 minor criteria named after them (see 
Appendix 6.5). A subject should have 3 major plus 3 or more minor criteria 
for the satisfactory diagnosis of atopic dermatitis (Hanifin and Rajka., 1980). 
The Hanifin and Rajka criteria have represented the corner stone for the 
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definition of individual cases of AD. Even though the criteria of Hanifin and 
Rajka are wideiy used in the diagnosis of atopic dermatitis, they may be less 
suitable for use in pop u iation -based studies in which their validity and 
agreement between and within observers are unknown (Williams., 2000a). 
Also, the long list of minor criteria would make it very difficult to use in 
epidemiological studies where the study requires collecting data from large 
numbers of subjects in a limited time. 
1.1.4.2 The UK Working Party's Diagnostic Criteria for Atopic 
Dermatitis 
The need for a valid definition for AD motivated a group of dermatologists 
from the UK to develop a set of criteria with known validity that could be used 
in epidemiological studies. After serial testing of the Hanifin and Rajka criteria 
(1980), the group proposed the UK working party's diagnostic criteria for 
atopic dermatitis (Williams, Burney, Hay, et al., 1994a; Williams, Burney, 
Strachan, et al., 1994b; Williams, Burney, Pembroke, et al., 1994c), see 
Table 1. Five out of the 6 UK diagnostic criteria for AD are questions and in 
order to qualify, as a case of AD the subject must have one major and three 
minor or more criteria. 
Tnhisy, I- Thp- UK diaanostic criteria for AD 
Must have one major 
"An itchy skin condition in the last 12 months" 
Plus three or more of the following minors 
1 History of involvement of the skin creases such as folds of elbows, behind 
the knees, fronts of ankles, or neck. 
2 A personal history of asthma or hay fever (or history of atopic disease in a 
first-degree relative, in those under 4 years). 
3 A history of a generally dry skin in the last year. 
4 Onset under the age of 2 (not used if child is under 4) 
isible flexural dermatitis (or dermatitis involving the cheeks or forehead and 
outer limbs in children under 4) 
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When tested on patients from the hospital the UK diagnostic criteria had 
87.9% sensitivity and 92.8% specificity. In a community study, the sensitivity 
decreased to 80%, but the specificity increased to 97%, when compared with 
dermatologist diagnosis. Positive and negative predictive values were 80% 
and 97% respectively (Williams, Burney, Pembroke, et aL, 1996). 
1.1.4.3 Other criteria 
In recent years other dermatologists have proposed different criteria to define 
AD. Schultz-Larsen et al in 1996 have developed and validated a self- 
administered questionnaire that ascertain AD in children by asking parents 
about the presence of physical and historical features (Schultz-Larsen, 
Diepgen, Svensson., 1996). Recently another set of criteria was developed 
based on atopic features of AD (IgE response to allergens) called the 
"millennium criteria" for diagnosis of AD, which has two components. The first 
component (the mandatory criterion) is the presence of allergen-specific IgE. 
The second component comprises a set of principle criteria, (2 of 3 must be 
present): pruritus, chronic or chronically relapsing course, and typical 
distribution and morphology of eczema lesions "infant, childhood, or adult 
type". However, if the distribution is not typical, it is important to exclude other 
entities (e. g. contact dermatitis, or contact urticaria). These authors proposed 
an additional criteria that should be used in case of doubt (Bos, Van Leent, 
Sillevis Smitt., 1998). The fact that 20-40% of individuals with typical clinical 
AD exhibit normal values of total or specific IgE (Dotterud, Kvammen, Lund, 
Falk., 1995), would probably make this definition redundant in a significant 
proportion of AD patients. Even so, it might be helpful if a better 
understanding of AD immunopathology were available. 
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Prevalence 
The prevalence of atopic disorders (atopic dermatitis, allergic rhinitis, allergic 
asthma) has shown a marked increase over the last four decades, and this 
finding so far has remained unexplained. Environmental factors and 
individual parameters such as life style factors are thought to have 
contributed most to this trend (Williams., 1992). Taylor et al reported an 
increase in the prevalence of atopic dermatitis from 5.1% in children borne in 
1946 to 7.3% in those born in 1958 to 12.2% in the 1970 cohort. This was 
based on parental recall when children were aged 5-7 years (Taylor, 
Wadsworth, Wadsworth, Peckham., 1984). Schultz-Larsen (1993) using a 
twin population in Denmark, also found that the cumulative incidence rate of 
twin individuals who develop atopic dermatitis between 0 and 7 years of age 
rose significantly from 3% in twins born between 1960-64 to 12% in twins 
born in 1975-79. Each case was identified by recall of eczema as a child 
according to the patients and/or parents, and the diagnosis was verified by a 
questionnaire (Schultz-Larsen, Holm, Henningsen., 1986; Shultz-Larsen., 
1993). 
In a follow-up analysis of the 1970 British National Cohort Study, 12.3% of 
five-year-olds were reported as having had eczema at some stage during 
their lives, and in 5% the condition was reported to have been present in the 
12 months prior to interview (Golding and Peters., 1987). In studying AD and 
birth factors, Olesen and colleagues documented a 18.7% cumulative 
incidence of AD at the age of 7 years (Olesen, Ellingsen, Olesen, et a/., 
1997). 
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From a community-based study it has been reported that the 1 -year 
prevalence of AD was 16.5% (95%CI: 14.7 to 18.2%) with 84% in a mild 
form, 14% moderate and 2% in a severe form. The authors also showed that 
only 6% of the cases were referred to secondary health care services. Of 
those referred, 82% were in a mild and moderate form (Emerson, Williams, 
Allen., 1998). These figures show that the vast majority were under GFS 
care. 
Based on clinical examination by an experienced dermatologist, Schafer et al 
(2000) showed that the overall prevalence of atopic dermatitis in East and 
West Germany was 10.4% in the 5 to 6 years old pre-school children. The 
prevalence was 12.9 in East Germany that was significantly higher than the 
8.2% in West Germany (Schafer, Kramer, Vieluf, et aL, 2000). The authors 
showed that the prevalence has decreased in East Germany from 17.5% in 
1991 to 11.2% in 1997 by repeated cross-sectional studies in 1991,1994 and 
1997. It is not clear whether the investigators had followed the same group or 
if they recruited new patients each time. The authors also reported (Schafer 
et al., 2000) that children whose parents had a higher level of school 
education were affected more frequently, which is in agreement with 
Williams' finding in the UK (Williams, Strachan, Hay., 1994d). 
A recent study on schoolchildren from urban and rural areas in Oregon, 
America (Laughter, Istvan, Tofte, Hanifin., 2000) showed that the overall 
prevalence of atopic dermatitis was 17.2% using the standard scoring criteria 
for the Schultz-Larsen Questionnaire (Sch u Itz- Larsen, et al., 1996) and 6.8% 
according to highly stringent criteria using dermatological examination 
(Laughter, Istvan, Tofte, Hanifin., 2000). However, the latter study had a low 
response rate (32%) especially from the urban area. 
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In general, the prevalence of AD is reported to range from 2 to 20% or even 
higher and peaks among infants and children than in adults (Hanifin., 1992), 
and even in adults AD is clearly predominant in younger persons (Schmied 
and Saurat., 1991). However, there is still insufficient prevalence data from 
the UK based on examination by dermatologists of prospectively defined 
populations (Williams., 2000a). 
1.1.6 Summary 
9 In summary AD is a well-recognised entity and atopic eczema its 
commonest synonym. 
9 AD occurs in genetically predisposed individuals and in most cases is 
associated with asthma and/or hay fever 
* The UK working party's diagnostic criteria remain the most thoroughly 
validated and easy to use in epidemiological studies. However, it is still 
possible that a better disease definition may be developed. 
9 There is an increase in the prevalence of atopic dermatitis and other 
atopic diseases. The peak prevalence of AD among infants and children. 
e AD is more common in children and most of the sufferers have it in a mild 
form. 
9 The vast majority of AD cases were under the GPs care. 
9 Prevalence studies of AD based on a dermatologist's examination are 
largely lacking. 
9 There is no adequate explanation for the increasing prevalence of this 
condition. 
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1.2 Section 2: Aetiology and clinical features 
Aetiology 
The aetiology of atopic dermatitis to date is still unknown but it has been 
suggested that more than one factor, acting at the same time, may 
precipitate the disease. The relative importance of genetic, immunological, 
environmental, and local cutaneous factors in the aetiology of AD may vary 
between cases, a proposal that is supported by the variation in clinical 
presentation and prognosis. Atopic dermatitis may, therefore, represent a 
spectrum of disease process, with environmental factors dominating at one 
end of the spectrum and purely genetic factors at the other end (Rajka., 
1960; Coleman, Trembath, Harper., 1997). 
1.2.1.1 Genetic factors 
Familial aggregation, suggesting a genetic predisposition, is a long 
established feature of atopy (Coca and Cooke., 1923). Family history of 
atopic disease is one of the recognised diagnostic criteria for AD (Hanifin and 
Rajka., 1980; Williams, et aL, 1994a). Schultz-Larsen et al (1986) 
demonstrated the central importance of genetic determinants. They reported 
a higher concordance of atopic dermatitis in monozygotic (77%) than 
clizygotic (15%) twins. The former finding and family history of atopy are 
strong indicators of the genetic basis of the disease (Schultz-Larsen, Holm, 
Henningsen., 1986). Diepgen and Blettner (1996) reported a higher odds 
ratio of atopic dermatitis between mothers and sibling than fathers and 
sibling. The familial aggregation between mother and child can be explained 
by the sharing of the same enwonment at home, or by intrauterine 
influences. They assumed that environmental factors would be shared more 
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between mother and child than father and child (Diepgen and Blettner.. 
1996). 
Recent developments in molecular biology and genetics have led to the 
identification of a number of candidate genes, which are related to atopic 
diathesis or to increased IgE production. A study of allergic rhinitic or 
asthmatic families suggested that dominant inheritance of the IgE response 
was linked to a gene locus on chromosome 11 q (Cookson, Sharp, Faux, 
Hopkin., 1989). However, in another study the authors were unable to detect 
or exclude linkage of atopic dermatitis to this gene (Coleman, Trembath, 
Harper., 1993). A finding that contrasted with a later study where the authors 
found that there was significant association of atopic dermatitis with beta 
subunit of the high affinity IgE receptors gene (Cox, Moffatt, Faux, et al., 
1998). In partial agreement with the Coleman's study (1993) and 
disagreement with Cox's study (1998) there was lack of linkage to 
chromosome 11 q1 3 but linkage to chromosome 5q31, in a study in which 
Forrest et al identified the major locus that causes general predisposition to 
atopy at 5q3l. They proposed that there are different genes, which in the 
presence of environmental factors determine how the atopy is expressed in 
form of eczema, asthma or rhinitis (Forrest, Dunn, Williamson, et al., 1999). 
In a recent review of the genetic studies of atopy and atopic dermatitis, 
Coleman et al concluded that atopy and atopic disorders occurs as result of 
multifactorial inheritance with interaction between genetic and environmental 
factors in which the exact contribution of each factor remains unclear 
(Coleman, Trembath, Harper., 1997). It can be concluded that genotype is an 
important risk factor for the development of AD. This may represent more 
than a single gene defect, varying from inheriting a high-risk gene pattern 
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where environmental factors do not play a major role, to a low risk genotype 
expressed under certain environmental conclitions. Finally, Cookson 
concluded recently that with the availability of the complete sequencing of the 
human genome and the ability of looking at the expression of many genes at 
once, the identification of the responsible genes will be much easier 
(Cookson., 2001). 
1.2.1.2 Environmental factors 
While atopy has strong genetic determinants, still unrecognised factors in the 
environment can affect the occurrence of AD in genetically susceptible 
individuals. It is unlikely that genetic factors are solely responsible for the 
rapid change in the prevalence of AD (Williams., 1992). Geographical 
variation of AD in the UK in a similar pattern to hay fever cannot be explained 
in genetic terms alone (McNally, Williams, Phillips, Strachan., 2000). Also, 
children of black Caribbean origin born in London have been shown to be at 
higher risk of AD than their white counterparts (Williams, Pembroke, 
Forsdyke, et al., 1995a). The former study suggested that environmentai 
factors associated with development and possibly urbanisation were 
important in the aetiology of AD. Environmental factors may act during foetal 
life or during infancy. 
Changes in the indoor climate as a result of central heating and double- 
glazing might for example, have increased children's exposure to house dust 
mite. Hide et al (1994) carried out an intervention study where they 
manipulated diet and the level of antigen exposure from house dust mite 
during gestation and early infancy in children at higher risk of developing 
atopic diseases. They found a significant reduction in the number of new 
cases of allergy than in the control group at the age of 2 years (Hide, 
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Matthews, Stevens, et al., 1994). However, the literature provides little 
information about the nature of these factors, specifically whether these are 
allergic in nature such as exposure to new or higher concentrations of 
airborne or dietary antigens, or whether they are mainly physical such as 
soap or detergents. 
1.2.1.3 Immunological factors 
It is beyond the scope of this thesis to review or discuss the recent 
immunological findings, however an overview will be given. Increased IgE 
levels, eosinophilia, decreased CD8 suppressor/cytotoxic cell number and 
function, increased expression of CD23 on mononuclear cells, expansion of 
IL-4 and IL-5 Th2-type cells (now called type 11 T-cell response), decreased 
number of IFN-gamma-secreting Thl-type cells (now called type I T-cell 
response), increased serum sIL-2 receptors levels, increased serum 
eosinophilic cationic protein levels, and other immunological abnormalities 
observed suggest an abnormal immunoregulation in AD (reviewed in Leung., 
1999). These all point out to the importance of the T-cell in AD 
pathophysiology and is supported by data from clinical trials that showed that 
therapies that inhibit T cells can ameliorate AD, for instance oral cyciosporin 
A (Harper, Ahmed, Barclay, et al., 2000), topical tacrolimus FK506 (reviewed 
in Smith., 2000), and SDZ ASM 981 (Harper, Green, Scott, et al., 2001). 
Also, in relation to disturbed cellular immunity, atopic dermatitis patients are 
said to be more susceptible to viral infection especially molluscum 
contagiosurn and herpes simplex (Hanifin and Lobitz., 1977b). It has been 
reported that atopic dermatitis patients have a lower sensitisation rate to 
dinitrochlorobenzene (DNCB) than unaffected people, but Uehara and Sawai 
(1989) have reported, from a longitudinal study, that the reduced response 
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was correlated with disease severity. Of the 20 patients who did not react to 
DNCB when they had extensive dermatitis, 18 reacted when their eczema 
was under control (Uehara and Sawai., 1989). 
Staphylococcus aureus is the predominant skin microorganism in skin lesions 
of AD patients as well as in clinically normal skin without any sign of infection 
(Leyden, Marples, Kligman., 1974). There is experimental evidence that S 
aureus may lead to the development or exacerbation of AD through an 
immunological mechanism. IgE antibodies against S aureus have been 
detected in some patients (Walsh, Richards, Douglas, Blumenthal., 1981), 
and S aureus enhances the expression of CD23, the low-affinity receptor for 
IgE, on B lymphocytes and Langerhans cells (Neuber and Konig., 1992). 
Also, enterotoxins released by some staphylococci may function as 
superantigens which are potent T-cell stimulators that can join the MHC class 
11 molecules on antigen presenting cells with lymphocytes bearing a T-cell 
receptor with a particular vp region (McFadden, Nobel, Camp., 1993). Anti- 
staphylococcal therapy has improved AD lesions, a rationale that was based 
on a positive linear correlation between eczema activity and the degree of S 
aureus colonisation - the denser the colonisation the more severe the 
eczema (Williams, Gibson, Aitchison, et al., 1990; Lever., 1996). 
Airborne allergens such as house dust mite, and animal dander have been 
proposed as triggers of atopic dermatitis (Rajka., 1961). There is an 
increased population of house dust mite in houses with fitted carpets, which 
appears to be the most important aeroallergen. Many patients with AD have 
specific anti-IgE antibodies to house dust mite antigen, and in many cases 
the concentrations of these are higher than those to other allergens (Platts- 
Mills, Mitchell, et al., 1983), implicating ýdust mites as the most important 
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aeroallergens. The concentration of house dust mite antigens detected in the 
beds of patients with AD was found to be parallel to the severity of the 
disease, which supports the hypothesis that mite antigens may have a role in 
the aetiology of AD (Beck and Korsgaard., 1989), although others could not 
demonstrate a correlation (Henderson, Kennedy, Thompson, Carswell., 
1990). At present, the role of the house dust mite is still controversial. 
However, it has been reported, from a controlled trial of dust mite avoidance 
measures in the treatment of AD, that there is a significant decrease in 
symptoms and extent of rash. The authors could not identify those subjects 
who might benefit from such interference and suggested that such methods 
are needed generally in the management of AD (Tan, Weald, Strickland, 
Friedmann., 1996). 
Finally, penetration of the mucosal surface by food allergens will lead to 
antigens reaching food specific IgE antibodies bound to mast cells. Mediators 
such as histamine, prostaglandin, and leukotrienes are released. Cytokines 
such as ILA IL-59 IL-6, and TNF-alpha may promote inflammation released 
by activated mast cells. Such cytokines are also produced by Thl cells that 
act to enhance migration of lymphocytes to the area involved establishing a 
chronic inflammatory reaction. Therefore, elimination of the properly identified 
responsible food allergen from the diet in some patients might result in a 
reversal of these immunopathogenic mechanisms and might improve the 
patient's skin condition (Sampson., 1997). However there is little clear 
evidence that ingested allergens are specifically related to AD in more than a 
small group of patients. Food as a risk factor will be shown in more details in 
subheading 1.3.2.3. 
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1.2.1.4 Local cutaneous factors 
Factors whether internal or external acting locally may contribute to 
occurrence and/or exacerbation of AD. Dry skin, white dermographism and 
facial pallor (physiological changes in the skin) are well-recognised features 
of AD (Hanifin and Rajka., 1980). Dry skin could be related to changes in 
epidermal water loss (Watanabe, Tagami, Horii, et al., 1991), lipid fractions 
(Yamamoto, Serizawa, Ito, Sato., 1991), or delivery of lamellar bodies 
(Fartasch, Bassukas, Diepgen., 1992). Abnormal cutaneous responses to 
acetylcholine (Lobitz and Campbell., 1953) and histamine (Uehara., 1982) 
have been documented to play a role in AD aetiology. 
Morren et al reviewed triggering factors for AD and concluded that low 
humidity, excessive exposure to soaps, hard water, wool, and disinfectants 
were associated with eczema exacerbation (Morren, Prezybilla, Bamelis, et 
aL, 1994). 
It can be concluded that there is not enough evidence to differentiate whether 
the abnormalities of immune function and cutaneous physiology reported in 
patients with AD are primary genetic defects or secondary changes resulting 
from environmental influences. For example, the barrier defect may enhance 
penetration of allergens or irritants, and on the other hand inflammation 
resulting from immune responses may alter the barrier function. 
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1.2.2 Clinical features 
The clinical features of AD include itching, macular erythema, lichenification, 
excoriation, dryness of the skin and secondary infection. These signs and 
symptoms and others seen in AD patients will be described in the following 
subheading. 
1.2.2.1 Symptoms and signs 
Erythema and pruritus are the earliest primary events and these tend to 
occur as the disease flares in an acute or subacute form. Follicular 
accentuation may be more obvious in black skin. Vesicles are more common 
in flares affecting palms and soles. Excoriation and lichenification are 
secondary features that arise as a result of scratching and rubbing 
respectively. 
The morphology of lesions in AD may vary with oozing being common in 
infants and lichenification more frequent later in life. Dry skin is a well- 
recognised and common feature, but is not specific, for AD. It is more 
common in winter months. Hyperlinear palms and keratosis pilaris typically 
occur in ichthyosis vulgaris. The latter has been reported in 2-6% of patients 
with AD and features of AD are seen in about 50% of patients with ichthyosis 
vulgaris (Rajka., 1989a). Staphylococcus infections in the form of smaH 
follicular pustules, mostly on the extremities, are seen in AD patients, and 
lesions may be crusted and impetiginised in childhood (Hanifin and Rogge., 
1977a). Kaposi's varicelliform eruption (eczema herpeticum) is the most 
serious viral complication of AD, which can be localised or generalised. It is 
important to mention that the occurrence and severity of herpes infection and 
eczema severity are not related. That means that a patient with mild eczema 
may still have severe herpetic infection (Lever., 1996). 
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Flexural dermatitis in areas such as the cubital and popliteal fossae is 
essential to the diagnosis of atopic dermatitis (Hanifin and Rajka., 1980; 
Williams, et al., 1994a), however these areas may be involved in other skin 
diseases such as psoriasis. Nipple eczema is relatively uncommon but 
specific of atopic dermatitis, and cheilitis is common in patients with atopic 
dermatitis. Eyelid dermatitis can lead to epidermal thickening and Hertoghe's 
patch (patchy loss of eyebrows) because of chronic rubbing. Infraorbital fold 
(Dennie-Morgan) is a single or double crease in the lower eyelid found in 50- 
60% of AD patients and also found in non-atopics. Periorbital darkening is 
possibly caused by chronic oedema and inflammation with secondary 
hype rpigmentation. Cataract, keratoconus, and increased risk of retinal 
detachment are ophthalmologic features associated with AD. Pityriasis alba 
is a temporary patchy loss of pigment associated with mild eczematous 
changes and is more evident in coloured skin (Rajka., 1989a). 
1.2.2.2 Clinical phases of atopic dermatitis 
As mentioned earlier it has been accepted that AD has three different 
temporal phases or stages (Hill and Sulzberger., 1935). 
1.2.2.2.1 Infantile Phase 
The eczema during this phase affects the scalp, the cheeks, the front of the 
neck, the anogenital region, few areas an the trunk, and extensor surfaces of 
the extremities. The morphology ranges from dry, scaly and erythematous in 
mild cases to exudative, crusting and impetiginisation in severe cases, 
particularly in hospitalised patients. 
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1.2.2.2.2 Childhood Phase 
From 18 months the distribution of lesions changes to involve flexural sites 
(neck, elbows, wrists, knees and ankles, possibly around the mouth and 
hands). The morphology also changes to become mainly papular with 
epidermal thickening as a result of itching and rubbing referred to as 
lichenif ication. 
1.2.2.2.3 Adulthood phase 
The distribution is similar to the previous phase with eczema being more 
marked on the face, the neck, the upper trunk, the upper iimbs and the hands 
with dryness and lichenification predominating. 
1.2.2.3 Associated conditions 
Other atopic diseases such as asthma and hay fever are strongly associated 
with AD. Hay fever has a similar epidemiology to that of AD in the UK 
(Strachan., 1989). About 30% of children with AD may have asthma and/or 
hay fever, despite the fact that the age of onset is different in these diseases. 
Asthma and hay fever are also more common in children with severe AD 
(Queille-Roussel, Raynaud, Saurat., 1985), and conversely asthma has a 
poor prognostic effect on clearance of AD (Rystedt., 1985). 
In addition to asthma and hay fever, other conditions such as increased 
susceptibility to mosquito bites, increased urinary tract infection, recurrent ear 
infection, and an increased tendency to headache have all been associated 
with AD. Also, it has been suggested that atopic patients have a lower risk of 
developing cancer. (Rajka., 1989a). Herpes simplex, viral warts, and 
dermatophyte infection may be associated with eczema (Lever., 1996). 
Nevertheless, atopic dermatitis should be excluded from other disease such 
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as infantile seborrhoeic dermatitis, allergic contact dermatitis, Hyper IgE 
syndrome, Wiskott-Aldrich syndrome, histiocytosis X, scabies, cutaneous 
lymphoma, and genodermatoses such as ataxia telangiectasia, 
phenylketonuria, and Netherton's syndrome (Holden and Parish., 1998). 
1.2.3 Summary 
41 Genetic factors play a substantial role in the prevalence of atopic 
dermatitis but the pattern of inheritance remains unclear and complex. 
e Immunological factors are clearly important, which is supported by clinical 
studies in which oral cyclosporin, topical tacrolimus, and topical 
ascomycin SDZ ASM 981 have proved to be effective treatments for AD. 
o Environmental factors can exacerbate disease in genetically predisposed 
persons. 
e Local factors may have substantial effects on disease exacerbation. 
o The aetiology of this disease is still unknown, despite the recent 
discoveries at cytological level. It is clear that AD is of complex aetiology 
and the described factors (genetic, immunological, environmental, and/or 
local cutaneous) may act in different ways. 
* The most important clinical features of AD are erythema, dry skin and 
flexural dermatitis. 
* AD has different clinical phases with prominent extensor involvement in 
the infantile phase and marked flexural predilection in childhood and 
adulthood phases. 
e Chronic dryness and lichenification are prominent features in childhood 
and adulthood phases. 
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1.3 Section 3: Risk factors 
A risk can be defined as the probability of an individual developing a 
condition over a specified time and a risk factor is any characteristic 
associated with a disease, although this association does not necessarily 
have to be causal. There is limited information about factors that may 
associate with AD prevalence as well as little information about risk factors 
that may have an association with atopic dermatitis severity. The absence of 
any standard and easily administered instrument of severity assessment has 
hampered such studies. It is perhaps sensible to emphasise that the 
following reported factors are mainly related to disease prevalence and these 
factors do not necessarily have the same relationship with disease severity. 
More explicitly a factor can have a significant association with disease 
prevalence and at the same time have no association with disease severity. 
A risk factor can be intrinsic such as sex or age at onset; or extrinsic such as 
the social class, area of residence etc, or iatrogenic such as the use of 
topical steroids or systemic treatment. 
Intrinsic factors 
1.3.1.1 Sex 
Atopic dermatitis affects both sexes with more females having the disease in 
adult life while more males are affected as children (Rajka., 1989a). Berth- 
Jones et al (1997) has shown that sex and risk of AD was not strongly 
associated (Berth-Jones, George, Graham-Brown., 1997). But the latter 
study looked at the prevalence of AD and not its severity. From an adult 
population, it has been reported that females had a higher risk of increased 
severity of persistent or recurring dermatitis (Rystedt., 1985), in which 
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number of sites was used to measure the severity of AD. The system used to 
assess disease severity in the former study has not been validated and data 
about the disease in the previous 20 years were collected retrospectively. 
1.3.1.2 Ethnic group 
Children, living in the UK, with a parent born in the West Indies or Africa are 
reported to be at greater risk of developing AD (Peters and Golding., 1987). 
However, these authors were not clear if this statistically significant difference 
was a consequence of the difference in using the term eczema by parents or 
physicians. To overcome the previous problem, Williams et al (1 995a) 
conducted a study in south London to explore the differences in AD 
prevalence between ethnic groups, using a valid and reliable definition for 
AD. They reported that London-born black Caribbean children appeared to 
be at an increased risk of having atopic dermatitis (Williams, Pembroke, 
Forsdyke, et aL, 1995a). Another population-based study conducted in 
another area of the United Kingdom with a large Asian community failed to 
show any ethnic group differences in atopic dermatitis prevalence (Neame, 
Berth-Jones, Kurinczuk, Graham-Brown., 1995). All these studies looked at 
the risk of developing AD and not the course or severity of atopic dermatitis. 
1.3.1.3 Age at onset 
Age of onset is one of a number of minor criteria used to diagnose atopic 
dermatitis (Hanifin and Rajka., 1980; Williams, et al., 1994a). Parents may 
not be motivated to report this factor because their child already has the 
disease, but age at onset has a potential role in exploring those factors that 
may have caused the disease. The impact of age of onset in AD has been 
reported, in most cases, from hospital-based studies (Rajka., 1989a-, Queille- 
Roussel, Raynaud, Saurat., 1985). Two studies in which cases were 
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ascertained from the community (Aberg and Engstorm., 1990; Williams and 
Strachan., 1998) reported a later onset of disease compared with hospital 
based studies. Despite the discrepancies and limitation of the studies, it has 
been shown that atopic dermatitis starts before the age of 5 years in 70% of 
cases. 
Queille-Roussel et al (1985) reported no association between age of onset 
and disease severity, a finding that conflicts with Rystedt (1985) who 
reported that early onset was associated with persistent lesions and poor 
healing. Both studies were based on hospital cases. Differences in the age of 
subjects at the time of follow up may explain this contrasting finding, 5.7 
years in the Quei Ile- Roussel's study (1985) and 44 years in Rystedt's study 
(1985). Although the former two studies mentioned the relationship between 
age of onset and disease severity, the authors did not use a valid systematic 
technique of severity assessment. 
1.3.1.4 Age 
It has been shown that AD improves with age and more than 50% of children 
outgr, ow their eczema (Williams and Strachan., 1998). A similar finding has 
been reported earlier from the UK in which AD patients had higher recovery 
rate. The author showed that atopic dermatitis patients have a tendency to 
spontaneous remission with age (Vickers., 1980). However, information 
about whether atopic dermatitis severity improves, deteriorates, or remains 
the same with increasing age does not exist. 
1.3.1.5 Family size 
Large family size was associated with decreased prevalence of AD (Golding 
and Peters., 1987). Rona et al (1997) reported that there was a negative 
relation between family size and wheezing or asthma, which may indicate a 
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protective effect of a number of children sharing an environment at a young 
age. The study was based on children aged 5 to 11 years in England and 
Scotland (Rona, Duran-Tauleria, Chinn., 1997). In another study based on 
adults aged 20 to 44 years, it was found that there was a negative 
association between family size and some symptoms suggestive of asthma 
'hay fever and nasal allergies' and sensitisation to grass in young adults. 
However, no consistent significant association was found between family size 
and eczema, total IgE or sensitisation to other allergens (Jarvis, Chinn, 
Luczynska, Burney., 1997). In Denmark, low parity (small family size) was 
associated with an increased risk of developing AD (Olesen, et aL, 1997). 
None of these studies have investigated the effect of family size on disease 
severity. 
1.3.1.6 Birth weight 
Olesen and colleagues (1997) found that children with high birth weights for 
their sex and gestational age had an increased risk of developing AD. The 
study was based on children recruited from private dermatology clinics and 
dermatology and paediatric departments in Aarhus, Denmark (Olesen, et al., 
1997). On the other hand, very low birth weight (1500 grams or less) was 
associated with significantly lower point prevalence and 1-year lifetime 
prevalence of AD than term or near-term infants (Buhrer, Grimmer, 
Niggemann, Obladen., 1999). Although they mentioned an independent 
association between birth weight and AD prevalence, they did not report 
whether they had controlled for social class or not. Since social class could 
be a confounding factor because it has been reported that lower social 
classes have modest excess of low birth weight (Macfarlane A and Mugford 
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M. Birth counts. Statistics of pregnancy and child birth. London: Her 
Majesty's Stationery Office, 1984: 89-117: cited in David and Ewing., 1988). 
Olesen's (1997) and Buhrer's (1999) studies, however, contradict the finding 
from a community based-study in Leicester, UK, in which the authors 
reported that there were no significant differences in birth weight between 
children who developed AD and those who did not (Berth-Jones, et al., 
1997). The difference in study setting and different case definition may 
explain the incongruity of the finding. None of these studies looked at the 
relationships between birth weight and disease severity. 
1.3.1.7 Gestational age 
It was thought that increased duration of pregnancy may alter the 
development of the immune system in children (Bjorksten., 1999). Olesen 
and colleagues (1997) found an association between prolonged gestational 
age and later development of AD, while Berth-Jones et al (1997) showed that 
differences in gestational age were not associated with significant differences 
in eczema prevalence. The potential disparity between these two studies has 
been discussed previously. Both studies did not mention the association 
between gestational age and eczema severity. 
1.3-1.8 Child's atopy 
Atopic dermatitis, asthma and hay fever represent a triad of atopic diseases 
that are associated with each other. About 50% of children with atopic 
dermatitis developed asthma and 45% developed allergic rhinitis 
(Gustafsson, Sjoberg, Foucard., 2000). On the other hand children who have 
asthma and/or hay fever were reported to have a poorer prognosis and 
persistent disease (Rystedt., 1985). Queille-Roussel et al (1985) have 
reported from a prospective studv that the duration of AD was shorter in pure 
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AD than when AD was associated with respiratory manifestations (asthma 
and asthmatiform bronchitis). Although the Quei I le- Roussel's study (1985) 
examined the severity of AD in a hospital population for the first time, the 
system used has not been validated. 
1.3.1.9 Parental Atopy 
It has long been known that hereditary factors play an important role in the 
development of atopic dermatitis. A positive maternal history of eczema 
and/or a positive maternal history of asthma or hay fever are associated with 
an increased risk of developing eczema (Peters and Golding., 1987). In a 
study performed by Berth-Jones and others (1997), it was found that the 
most significant predictive factor for a child developing AD was a parental 
history of eczema. The same findings were reported from Denmark. In this 
study it was found that a family history of atopy was associated with an 
increased risk of developing AD (Olesen, et al., 1997). 
Fergusson et al (1982) showed that parental history of eczema was the 
strongest predictor of rates of childhood eczema but parental asthma was 
also related to childhood eczema (Fergusson, Horwood, Shannon., 1982). In 
another study in London, the authors found that maternal atopy was 
associated with a higher risk of developing infantile AD than paternal atopy. 
This finding clearly has significant value in the prediction of allergy in 
childhood, but whether this may be due to genetic or congenital factors or 
both is uncertain (Ruiz, Kemeny, Price., 1992). Uehara and Kimura in Japan, 
showed that a personal history of respiratory atopy in parents had no 
influence on the development of AD in the children. The authors also 
demonstrated that the prevalence of atopic dermatitis was significantly higher 
in the children whose parents had a personal history of AD (Uehara and 
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Kimura., 1993). From these studies, it is possible to conclude that children 
whose family had a positive history of atopic diseases were at increased risk 
of developing AD than those without atopic diseases. However, none of 
these studies investigated the association between a positive family history of 
atopic diseases and disease severity. 
1.3.2 Extrinsic factors 
1.3.2.1 Social class 
The Registrar General's social class classification was introduced in 1911 
and became standard classification in the UK. Social class was divided into 
six categories with solicitors and doctors being ranked in social class one and 
unskilled occupations, for example porters were ranked social class five. In 
between, there is social class 2 such as sale managers, social class 3-non 
manual such as shop assistants, social class 3-manual such as underground 
coalminers, and social class 4 such as bus conductors (Leete and Fox., 
1977). 
Social class I (father in one of higher professions) and the reported history of 
eczema have been associated. In parallel with the association with socio- 
economic status, children who had been said to have eczema were more 
likely to live in 'well-to-do' urban areas. Also, high maternal social class and a 
reported history of eczema were associated (Golding and Peters., 1987). In 
an attempt to identify independent predictors of eczema, the same authors 
found that higher parental-educational qualification was associated with an 
increased risk of developing eczema (Peters and Golding., 1987). In a 
comparison of parental reports of eczema with visible eczema recorded by 
medical officers during a detailed physical examination, Williams and others 
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found that eczema is more prevalent among British school children in social 
classes I and 11 than those in lower classes (Williams, Strachan, Hay., 
1994d). A similar finding has been reported from a community-based study 
in which children born to unemployed fathers had a low tendency to develop 
AD: 4% of this group had AD (Berth-Jones, et al., 1997). However, the 
association between social class and disease severity has not been reported 
in previous studies. 
1.3.2.2 Area of residence 
Area of residence could have a different impact on atopic dermatitis because 
of the difference in the environmental factors such car exhaust and water 
supply. There is a dramatic variation across regions in the UK, in the 
prevalence of AD, with the highest rate of eczema being reported in the south 
east (14.7%) and south west (13.8%), and the lowest rate in Scotland (8.3%), 
Wales (9.3%) and the north of England (9.5%). The differences were highly 
significant (Golding and Peters., 1987). The authors did not specify whether 
these areas were urban or rural. However, a study In Finland reported that 
the prevalence of AD was higher in urban areas and lowest in rural areas 
(Poysa, Korppi, Pietikainen, et al., 1991). A similar high prevalence of asthma 
in the urban area was reported from South Africa. The authors reported that 
the prevalence of asthma in children was 3.17% in the urban area compared 
with 0.14% in the rural area (Van Niekerk, Weinberg, Shore, et al., 1979). In 
eastern Germany the prevalence of atopic disease has increased since 
German unification; between 1991 and 1996 there was a significant increase 
in the prevalence of hay fever, atopic sensitisation, and eczema in 9 to 11 
year old school children (Von Mutius, Weiland, Fritzsch, et al., 1998). All 
these studies provide evidence for an increased prevalence of AD in the 
48 
urban areas. However there is currently very little information about the 
association of an urban environment with atopic dermatitis severity. 
1.3.2.3 Food 
Food can provoke both an allergic and a non-allergic reactions. The foods 
provoking most reactions were eggs, peanuts, milk, fish, soy, and wheat 
(Lever., 2001). It has been reported that exposure to an eady diverse solid- 
food diet conveyed an increased risk of eczema (Fergusson, Horwood, 
Shannon., 1982). To decrease the risk of eczema, Atherton et al (1978) 
carried out study that involved cow's milk and egg exclusion diet. Atherton et 
al suggested, from this double-blind controlled crossover trial, that the value 
of diet in controlling atopic dermatitis is greater than previously believed 
(Atherton, Sewell, Soothill, Wells., 1978). However, it may be difficult for 
parents to discover such allergies: for example 3% of children aged 1 year 
have a positive prick test to milk, but by the age of 3 years, only 1% 
expressed such positive prick tests, representing an approximately 80% 
reduction in type I allergy (Host and Halken., 1990). In a cross-sectional and 
prospective study design, food allergy was detected in 65% of cases with 
mild to moderate AD. The authors concluded that the presence of food 
allergy is more likely to indicate a poor prognosis of severe AD and should be 
considered a potentially significant predictor of respiratory atopy (Guillet and 
Guillet., 1992). 
Zeiger (1997) reviewed the role of prevention of food allergy and its affect on 
atopic disease and highlighted the need for more definitive data before any 
allergy prevention programmes are developed (Zeiger., 1997). Recently, 
David et al (2000) reviewed the data available about the effect of food on 
atopic dermatitis. They concluded that dietary elimination as an effective tool 
?, -I 
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in the management of AD has yet to be established by controlled trials and 
the evidence of long term benefit from dietary elimination does not exist 
(David, Patel, Ewing, Stanton., 2000). Therefore, the role of food remains a 
controversial issue that should be explored further. 
1.3-2.4 Breast feeding 
The effect of breastfeeding on the prevalence of atopic diseases remains a 
controversial issue. On one hand it has been shown that there is no evidence 
to suggest that breast feeding practices had any effect on rates of eczema 
(Fergusson, Horwood, Shannon., 1982; Peters and Golding., 1987). And on 
the other hand a study from Finland showed that 6 months of breastfeeding 
had prevented eczema during the first 3 years of life (Saarinen and 
Kajosaari., 1995). In agreement with the latter study Berth-Jones et al (1997) 
reported that exclusive breast-feeding was lower in children with AD than 
those without (28% versus 46%). However, the previous two studies' findings 
contradict with the findings reported from Japan which showed that 
breastfeeding elevated the risk of AD slightly, without statistical significance 
(Nakamura, Oki, Tanihara, et al., 2000). 
Breast-feeding did not appear to affect the risk of developing AD. However, 
none of the above studies reported the effect of breast-feeding on atopic 
dermatitis severity. 
1.3.2.5 Wool 
There is a tendency for itching and/or an eczematous reaction to develop 
after contact with irritants. Intolerance to wool has been included as a minor 
diagnostic criteria for AD (Hanifin and Rajka., 1980). It is not clear why 
patients with AD have irritable skin in general, and in particular to wool. it 
may be secondary to the d, rvness of their skin, which is possibly related to 
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disturbance of lipid content and hydration of the epidermis (Imokawa, Abe, 
Jin, et aL, 1991) To date there is no information about the effect of exposure 
to wool on disease severity. 
1.3.3 Medical intervention 
A wide range of effective remedies is used to treat flare-ups of atopic 
dermatitis. Emollients and topical steroids are the most commonly used 
therapies to control AD. Systemic therapy has been reported to be effective 
in controlling disease in severe cases not responding to conventional 
therapy. However, there is a lack of inforimation about the effect of these 
therapies, whether topical or systemic, on the long-term outcome of disease. 
It is certainly true that many of the available remedies are effective in the 
short term and that patients may expect to achieve marked improvement in 
disease severity, but data on the long-term effect is still lacking. Medical 
intervention, nevertheless, could have a harmful effect despite the benefit 
effect. Unfortunately, the design implemented in the current study does not 
allow for the exploration of these effects because patients with severe 
disease are likely to be on treatment. 
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1.3.4 Summary of risk factors 
* Child's atopy, black skin, first year of life, parental atopy and upper 
social classes were associated with an increase in the prevalence of 
AD. 
* An increase in age or family size was associated with a decrease in 
the prevalence of AD. 
* The relationships between AD prevalence and the following factors; 
breastfeeding, foods, sex, birth weight, and gestational age remain 
inconsistent and contrasting. 
* Although it was documented that there was geographical variation in 
AD prevalence with higher prevalence in urban areas, none of the 
studies looked at the difference in disease severity between urban and 
rural areas. Comparing rural and urban populations may help in 
identifying factors that may affect disease severity and justify further 
studies investigating the effect of the urban environment on AD. 
It is notable that most of the studies looked at the effect of the reviewed 
factors on disease expression and few studies mentioned the effect on 
disease severity. The lack of information about factors that may affect 
disease severity was, therefore, very recognisable and justify investigating 
the effect of these factors on disease severity in this study. Also, the majority 
of the studies were hospital-based and few community-based, and a hospital 
population is more likely to be biased towards severe cases and under- 
represent mild cases that form the bulk of AD. 
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1.4 Section 4: Disease severity assessment 
General background 
Data on the severity of illness are relevant to healthcare workers, 
pharmaceutical companies, the government, and most important, the patient. 
In everyday clinical practice physicians routinely make global assessments 
on patients'status and may make widely different decisions at different times, 
when presented with the same clinical data. Nonetheless, patient care relies 
on these global assessments. These informal judgements can be 
incorporated into standard systems to be used in clinical trials. In 
rheumatology, increasingly different indices have used individual endpoints to 
form a single outcome measure (Bombardier and Tugwell., 1982). This is 
often expressed in the form of scales, where the weighting and combining of 
each individual endpoint is made according to defined rules. Scales are 
helpful to simplify clinical information on individuals or groups, but 
fundamentally they are valuable tools to maximise the statistical power of a 
study design allowing the sample size to be small (Helewa, Goldsmith, 
Smythe., 1982). However, any instrument, index or technique designed to 
measure disease severity should be valid, reliable (reproducible), sensitive to 
change and acceptable for use by observer and patient (Streiner and 
Norman., 1995). 
1.4.2 Disease severity measurement in dermatology 
Easily administered standard instruments to measure disease severity for a 
range of dermatological disorders are quite limited and there is no single 
instrument that would be applicable to all inflammatory diseases or when 
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there is uncertainty about the diagnosis (Faust, Gonin, Farmer, et al., 1997). 
At present assessments of disease severity in a patient with inflammatory 
skin disease are based on either a complex objective scale developed for 
clinical trials (e. g., Psoriasis Area Severity Index, Fredriksson, Pettersson., 
1978; The assessment of acne vulgaris - the Leeds technique, Burke and 
Cunliffe., 1984), or global rating by a dermatologist into mild, moderate, or 
severe categories. There is a need for a scale that is reliable, quick, easy to 
use, and valid for categorising disease severity across a broad spectrum of 
skin diseases (Williams., 1997). 
1.4.3 Atopic dermatitis severity measurement 
Physicians most frequently assess this common skin disease in everyday 
clinical practice and clinical trials. It is necessary, therefore, to measure 
disease activity in a systematic way. However it is only recently that 
dermatologists have tried to develop a stanclardised system to assess AD 
severity. In 1989 the first scoring systems for AD severity assessment were 
published (Costa, Rilliet, Nicolet, Saurat., 1989; Rajka and Langeland., 
1989). Hanifin (1989) in the same year published a proposal on how to grade 
AD in clinical research studies but this was not a tested scoring system 
(Hanifin., 1989). Since 1989 there has been an increasing interest in 
developing such systems. In total 7 systems to measure AD severity, shown 
in Table 2 in chronological order, have been published as full articles since 
1989. Other scoring systems such as the Eczema Area and Severity Index 
(EASI) (Tofte, Graeber, Cherill, et aL, 1998) which was published in an 
abstract form have not been included in the table. Many other systems such 
as the Skin Intensity Score (SIS) and the Basic Clinical Scoring System 
(BCSS) were developed to measure disease severity in particular studies, 
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were also not included in Table 2. All these scoring systems, and many other 
scales using different combinations applied to assess disease severity in 
other studies, were thoroughly reviewed by Charman and Williams (2000b). 
They concluded that the SCORAID Index was the only scale for which 
validity, reliability, sensitivity to change, and acceptability has been tested 
(Charman and Williams., 2000b). 
Table 2. AD Scorinq svstems where a full-article was oublished 
Name of the Scale 
Year of 
publication 
Simple Scoring System (SSS) 1989 
Rajka and Langeland 1989 
Atopic Dermatitis Area and Severity Index (ADASI) 1991 
SCORre Ato ic Dermatifis (SCORAD) 1993 
Six Area Six Signs Atopic Dermatitis (SASSAD) 1996 
Assessment Measure for Atopic Dermatifis (ADAM) 1999 
Nottingham Eczema Severity Score (NESS) 2000 
_j 
1.4.3.1 The SCORAD Index 
The SCORAD (SCORe Atopic Dermatitis) was developed by the European 
Task Force on Atopic Dermatitis as a disease-specific severity measure 
(European Task Force on Atopic Dermatitis., 1993). The SCORAD is 
composed of three parts. First; the extent of involvement using the rule of 
nine. Second; six intensity items (erythema, oozing/crusting, 
oedema/papulation, excoriation, lichenification and dryness), each one on a 
scale from 0 to 3 according to an atlas of reference photographs (0 = absent, 
1= mild, 2= moderate and 3= severe), These features were chosen 
because of their incidence, clinical importance and potential for variation. The 
area chosen must be representative (average intensity) for each item in a 
given patient as determined by the investigators, thus excluding one target 
area or the worst affected side (European Task Force on Atopic Dermatitis., 
1993). Half point scodng is not recommended and the same area may be 
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chosen for 2 or more items. Third; subjective symptoms (pruritus and sleep 
loss), in the last 3 days/nights are assessed by the parents on a0 to 10 
visual analogue scale. 
The SCORAD Index was the most suitable system to use in this study 
because it has proved to be applicable and useful in epidemiological studies 
(Schafer, Dockery, Kramer, et aL, 1997). Although SCORAD was the most 
tested instrument, it does have following shortcomings: 
1. Using the rule of nines in assessment of the lesion extent has been shown 
to have very poor inter-observer agreement (Charman, Venn, Williams., 
1999). Inter-observer variability can affect the reliability of the instrument, but 
has no effect on this study because the same observer will assess disease 
severity all the time. 
2. It is a point severity measure and does not reflect disease fluctuation over 
the previous weeks or months. 
3. It combines both subjective and objective scores, a feature which is 
considered to be a drawback against its validity. 
4. There is some redundancy of information because of overlap between 
signs such as scaling and erythema; a drawback not only of the SCORAD, 
but of all other assessment systems. 
1.4.3.2 Rajka and Langeland scoring system 
The Rajka and Langeland system is based on clinical course, intensity, and 
extent of atopic dermatitis. The extent uses the rule of nines, the course from 
the history and the intensity from information about disturbance of night's 
sleep by itching. The broader categories (mild, moderate and severe) of this 
system, would make it more suitable in selection of patients entering a 
clinical trial rather than for detection of short-term change after intervention 
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(Rajka and Langeland., 1989b). There is no published data on the 
responsiveness of this scoring method to change and the lack of any 
reliability testing goes against the use of this system. 
1.4-3.3 The Simple Scoring System (SSS) 
The SSS is a simple technique that adds observer assessment of signs to 
patient's assessment of symptoms (Costa, Rilliet, Nicolet, Saurat., 1989). It 
consists of 10 severity criteria on a scale from 0 (no lesion at all) to 7 
(extremely severe) giving a maximum score of 70, and ten topographic sites 
are used to assess the extent of disease in each area on a0 to 3 scale 
(maximum 30). The most severely affected area was chosen for assessment 
with each criterion, giving a maximum total score of 100. Choosing the most 
severely affected area would make assessment quite difficult in a community- 
based study, in which most cases are mild. Although combining patient's 
(subjective) scores and observer's (objective) scores was considered to be a 
disadvantage of using this system, it may prove necessary to provide a 
comprehensive assessment of the atopic dermatitis status. However, in 
every-day practice collecting information about 20 parameters for each 
patient is impractical. 
1.4.3.4 The Atopic Dermatitis Area and Severity Index (ADASI) 
The ADASI is based on three colour codings (Green, Blue and Red) of 
diseased areas according to severity on a body scheme. Green-, discrete 
erythema with or without some scaling, but no infiltration. Blue; erythema with 
some infiltration, more or less scaling. Red; marked erythema with infiltration, 
with or without scaling; or lichenification with or without excoriation, with or 
without superinfection. The extent of the coloured areas is evaluated by point 
counting and the AD severitv calculated by mathematical equation (Bahmer, 
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Schafer, Schubert., 1991). There is no published data on reliability testing 
and the scheme is not as simple as it might first appear. 
1.4.3.5 The Six Area, Six Sign Atopic Dermatitis (SASSAD) 
The SASSAD score is obtained by grading six signs at six sites. The signs 
are erythema, exudation, excoriation, dryness, cracking, and lichen if ication, 
each on a scale of 0 to 3 (0 = absent, 1= mild, 2= moderate, and 3= 
severe). Each of these six signs is evaluated at each of the following six 
sites; head and neck, arms, hands, trunk legs, and feet. The maximum score 
is 108 (Berth-Jones., 1996a). Subjective symptoms are measured separately 
using a visual analogue scale. The SASSAID was proposed mainly as a 
severity measure to quantify response to treatment in clinical trial, although it 
may have additional applications. The system might be expected to show a 
substantial inter-observer variation. Although the author mentioned in the 
original article that the SASSAD proved to be useful in a community-based 
epidemiological study (Berth-Jones., 1996a), there was no evidence from the 
published literature to support this statement. The SASSAID contained many 
of the clinical features assessed in the SCORAD but does not have any 
published data on reliability testing. Four of the six signs are used in the 
SCORAD (erythema, excoriation, lichen if ication, and dryness). It was 
concluded, therefore, the SCORAD would be better for use in assessing AD 
severity in this study than the SASSAID because of the availability of data on 
its validity, reliability and sensitivity to change. 
1.4-3.6 Assessment Measure for Atopic Dermatitis (ADAM) 
This scale involves an assessment of 6 body areas (face, arms, hands, legs, 
feet, and trunk) for lichenification, scale/dryness, erythema, and excoriation 
(scale of 0 to 3), and another 4 body areas (scalp, napkin area, head and 
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neck, and limbs) for the presence or absence of eczema. The scoring system 
was derived by a iog transformation and ccmplex mathematical mode 
(Charman, Varigos, Horne, Oberklaid., 1999a: Charman and Varigos 1999b). 
Again the complex calculation of the total score, lack of validity testing and 
the inclusion of similar items, made the SCORAD more suitable to use. 
1.4.3.7 The Nottingham Eczema Severity Score (NESS) 
The NESS is the most recent atopic dermatitis severity system designed to 
measure disease severity in epidemiological studies (Emerson, Charman, 
Williams., 2000). The NESS was based on the Rajka and Langeland scoring 
system described in 1989 (Rajka and Langeland., 1989b), 
The eczema severity is measured by evaluating the three elements of clinical 
course, disease intensity and the extent of eczema examined. First; clinical 
course assessment by asking the parents about the total duration of the 
child's eczema in the last 12 months, with less than 6 weeks equal to one 
and more than 9 months equal to five. Second; clinical intensity assessment 
by asking the parents about the sleep loss due to itching or scratching over 
the last 12 months. Parents were given 5 options with no sleep disturbance 
on an average week equal to one and 6 or more nights equal to five. Third; 
the extent of eczema by examination. The system has avoided the rule of 
nines that Rajka has used by using a system of tick boxes. The body surface 
area was divided, according to clinical distribution, into 45 areas. Numbers of 
areas involved were ranked into 5 categories with 0-2 equal to one and more 
than 20 equal to five. The maximum score of the NESS was 15 and subjects 
can be divided into three categories mild (3-8), moderate (9-11), and severe 
(12-15) (Emerson, Charman, Williams., 2000). 
59 
Its development was tested on pre-school children aged 1 to 5 years. There 
was an exact agreement observed between the NESS and dermatologist 
assessment in 88% of cases, and between the NESS and the parental 
assessment of eczema in 75% of cases. Poor correlation was observed 
between the NESS and the Children's Life Quality Index (CLQI), which is 
designed to measure OOL in all childhood diseases and not just skin 
diseases. At the time of writing, the CLQI has not been published together 
with work on the development of the index with Professor Andrew Finlay 
(personal communication with Dr Emerson), A trend in using different steroid 
cream potency (62% of mild cases, 94% of moderate cases and 100% of 
severe cases) was observed, consistent with severity grades by the NESS. 
Initial use showed satisfactory results when employed as a tool for disease 
severity measurement in epidemiological studies. However, further validation 
studies were recommended by the authors (Emerson, Charman, Williams., 
2000b), and the 12 months recall time would have made the use of this 
system not compatible with this study design. 
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1.4.4 Summary of disease severity assessment 
e Systematic way of severity assessment is really needed for evaluating the 
outcome in clinical trials and everyday practice. However, the ideal 
standardised, valid, reliable, sensitive, and easy to use scoring system 
still does not exist. 
9 In dermatology there are attempts to develop stanclardised systems to 
assess disease severity such as the PAS score for psoriasis and the 
Leeds technique for acne. 
9 There are quite large number of scoring systems for atopic dermatitis 
severity, in which data on validity and reliability still lacking. 
* The SCORAD Index is the most tested instrument but shows inter- 
observer variation. 
* The SCORAD and SASSAID give wide scale ranges that probably are 
beneficial in assessing small changes in clinical trials. 
e The SASSAID has been used in many clinical trials but data on reliability 
have yet to be published. 
9 The Nottingham Eczema Severity Score (NESS) seems to be easy to use 
in epidemiological studies. But further data on its validity and 
reproducibility are needed. The 12 months recall time may underestimate 
disease severity. 
* The SCORAD Index was judged to be the most suitable system to use in 
this study because data were available on its validity and reliability. It also 
has been shown to be a practical tool in epidemiological study. It was 
therefore decided to use the SCORAD to assess atopic dermatitis 
severity in this study. 
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1.5 Section 5: Quality of life 
1.5.1 Background 
Quality of life (QOL) in broad terms includes all factors that have an impact 
on an individual life, but health-related OOL is more specifically confined to 
health aspects. Apprehension of the U quality' of human life is not new. 
Philosophers throughout history have questioned how life gains quality, but 
assessment of the QOL has received an increasing interest in the last 50 
years from the health care perspective. Treatment of chronic disabling 
conditions such as rheumatoid arthritis has focussed attention of the western 
health and social care systems on this aspect of illness (Doward and 
McKenna., 1998). In addition, it is now well recognised that the personal 
impact of disease cannot be comprehensively portrayed by measures of 
disease level such as size of infarction, tumour load, and forced expiratory 
volume. Other personal factors such as pain, restricted mobility, and financial 
cost must also be involved in the evaluation. The outcome of recognising this 
term resulted in a new area of research called "health-related quality of life". 
It evaluates different kinds of burden from disease, their change with 
treatment and their effect on personal life (Muldoon, Barger, Flory, Manuck., 
1998). 
With time, QOL has evolved from an arbitrary concept into a topic of scientific 
enquiry (Bech., 1992; Parmenter., 1994). The first publication using a QOL 
measure appeared in the 1960s and the term was introduced as a heading 
on MEDLINE in 1975 and accepted as a concept by Index Medicus in 1977 
(Doward and McKenna., 1998). Since then, there has been a great increase 
in publications using the term and most of these are experimental in nature. 
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In many cases steps taken to measure QOL in quantitative rather than purely 
qualitative terms, include an attempt to validate a scale of measurement or to 
demonstrate the extent of success from a particular treatment. In cases such 
as heart transplants, the improvement in QOL is significant and any 
technique of measurement can easily demonstrate the benefits of the 
operation. However, in other treatment areas where the effect is marginal, it 
is frequently the way of measuring QOL rather than the treatment itself, 
which means using the appropriate instrument that is sensitive to recognise 
the change. Over the next one or two decades other scales will be developed 
to measure health and then may replace existing systems. Until then the 
results of the use of such techniques should be interpreted with caution. 
In the Constitution of the World Health Organisation (WHO), health is defined 
as i(a state of complete physical, mental and social well-being and not merely 
the absence of disease and infirmity" (cited in: Finlay., 1997). QOL is a global 
concept that theoretically should involve all aspects of an individual's life and 
has been defined by the WHO Quality of Life, (WHOQOL) Group in 1993. 
"QOL is defined as an individual's perception of their position in life in 
the context of the culture and value systems in which they live and in 
relation to their goals, expectations, standards and concerns. It is a 
broad ranging concept affected in a complex way by the person's 
physical health, psychological state, level of independence, social 
relationships, and their relationships to salient features of their 
environment" 
(WHOQOL Group 1993, cited in: Bowling 1995) 
However, in simple terms, good quality of life is present when 'the hopes of 
an individual are matched by experience' (Calman., 1984). QOL assessment 
should be made as comprehensive as possible by encompassing the 
psychological, social, occupational and physical impact of a disease. A 
quality of life instrument should also be valid, reliable, responsive to change, 
and acceptable. Acceptability indicates the extent to which different people 
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(e. g. child, parents, nurses, physicians and other health-care professionals) 
are willing to use an instrument. Reliability (reproducibility) means that the 
instrument has the ability to detect true differences between subjects and 
consistent scores under identical circumstances. Responsiveness refers to 
the ability of an instrument to detect meaningful change when it occurs. 
Validity means that the scale measures what it is intended to measure 
(Streiner and Norman., 1995). Because of the lack of a gold standard validity 
is usually measured by the construct validity, in which the scale will show a 
positive correlation with other scales used by different observers to assess, 
for example disease severity. 
Health-related quality of life approaches have led to development of many 
generic instruments such as the Sickness Impact Profile (SIP) instrument 
(Bergner, Bobbitt, Kressel, et aL, 1976), and the Short-Form (SF-36) 
questionnaire (Ware and Sherbourne., 1992). The SIP was developed in the 
seventies as a generic measure of perceived health status. The aim was to 
describe the changes in a person's behaviour in response to sickness. The 
SIP has been revised later and the final version contains 136 items in 12 
categories (Bergner, et al 1976; Bergner, Bobbitt, Carter, Gilson., 1981). The 
SF-36 is a generic measure of health status covering eight domains: physical 
functioning, body pain, role limitations due to physical health, role limitations 
due to personal or emotional problems, emotional well-being, social 
functioning, energy/fatigue, and general health perceptions. 
1.5.2 Measuring quality of life in dermatology 
QOL in dermatology is estimated for both research and clinical use, and as 
an audit for political and financial purposes. Doctors and patients may have 
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differing views on assessing the impact of an illness on quality of life from 
their patients (Slevin, Plant, Lynch, Drinkwater, Gregory., 1988). 
Some of the components of the generic health questionnaires may be 
redundant in assessing quality of life in skin disease. For example in atopic 
dermatitis, an instrument that does not contain a question about the effect of 
itching may underestimate the impact of the disease on patient's life. As it 
has been reported that sleep disruption in pre-schoolers with atopic eczema 
was the ultimate outcome of itching and scratching. It caused tiredness, 
irritability and reduced attitude to perform normally (Reid and Lewis- 
Jones., 1995). Such generic measures of QOL also do not include many of 
the salient factors known to be associated with skin diseases, which may 
respond to treatment. 
Skin disease has always had a major negative impact on a patient's life, but it 
is only recently that this impact has been measured in the repeatable way in 
which the Psoriasis Disability Index (PDi) was used to measure disability 
caused by psoriasis (Finlay and Kelly., 1987). After 1987 there was a 
flourishing interest in developing instrument(s) that could measure QOL in 
dermatology. Several questionnaires were the outcome of this growing 
interest; the Acne Disability Index (ADI) (Motley and Finlay., 1989), the atopic 
Dermatitis Disability Index (ADDI) (Eun and Finlay., 1990), the Eczema 
Disability Index (EDI) (Salek, Finlay, Luscombe, et al., 1993), the 
Dermatology Life Quality Index (DLQI) (Finlay and Khan., 1994), the 
Children's Dermatology Life Quality Index (CDQLI) (Lewis-Jones and Finlay,, 
1995), the Dermatology Quality Of Life Scales (DQOLS) (Morgan, McCreedy, 
Simpson, Hay., 1997) and the Dermatitis Family Impact (DFI) questionnaire 
(Lawson, Lewis-Jones, Finlay, et al., 1998). The Infants' Dermatitis Quality of 
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Life Index (IDQL) has been developed recently by Lewis-Jones and others 
(2001) to assess quality of life in infants (Lewis-Jones, Finlay, Dykes., 2001). 
Badia et al (1999) from Spain used the Spanish version of the DLOI in 
patients with mild to moderate eczema and psoriasis treated with topical 
steroids. They indicated that the Spanish version of the DLQI (Badia, 
Mascaro, Lozano., 1999) was generally valid and reliable, similar to its 
English version (Finlay and Khan., 1994). In Sweden, investigators had used 
the DLQI and other instruments such as the SF-36 (Ware and Sherbourne., 
1992) to assess quality of life in adult patients with atopic eczema and 
psoriasis attending the dermatology outpatient clinic at a University hospital. 
They confirmed that patients with skin disease have an impaired quality of life 
(Lundberg, Johannesson, Silverdahl, et al., 1999). The DLQI was also 
translated into Danish and it has been reported that the translated version 
has showed satisfactory reliability and was a valid measure to assess the 
impact of skin disease on quality of life using subjects with different skin 
diseases from inpatients and outpatient dermatology clinic, and healthy 
volunteers as a control. They showed that hospitalised patients had greater 
impairment in quality of life than both outpatients and healthy controls. Atopic 
dermatitis and psoriasis patients expressed higher scores than patients 
suffering from other dermatological diseases (Zachariae, Zachaeiae C, Ibsen, 
et al., 2000). 
1.5.3 Measuring children's quality of life 
Measuring QOL in children has many difficuities, It includes the changing 
ability of children to read and understand questions, variation in normal 
activities and the recognition of aspects of life at different ages. Adult 
measures were not suitable for use in children because of the differing 
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experiences and their interpretation (Feeny, Juniper, Ferrie, et aL, 1998). 
Another crucial problem is separating the parents' from the children's 
perception of the disease affecting the child. Nevertheless, children's QOL 
measurement has received very little attention from researchers in health- 
related QOL (Lindstrom and Eriksson., 1993). 
Skin disease such as atopic dermatitis can lead to severe disability and 
handicap in children (Long, Funnell, Collard, Finlay., 1993). A systematic way 
to evaluate the effect of skin diseases on children's life was needed. 
Therefore the Children's Dermatology Life Quality Index CDLQI was 
developed to measure the impact of any skin disease on children's QOL over 
the previous 7 days. It consists of 10 questions about different aspects of the 
child's life (Lewis-Jones and Finlay., 1995). On the initial validation of the 
CDLQl, Lewis-Jones and Finlay (1995) reported a high mean score for 
eczema, psoriasis, and acne. They were more highly significant than scores 
for moles and naevi. They confirmed the huge impact of inflammatory 
disease and in particular atopic dermatitis on children's QOL (Lewis-Jones 
and Finlay., 1995). However, information gained from this study was from 
children attending the paediatric dermatology clinic and not from a 
community-based study. 
Although the CDLQl was designed to measure children' quality of life, it has 
not got around the difficulties mentioned earlier, and the parents were 
allowed to help in completing the questionnaire. Parents may provide a 
different view from their children. It could also be a source of information bias 
as there may be two different subjects answering the questions. 
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1.5.4 Measuring quality of life in atopic dermatitis 
In a chronic disease such as AD with partial or temporary improvements, a 
valid, reliable and comprehensive instrument is required to judge the 
treatment. The prevalence of AD has increased over the last three decades 
and has caused a major impact on health care services and individual 
patients (Herd, Tidman, Prescott, Hunter., 1996). Increased prevalence 
multiplied by major impact necessitated more research to quantify the 
magnitude of this non-life threatening but stressful disease on health 
services, and eventually, may justify redistributing the resources available for 
medical researches and services. 
The first questionnaire used to measure the impact of eczema on quality of 
life was called the Atopic Dermatitis Disability Index (ADDI), which contained 
11 questions that cover all aspects of atopic dermatitis disability (Eun and 
Finlay., 1990). The authors modified the Psoriasis Disability Index (PDI) 
(Finlay and Kelly., 1987) to measure the impact of adult atopic dermatitis on 
quality of life. Thereafter another questionnaire was developed to measure 
the impact of atopic dermatitis on adult patients. The questionnaire was 
named the Eczema Disability Index (EDI), which was an adapted version of 
the PDI (Finlay and Kelly., 1987). Using the ED] and the Sickness Impact 
Profile (Bergner, et al., 1981) in a clinical trial the authors were able to show 
that cyclosporin greatly improved the quality of life in adult patients with AD 
(Salek, et aL, 1993). However, the EDI used in clinical trials has not been 
tested for validity and reproducibility. 
In a dermatology-hospital based clinics throughout the UK, using the DQL1, 
Finlay (1996) measured the effect of severe adult atopic eczema on OOL. He 
confirmed the major impact of severe atopic dermatitis on an adult's OOL 
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(Finlay., 1996). Berth-Jones et al (1 996b) used a locally derived 
questionnaire, not formally validated, to assess quality of life in children with 
severe atopic dermatitis from hospital populations. The scores showed 
dramatic improvement after treatment with oral cyclosporin (Berth-Jones, 
Finlay, Zaki, et aL, 1996b). 
In an abstract publication, it has been shown that the CDLQl scores 
improved after an inpatient treatment of atopic dermatitis or psoriasis. The 
authors also showed that the mean CDLQl scores had significantly improved 
after treatment for acne (Lewis-Jones, Lawson, Hill, et al., 1996). 
In a community study, Herd et al (1997) have used the DLQI and the 
Patients' Generated Index (PGI) to assess disability caused by atopic 
dermatitis. The PGI was designed to assess the impact of a specific disease 
on aspects of patient's lives that they see relevant, in the mean time they can 
rate the extent of the impact and judge their treatment (Ruta, Garratt, Leng, 
et aL, 1994). The PGI has not been used in dermatological diseases before, 
but was used in patients with back pain and showed good reliability and 
validity. When the PGI was used to assess disability caused by eczema, 
there was a significant correlation between the PGI and an overall DLQl 
scores. The authors concluded that the PGI can be used to assess disability 
experienced by dermatological patients. But the analysis included adults 
(over 16 years old) with atopic dermatitis and all children with AD were 
excluded (Herd, Tidman, Ruta, Hunter., 1997). In Denmark, the Danish 
version of the DLQI was used to assess quality of life in adults with atopic 
dermatitis and showed a positive correlation between the DLQI and 
SCORAD scores (Linnet and Jemec- 1999). 
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1.5.5 The impact of childhood atopic dermatitis on the 
family 
Parents have the legal obligation to make decisions on behalf of their 
children and it is therefore important to seek their views on their child's health 
status. Severe AD has been documented as having a major impact on the 
quality of life in adults (Finlay., 1996), but the literature provides scanty data 
about the effect of childhood AD on the family's life (Lawson, et al., 1998). It 
has been shown that severe AD has a traurnatising effect on the family's 
quality of life, and can be minimised by oral remedies such as cyclosporin 
(Berth-Jones, et aL, 1996b). However, the instrument used in the latter study 
has not been tested for validity. Daud et al (1993) had studied the 
psychological effects of atopic dermatitis, looking at the impact of AD on 
parental stress and parenting. The mothers of children with AD were 
significantly more likely to report being highly stressed about their child than 
controls (51 % vs. 20% respectively). Global quality of parenting was judged 
to be lower in mothers of children with AD than controls. For instance, 
mothers tend to assent to their children's demands more often than controls 
(Daud, Garralda, David., 1993). Lewis-Jones et al (1998), in an abstract 
publication, have reported, from a community study, that childhood atopic 
dermatitis had affected their lives as well as their families' QOL and the 
quality of life scores were correlated to disease severity scores (Lewis-Jones, 
Finlay, Hill, Dykes., 1998). However, in the latter study, parents assessed 
disease severity in the children and completed the OOL questionnaires sent 
to them by post. Even so, critical examination of the effects of AD on families 
has been limited (OHare and Krowchuk., 1998). 
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1.5.6 The effects of atopic dermatitis on Health Care Costs 
Despite the high incidence of skin diseases and the serious quality of life 
issues for sufferers, very little health economic work has been done in the 
field of dermatology. Atopic dermatitis is an ideal model for health economic 
analysis in dermatology. It has an early onset, chronic relapsing course, 
unknown aetiology, is quite often refractory to treatment, and finally may lead 
to alarming complications if not treated properly. Atopic dermatitis, therefore, 
can be an excellent example for measuring the effect of skin disease on 
quality of life and health economics, in which both patients and payers are 
affected. Nevertheless, few studies have been carried out on the economic 
impact of atopic dermatitis, in spite of the fact that it is a common disease 
and has caused a significant morbidity in children of all ages (Arikian, 
Einarson, Doyle., 1998). 
Atopic dermatitis has been reported to be the most frequent diagnosis made 
in paediatric dermatology clinics and is the most common skin condition in 
children younger than 11 years old (Hanifin and Rajka., 1980). 
In the UK, extrapolated total expenditure on atopic dermatitis was F-465m per 
year and the annual cost per capita was P-7.38. Selection bias could not be 
totally ruled out, but the data give some idea about the relevance of the 
problem. The study was carried out in a semi-rural general practice in 
Livingston, Scotland. All patients with AD (infants, children and adults) were 
included (Herd, Tidman, Prescott, Hunter., 1996). In Australia, Su et al (1997) 
investigated the impact of childhood atopic dermatitis on family QOL and its 
financial costs. They instituted a questionnaire designed by Stein and 
Riessman (1980) to determine the effects of a chronic illness on parents and 
families with conditions such as spina bifida, ventilator dependence and 
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behavioural disturbance. The questionnaire was based on four scales (1) 
financial burden; (2) familial/social impact; (3) personal strain; and (4) 
mastery of coping strategies implied by the family to master the illness (Stein 
and Riessman., 1980). They found that childhood atopic dermatitis has a 
huge impact on social, personal, emotional, and financial perspectives of 
families. The estimated annual cost for managing a mild, moderate, and 
severe case of eczema was 330,818 and 1255 Australians dollars 
respectively (Su, Kemp, Varigos, Nolan., 1997). In Germany, the total cost of 
corticosteroids alone was approximately DM 450 million and the annual cost 
of treating AD to society including doctor's fees, and care in hospitals was 
DM 7 billion. Subjects were adults aged 17-55 years with atopic eczema 
(Gieler, Hohmann, Niemeier, et al., 1999). Finally, a very recent study from 
Nottingham showed that the annual UK cost of AD in children between 1 and 
5 years inclusive between 1995-96 was estimated to be 47 million British 
pounds (Emerson, Williams, Allen., 2001), implying the high financial burden 
to the UK economy. 
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1.5.7 Summary of quality of life 
* Instruments designed to measure quality of life in general may not be 
valid in dermatological diseases. Finlay and colleagues (1987) developed 
the first formal health-related quality of life assessment in dermatology. 
0 It is quite clear from the review of the literature in this section that there is 
a very limited amount of data about the quality of life in dermatology 
generally. In particular, there is a lack of information from prospective 
community-based studies, where the vast majority of cases with AD. 
e Scanty data are available about the relationships between QOL measures 
and disease severity parameters. Also, the relationship between changes 
in family and children's quality of life and changes in disease severity in 
children with atopic dermatitis has not been documented, especially from 
a community-based epidemiological study. 
9 The DFI and CDLQl have been shown to be reliable and valid instruments 
to measure QOL of the family and children respectively in hospital-based 
studies. 
e This lack of information necessitates the need to document the impact of 
eczema on children and families' lives and then to justify the claims for 
more resources to carry out further research on this non-life threatening 
disease that did not have significant attention from the fund holders. In 
addition, it may provide some idea about the validity of QOL 
questionnaires used on assessing quality of life in the community, 
because they were all developed in a hospital based setting. 
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1.6 Section 6: Therapy, prognosis, and 
prevention 
Therapy 
1.6.1.1 General measures 
Managing AD requires an adequate knowledge of its natural history. It is a 
chronic relapsing disease that is pruritic, easily irritated, chronically dry and 
characterised by episodes of inflammation. Patients are usually advised to 
avoid known irritants such as soap, wool fabrics, detergents, and occlusive 
fabric such as nylon. Patients should also avoid any work that involves 
frequent exposure to soaps, solvent detergents, or harsh chemicals. In some 
cases other triggering factors such as house dust mite should be avoided if 
possible. Bacterial, fungal, or viral infection can trigger AD and must be 
treated with the appropriate therapy when necessary. Oral acyclovir must be 
used when there is any suspicion of eczema herpeticum. Stress can 
exacerbate AD and patients with severe AD may benefit from psychological 
counselling. Dietary restriction in managing patients with refractory AD, not 
responding to conventional therapy, may be beneficial in a small selected 
group of patients, in particular children (Graham-Brown., 1998; Thestrup- 
Pedersen and Ring., 1999). 
1.6.1.2 Topical therapy 
Frequent bathing and regular application of moisturisers after bathing remain 
central steps in AD management. Patients should use soap substitutes such 
aqueous cream and avoid using creams containing fragrances or 
preservatives. Wet wrapping can be used to treat dry skin and minimise skin 
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damage caused by scratching during the night. Coal tar or tar gels may be of 
limited benefit in AD (Graham-Brown., 1998). 
Topical steroids remain amongst the most effective remedies available for 
the treatment of AD. Ointment should be used when the skin is dry and 
cream or lotion when it weeping or oozing. The strength of steroid can be 
adjusted according the site and severity of the lesions. Diluted topical 
steroids can be applied and then covered by wet wraps (wet wrapping) in 
patients who have more severe disease. Although several studies have 
reported their efficacy and safety in the management of AD, information on 
the long-term management can only be assumed. The lack of controlled data 
on long-term efficacy and safety of corticosteroids causes many 
dermatologists be wary of their extended use. Local and potential systematic 
side effects of topical steroids have led to researchers to study the effect of 
other topical remedies such as topical tacrolimus (FK506) that has shown 
promising results in the treatment of severe AD in adults and children. Local 
irritation is the most frequent side effect of tacrolimus, and relapse after 
stopping treatment has been reported. Information about the long term 
outcome are not available (reviewed in Smith., 2000). Harper and others 
(2001) have reported the first use of topical SDZ ASM 981 in children with 
atopic dermatitis (Harper, et aL, 2001), however it is not clear how these will 
contribute to the long-term management of severe AD. 
1.6.1.3 Systemic treatment 
Ora) antihistamines, preferably sedative, are used to control itching and 
improve sleeping time of the patients in some cases. Patients with AD may 
benefit from short courses of oral antibiotics and those not responding to 
topical therapy can have a sustained benefit from short courses of 
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prednisolone. Chinese herbs have a recognised effect in controlling AD, but 
the cost and lack of defined ingredients make them unacceptable, although 
many patients find them beneficial. Other systemic treatments such as 
cyclosporin, azathioprine, methotrexate, and interferon-gamma, which have 
been shown to be effective in severe AD not responding to conventional 
therapy, can be used when the indication is justified (Sidbury and Hanifin., 
2000). 
Light therapy (UVA or UVB) is useful in patients who are resistant to other 
therapeutic modalities. Few patients have unexplained photosensitivity and 
cannot tolerate UV light. Photochemotherapy (PUVA) has been used to treat 
severe AD in children and adults and many show a sustained improvement. 
The carcinogenic effect of UV light limits its usage for longer times (Thestrup- 
Pedersen and Ring., 1999). 
1.6.2 Prognosis 
Atopic dermatitis typically first occurs at 6-8 weeks of age coinciding with a 
period of co-ordinated motor activity that allows scratching and rubbing to 
take place (Hill and Sulzberger., 1935). Early disease onset, severe early 
disease, concomitant asthma, and a family history of atopic dermatitis appear 
to be the strongest and most constant predictors of poor prognosis (Rystedt., 
1985). Vickers followed up patients with AD for 20 years and found that the 
recurrence rate was less than 10%. However, the study included patients 
with infantile seborrhoeic dermatitis who potentially carry a good prognosis. 
He reported that patients with eczema that started during the second year of 
life and later with involvement of extensor surfaces had a worse prognosis 
(Vickers., 1980). A less favourable prognosis has been reported in children 
with juvenile onset (age less then 5 years) AD, in which about two-thirds of 
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children will continue to have symptoms into childhood (Musgrove and 
Morgan., 1976; Van Hecke and Leys., 1981). Linna et al (1992) reported that 
eczema had disappeared in 18% of children when they re-examined them 
11-13 years later and in 65% the eczema persisted but with lesser severity 
(Linna, Kokkonen, Lahtela, Tammela., 1992). 
From another long-term follow-up study of two groups of patients, one which 
had been hospitalised and a second group treated in an out-patient 
department, not less than 24 years previously. At the time of the follow-up 
examination 62% of the hospitalised group and 40% of an out-patients group 
still had active AD in a mild form (Rystedt., 1985). In a follow-up study carried 
out by Lammintausta et al (199 1) in Turku, Finland, atopic subjects were re- 
examined after 20 years. These patients had been previously examined at 
the dermatology department when they were 12-16 years old. The 
investigators reported 20 years later that the majority of cases show 
moderate or mild disease; only 6% and 35% had severe and moderate AD 
respectively (Lammintausta, Kalimo, Raitala, Forsten., 1991). 
A recent study from the UK reported a worse long-term prognosis than some 
previous studies had suggested with the apparent and short-term clearance 
rates of 53% and 65% respectively. The study used data from the National 
Child Development Study (NCDS), which has a longitudinal design and is 
truly unselected (Williams and Strachan., 1998) whereas the previous studies 
have used selected patients. 
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1.6.3 Prevention 
1.6.3.1 Primary prevention 
Primary prevention means a policy of preventing disease from happening for 
the first time in unaffected individuals. Factors operating early even in utero 
may have an effect on determining the prevalence/incidence of AD. If it were 
possible to identify risk factors that are accessible to public health 
manipulation, high-risk groups such as families with atopic diseases might 
benefit from an intervention study. It has been shown that there was 
significant reduction in the subsequent prevalence of AD after manipulation 
of diet and house dust mite in infants at high risk of atopic diseases (Arshad, 
Matthews, Gant, Hide., 1992; Hide, et aL, 1994). These intervention studies, 
when possible, should have a long term follow up period to make sure that 
the onset of atopic disease is not simply delayed. 
1.6.3.2 Secondary prevention 
Secondary prevention means the implementation of a policy to reduce 
disease activity in those with established disease. Identifying environmental 
factors that affect disease severity, exacerbation, or flare-ups and 
manipulating those accessible factors may help in preventing severe disease 
and eczema in remission from flare-up. This is supported by the evidence 
that the avoidance of irritating factors may help prevent exacerbation of AD 
(Rajka., 1989a). At our current state of knowledge of AD, this is a very 
important step in managing the disease. Keeping eczema in a mild and 
stable form that could lead to the patients having normal lives, and can be a 
rewarding goal. 
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The outcome of primary and secondary prevention needs to be assessed by 
patients as well as doctors. Relying on the latter in assessment of intermittent 
disease such as AD may exclude the input from many individuals who might 
benefit from simple measures such as information programmes on how to 
use emollients (McHenry and Williams., 1995). 
1.6.4 Summary 
e Identify any triggering factors and avoid when possible. 
* Skin hydration and application of suitable moisturisers. 
e Topical steroids still remain the main topical treatment of AD and topical 
tacrolimus and other immunomodulatory preparations show promising 
results. 
9 Always consider other systemic treatments including light therapy in 
severe cases not responding to conventional treatment. 
* Atopic dermatitis has a relapsing course and about 50% of cases grow 
out of it. 
e Prevention of atopic dermatitis could be an achievable task by better 
understanding of those factors that may have an effect on disease 
behaviour. 
Although plenty of remedies are available to treat AD, none provide a cure 
and relapse rate is relatively high in most of these medicines. It is therefore 
important to know about those factors that may affect disease severity and 
thereafter lead to deterioration in the AD status. This would help in the 
implementation of prevention policy and make it an achievable task. The 
available treatments have their own limitations and knowing about these 
factors may help to rationalise drug usage and therefore decrease the 
noinnco mto 
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1.7 Section 7: Hypothesis and Aims 
General summary of introduction 
There are five clear points that can be concluded from this brief introduction 
about atopic dermatitis: 
1. The aetiology is unknown 
2. There is no cure for the disease. 
I Very little information is available about factors that may affect disease 
severity. 
4. The impact of AD on children and families' life and the relationships 
between disease severity and quality of life measurements have not been 
documented prospectively, especially from a community-based study 
where most cases present. 
5. In most of the studies the design has been cross-sectional design and not 
longitudinal; a few used a prospective design. 
For this reason this study focuses on a different aspect of the problem; not 
why it occurs but what makes it worse. Exploring factors that may have an 
effect on disease severity might help not only in a better understanding of the 
disease process but also in disease control and prevention. Factors such as 
diet and environment in general are possibly amenable to public health 
manipulation. Other factors such as early onset and area of residence may 
produce a better understanding of disease pathophysiology. 
Documentation of the impact of disease on quality of life and its relation to 
disease severity is also necessary. Not only will this improve our 
understanding of individual attitudes, which are often strikingly different, it 
, ql--Qn rAIntIP-cz thin-Cin tn Annnnmirý -id psychological aspects of the children's 
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and the family's life. Such information is also required to support the search 
for further resources in research and services. 
1.7.2 What was the hypothesis? 
This study concentrated on two aspects of atopic dermatitis; firstly by looking 
at factors that may have an effect on disease severity, and secondly by 
documenting the impact of childhood AD on quality of life. 
Regarding the first aspect there was no prior hypothesis and the following 
statement justifies the implemented approach: 
"Scientific design of experiments dictates that one should start with a 
clear hypothesis, and collect such information as will assist in the 
testing of that hypothesis. This obviously included the collection of any 
variables that may confound or interact with the basic data. 
Such minimal designs are admirable in the field of randomised 
controlled trials or animal experiments. It is by no means obvious that 
they are ideal in observational epidemiological studies. There are two 
possible major reasons for mounting an epidemiological study. One is 
to confirm a hypothesis or a given set of preliminary findings. The 
other is to start with a blank canvas and ask the broad question of how 
does a particular disease vary in a given population - what factors are 
associated with increased or decreased risk" * (Golding and Peters., 1987) 
In view of the previously mentioned statement by Golding and Peters (1987), 
it was thought more sensible to initiate work from a broad base and ask 
different questions about the disease behaviour. However, in a sense, the 
study attempted to address a generalised hypothesis, which is, that those 
factors that affect the disease prevalence may or may not have the same 
effect on the disease severity. This broad non-specific approach was used 
because there is little information from the literature regarding factors 
influencing disease severity. 
The second aspect was concerned with the documentation of quality of life 
and its relationship to disease severity scores. The hypotheses were, First: 
Does eczema have an impact on QOL (children and family)? and Second: 
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How do OOL scores correlate with disease severity? Thirdly the study has 
recognised that eczema varies over time and the impact of the disease has 
also been followed overtime. 
1.7.3 Aims 
In summary, the general aims of the study were to: 
e Determine risk factors that may affect atopic dermatitis severity over time. 
a Document the impact of atopic dermatitis in children on themselves and 
their families' quality of life. 
* Assess the relationships between atopic dermatitis severity scores and 
quality of life scores at a point in time and over time. 
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2 CHAPTER 2 METHODS AND SUBJECTS 
83 
2.1 Section 1: Ethics 
The study received ethical approval by St Thomas' Hospital Research Ethics 
Committee for the London-based population and by Dyfed Powys Research 
Ethics Committee for the mid-Wales population. Preliminary parental consent 
to help with the study had been obtained by post, and at the time of 
examination another informed parental consent was obtained. Before signing 
the consent form, parents and children were asked if they had any questions 
about the study and they were told that they could withdraw from the study at 
any time. 
The project has been registered with the Data Protection Registrar 
(Application number: PX3885353). 
2.2 Section 2: Study design and subjects 
2.2.1 Study design 
A follow-up longitudinal study design was implemented in order to evaluate 
risk factors for AD severity and to document the impact of AD on the QOL 
over tilme. This design generally means a defined group followed over a 
period of time. In studying disease behaviour, an investigator might make use 
of observations of the outcomes of patients whose eczema may improve, 
flare up, or get worse under natural circumstances. However, "drop outs" are 
one of the disadvantages of this design. Subjects may move away or leave 
the study for other reasons, including death from causes other than the 
disease under investigation. Substantial losses to follow-up can affect the 
validity of the results, especially if the outcomes of subjects lost from the 
study differ from those who remain in the study (Barker and Rose., 1995). 
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This study included two populations recruited through general practices in a 
city population, South London (Lambeth, Southwark, Lewisham and 
Greenwich) and a rural community, mid Wales (Rhayader, Caersws and 
Newtown). The first area surveyed, South London, had the highest 
population density while the second area, Dyfed Powys, had the lowest 
population density in the UK. South London represents an urban environment 
and mid-Wales a rural environment. The three practices in mid Wales are in 
the middle of a rural area; those from the urban areas of mid Wales were 
excluded from the mailing list according to population density. Interview and 
clinical examination of subjects took place to time with March 1998, October 
1998, March 1999 and October 1999 (Figure 1). The last follow-up period 
started in October 1999 after which no more new subjects were examined. 
To improve the follow-up rate, 17 children who did not turn up for many 
appointments (3) were contacted after this date and by March 2000 the study 
was stopped. 
AD severity was assessed every 6 months by the same observer using the 
SCORAD Index (European Task Force on Atopic Dermatitis., 1993). The 
children's quality of life was assessed by the Children's Dermatology Life 
Quality Index (CDLQI) (Lewis-Jones and Finlay., 1995) and the family's 
quality of life by the Dermatitis Family Impact (DFI) questionnaire (Lawson, et 
al., 1998). Quality of life, for children and families, was measured only at the 
two visits in 1999 (March and October 1999). 
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2.2.2 Questionnaire construction 
2.2.2.1 Purpose 
Standard and systematic methods of collecting information produce the ideal 
way of carrying out this research. The main purpose of constructing the 
questionnaire was to collect information about potential risk factors and 
confounders in a standardised way. Questionnaires are sometimes the only 
means of gathering information-, thus their construction demands 
considerable thought, as with any other form of measurement in medicine 
(Fallowfield., 1995). However, the questions should be both valid and 
reliable, but unfortunately, a well validated and stanclardised measure was 
not available for this project. The studied population included children who 
may not have been able to answer or understand the questions, and even if 
they could have understood, the reliability of their answers would be 
debatable. On the other hand the perspectives of parents may differ 
markedly from those of their children. Nevertheless the recruitment and 
follow-up questionnaires were designed to be completed by the parents, in 
order to make a sensible comparison and statistical analysis of data of the 
same quality. 
2.2.2.2 Questions about potential risk factors and confounders 
After reviewing the literature and interviewing parents of patients with atopic 
ýdermatitis, 100 questions related to potential risk factors for severity and 
behaviour of disease were developed. The main aim of reviewing the 
literature was to collect the available information regarding these factors. 
However, there have been no systematic studies designed to identify factors 
that may affect atopic dermatitis severity in a community-based study. In 
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constructing the questionnaire, it was assumed that factors that have an 
effect on disease prevalence might have the same effect on disease severity, 
although this is not necessarily true. In addition questions about factors 
implicated in the published literature as potential contributors to the 
occurrence or severity of atopic dermatitis such as age of onset and ethnic 
group were also included. The questionnaire included an enquiry into 
environmental factors at home such as type of heating, presence of fitted 
carpet, and frequency of household and mattress vacuuming. 
Identifying potential confounding factors is a crucial step that should be taken 
before carrying out research of this nature in order to make controlling for 
confounders during inclusion or later in the analysis an easier task (Barker 
and Rose., 1995). Well-known potential cofounders such as ethnic origin and 
social class were included in the questionnaire. 
The longest recall time was encountered in questions about birth weight, 
gestational age, breast-feeding, atopy in the family, and grading the severity 
of eczema when it first started. 
It was thought that the observer could not be blinded to exposure such as 
sex, area of residence, and ethic group, which could be source of bias. It was 
therefore decided to ask parents in the questionnaire to grade their child's 
eczema on a0 to 10 scale (0 no eczema and 10 the worst eczema the child 
has ever had). This grading was included in the preliminary questionnaire 
and then was positioned in question number 29 in the recruitment 
questionnaire (Appendix 6.2) and question number 17 in the follow up 
questionnaire (Appendix 6.3). 
The preliminary questionnaire had 100 questions in 10 pages and the final 
questionnaire had 41 questions in 5 pages. Most of the response format was 
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on a categorical scale and few in a simple dichotomous assessment in the 
form of yes/no responses. Other response formats included 0 to 10 scale 
(questions 20,29 and 39) and open-end responses (questions 4,6,7, and 
41). Regarding answer choices (boxes), most of the questions had less than 
7 boxes except the following questions in the recruitment questionnaire: 5 
about child ethnic group (10 boxes), 19 about history of atopic diseases in 
the family (23 boxes) and 25 about age(s) when the child has been free of 
eczema (12 boxes). 
2.2.2.3 Pilot study 
The reliability and validity of a question may be improved by precise wording, 
avoiding ambiguous and technical terms, and by repeating the questions in a 
different fashion to stimulate recalls (Fallowfield., 1995). The aim of the pilot 
study was therefore to improve the validity and reliability of the questionnaire. 
However, it was not feasible to test it statistically. Testing the reproducibility 
would have required asking the parents to fill in the questionnaire more than 
once. It was not feasible to do this because parents were generally unwilling 
to attend another appointment. 
Bearing in mind the ideal population would have been from general practice 
but at that time GPs agreement to help was awaited. It was decided to pilot 
this instrument on patients with active disease in a hospital outpatients 
department, who had a diagnosis of atopic dermatitis in the age range of the 
targeted population (5-10 years). The pilot took place at the St John's 
Institute of Dermatology outpatient department from May to July 1997. 
First the permission of the consultant in charge was sought and then the 
permission of parents to complete the questionnaire was gained. They were 
asked to complete the questionnaire in its provisional form and were 
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requested to make comments on any questions. In total parents of six 
children agreed to complete the questionnaire of whom 4 were white and 2 
black. The ages of children were 7,5,5,9,6, and 8 years. All parents taking 
part were able to read the questionnaire. Thereafter the questions were 
modified when there was ambiguity or confusion to improve their accuracy 
according to suggestion made by the parents. Piloting helped remove 
irrelevant questions, to rephrase any ambiguous questions, and to rearrange 
the questions in order to avoid positional bias. 
2.2.2.4 Recruitment questionnaire 
By the end of the pilot study, the questionnaire was ready in its final form (41 
questions in 5 pages) and was deemed suitable for analysis by a statistician. 
The final form of the questionnaire used on recruitment is shown in Appendix 
6.2. 
2.2.2.5 Follow-up questionnaire 
Collection of information regarding factors that may change over time such 
as frequency of topical steroid applications and severity assessment by the 
parents requires a standard form also. Thus the initial recruitment 
questionnaire was modified to collect information about events in the 
previous 6 months. Questions regarding factors that would not change during 
this time such as ethnic origin, breast-feeding and gestational age were 
removed. This reduced the list to 22 questions in 3 pages (see Appendix 
6.3). This questionnaire was not piloted because the recall time only was 
modified without any change in content and answer format of each question. 
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2.2.3 Subjects' recruitment, examination and follow-up 
2.2.3.1 Potential subjects and recruitment 
The study was initiated by contacting GPs in south London and mid Wales in 
January 1997. GPs were told that access to patients' notes was not required 
for carrying out this study. Travel expenses would be refunded but subjects 
would not be offered any payment for their participation. The latter was 
implemented to avoid any selection bias. It was a longitudinal survey to 
collect information prospectively and events that happened in the past would 
be gathered by a questionnaire. What was required from the GP's was a list 
of potential patients and a place to examine them, if that was convenient for 
the surgery staff. 
A copy of the detailed protocol, recruitment letters, and questionnaires were 
sent to the GPs who indicated their interest in helping with this study. They 
were asked to create a list of all patients under a diagnostic code of eczema 
or dermatitis in the age range from 5 to 10 years (DOB: 01/01/1988 to 
31/12/1992). The age was restricted in the contents of homogeneity for a 
number of reasons: Firstly; eczema behaves differently from one age group 
to another, especially from a younger age group (under 4 years) to an older 
age group. Second; older patients might have different perspectives and 
interpretation of life. Patients in this age group were expected to have the 
same morphological signs of atopic dermatifis (Rajka., 1989a). Repeat 
prescriptions for emollients and/or topical steroids were also used by some of 
the GPs to supplement the list of potential patients for screening. 
After receiving the patients' list, all parents of children were sent two letters: 
one approved by their GP asking for preliminary agreement, one from the 
investigator explaining the study, a one page questionnaire about the UK 
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diagnostic criteria (Appendix 6.1) and a stamped (first class) addressed 
envelope for their reply. 
In November 1997 GlPs number one and two, in south London, released the 
first list. Patients from this practice were contacted by post in January 1998 
and those who responded were examined in March 1998. It took practices 
number three and four in south London another 3 months to release the list 
of potential patients. Meanwhile, the ethical approval for the rural area (mid 
Wales) was awaited. 
In August 1998, the study has the approval by the Dyfed Powys Ethics 
Committee. After this, GPs number seven, eight, and nine, from the rural 
area, released a list of potential patients. These patients were contacted by 
post in August 1998 and those who agreed to help were examined by the 
observer in October of the same year as well as patients from practices 
number three and four. Ethical approval was necessary before contacting 
any subject. 
In order to supplement the numbers of subjects in both areas an additional 
number of GPs were contacted in the urban and rural areas respectively. Of 
these, two GPs (GPs number five and six) in the urban area and one GP in 
the rural area agreed to help. GPs number five and six released the list of 
patients in January 1999. The patients were contacted by post immediately 
and those who responded were examined in March 1999. One GP from the 
rural area, who agreed to help, was unable to provide a list of patients before 
August 1999. It was, therefore, excluded. 
In total, parents of 377 children in both areas were contacted by post. Of 
these 165 responded and 137 children were included in the study of which 
40,70, and 27 were recruited during March 98, October 98, and March 99 
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respectively. One hundred and twenty attended the last follow up in October 
99. 
2.2.3.2 Case definition 
The UK diagnostic criteria, shown in Table 1, were used to define cases with 
AD. A one page questionnaire (Appendix 6.1) encompassing the UK working 
Party's diagnostic criteria for AD (Williams, et al., 1994a; 1994b; 1994c) was 
sent to the parents by post with the recruitment letters. The one page 
questionnaire contained 6 questions; one about one major criterion, four 
about minor criteria of the UK diagnostic criteria, and one about a past history 
of eczema. 
Feasibility issues were also considered in selecting this population. The 
subjects who responded but did not turn up for their recruitment 
appointments were excluded from the start. They were considered liable to 
be less motivated to join the study and therefore unlikely to continue 
participa ion. 
2.2.3.3 Subjects' examination 
2.2.3.3.1 Organising place to examine the children 
Many patients lived near their doctor's surgery. To maximise the attendance 
rate, GP's and their practice manager were asked about room availability to 
examine children. In the rural area the doctor's surgery or a home visit were 
the only places available for examination. In the urban area some of the 
practices were unable to provide a room for examination. The dermatology 
out patient departments at Guy's and St Thomas' hospitals were the 
alternatives; in some cases a home visit was made. 
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2.2-3.3.2 Organising the appointments 
Parents who agreed to help had provided their phone numbers. In a few 
cases a phone number were not available. Parents were contacted by phone 
and asked for the most convenient time, within the organ ised-specif ic time for 
examination with the practice, for them and their children to come for clinical 
assessment of their children. They were also asked about the preferable 
place for examination, e. g. doctor's surgery or at home. After arranging the 
appointments, a letter with a reminder of the date and place of examination 
was sent to the parents. The investigator performed all the arrangements. 
2.2-3.3.3 Organising Travelling 
The rural area in mid Wales is a remote area with limited public transport. 
Rhayader has no train station and very limited bus services. It was 
mandatory to travel between the three-targeted practices by car, which was 
cost-effective and time saving as well. It also, allowed the observer to make 
home visits to places where it was impossible to get to by public transport. 
Each patient required 45 minutes for examination during recruitment and 20 
minutes at follow-up. The observer was based in London and this 
necessitated a stay in a hotel in mid Wales for two weeks on recruitment and 
one week on each follow-up. However, buses and trains were used for 
travelling in the ur, ban area. 
2.2.3.3.4 Clinical examination 
The children's clinical examination took place in March 1998, October 1998, 
March 1999, and October 1999 (see Figure 1). All children were examined 
while wearing their underpants only in the presence of an adult guardian. 
Children were free to refuse examination regardless of parental consent. A 
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previously trained observer carried out the examination and severity 
assessments at all the times. At the same time as the severity assessment, 
the presence of visible flexural dermatitis, the only sign in the UK diagnostic 
criteria for AD, was documented according the published protocol (Williams, 
Forsclyke, Boodoo, et aL, 1995b). Children were examined in the same 
season, during spring and autumn, 6 months apart. All parents were able to 
read the recruitment and follow-up questionnaires, and the observer 
remained blind to the results of the questionnaire. Travel expenses were 
refunded to the parents on showing a receipt. 
2.2.3.4 Subjects' follow-up 
Parents attending for the recruitment visit were contacted by telephone 6 
months later to arrange a suitable time to examine their children. After 
arranging a convenient time for parents and children, a letter was sent to 
confirm the time and place of examination. Parents were asked again to fill in 
the follow up questionnaire (Appendix 6.3) and at the same time the same 
investigator evaluated eczema severity in the children. Examination of 
children took place in the same location as at recruitment and a home visit 
was always an option. The same process was repeated every 6 months, up 
to 4 times for some subjects. Children and family's quality of life was 
assessed on two visits during 1999. 
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Figure 2. On the day of clinical examination of the child 
(On the day of clinical examination) 
The session takes 
45 minutes on recruitment 
20 minutes on follow-up 
Assessment of disease severity by 
the observer using the SCORAD 
Index and recording any involved 
areas. 
4m 
Permission to examine is 
taken from the parents and 
child. 
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2.3 Section 3: Assessment of atopic dermatitis 
severity 
The severity of atopic dermatitis in children was assessed by the observer 
using the SCORAD Index (European Task Force on Atopic Dermatitis., 
1993). 
2.3.1 The SCORAD Index 
The SCORAD Index was chosen to assess disease severity because it was 
proved to be a practical tool in epidemiological studies. When the need is a 
detection of subtle modification in the severity of AD, as in follow-up of the 
progression of AD, a more elaborate scoring system such as the SCORAD is 
more appropriate (Sprikkelman, Tupker, van Aalderen, et al., 1997). It was 
also the most tested instrument available at the time of starting the study. 
Although patients generally over 7 years may well be capable of answering 
appropriately, children less than 7 years old might have been unable to read 
or understand the questions, thus parents exclusively answered the two 
questions to ensure that data had the same quality, The maximum score of 
the SCORAD is 103 and after exclusion of the dryness score, 92.5. This 
yields an atopic dermatitis severity score, which is a continuous variable. In 
the analysis of some factors such as family quality of life, the parents' scores 
were excluded and only the Objective SCORAD was used on its own (Kunz, 
Oranje, Labreze, et al., 1997). The SCORAD-D will be used to refer to this 
form of modified SCORAD (maximum score of SCORAD-D is 72.5). The 
proposed evaluation sheet takes about 10 minutes to fill in for a trained 
individual. See the guidelines in how to use the SCORAD in Appendix 6.4 
and the SCORAD sheet in Figure 3. 
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2.3.2 Training on how to use the SCORAD 
The SCORAD is a scoring system to assess the severity of AD. Lack of 
experience with the instrument used in research is a source of bias and this 
could affect the result of the study. To minimise this, the investigator 
(observer) was trained on how to use SCORAD according to the practical 
guide in a SCORAD CD ROM (Stalder., 1995). Further information and 
automatic calculation of the SCORAD are available at the following website 
(http: //Scorad. sante. uinv-nantes. fr). 
Training was achieved by practising the SCORAD on patients with AD from 
the outpatient's department. Permission from the patients' parents and the 
responsible doctor was first sought. Full examination of the child and 
recording of the extent of involvement using the rule of nine was applied, The 
six intensity items (clinical signs) were evaluated on a scale from 0 to 3 
according to reference photographs. Dryness was assessed during a training 
session, because patients often do not apply cream before visiting their 
doctor. Parents were asked to assess the subjective symptoms in the last 3 
days/nights on a0 to 10 visual analogue scale. 
During training the minimum and maximum values obtained were 7.5 and 
71.2 respectively. These values provided an adequate range of the variation 
in severity of the disease. Thus, the investigator was able to practice this 
scoring system on patients with varying degrees of severity with the aim of 
reducing the potential for observer bias (measurement bias). In the meantime 
the observer gained experience in assessing flexural dermatitis, the only 
clinical sign in the UK diagnostic criteria (Williams, et al., 1994a). 
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2.4 Section 4: Assessment of quality of life 
Quality of life in children and their family were quantified by two different 
questionnaires. The contents of these two questionnaires will be explained 
separately. An ideal use of quality of life measures should be carried out at 
two key times to provide for example information before and after treatment. 
If it takes place too frequently, patients lose interest and become less careful, 
which may lead to loss of accuracy (Finiay., 1997). However, in this study, 
there is no active interference and it was decided that measuring quality of 
life at two points would provide the information needed to document the 
impact of AD on quality of life at a point in time and over time. 
2.4.1 Family's quality of life 
The parents attending visit 3 (March 1999) were asked to complete the 
Dermatitis Family Impact (DFI) questionnaire (Lawson, et al., 1998) and then 
again 6 months later (October 1999), to assess the impact of atopic 
dermatitis on the family. The DFI, shown in Figure 4, was developed by 
Lawson et al as a disease-specific measure. It is a one-page questionnaire 
that measures how much atopic dermatitis in children has affected the life of 
the family over the previous 7 days. It consists of 10 items; house work, food 
preparation, sleep of others in the family, leisure activities such as swimming, 
time spent on shopping, cost related to treatment or clothes, causing 
tiredness or exhaustion, emotional distress, relationships in the family, and 
the impact of helping with treatment on the main carer's life (Lawson, et al., 
1998), see Figure 4. 
Each question has four answers: 'not at all=O', 'a little =1', 'a lot =2', and 'very 
much=3'. The overall summary score aggregates the score of each item and 
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ranges between 0 (the best score) and 30 (the worst score). That is, the 
higher the score, the poorer the quality of life for the family. Parents have 
completed the DFI questionnaire at the same time as the children's eczema 
severity was assessed. 
2.4.2 Children's quality of life 
Unfortunately, a system that is designed to allow children to assess the 
impact of eczema on their quality of 'life without the help of their parents was 
not available. It was, therefore, decided to use the CDLQI, shown in Figure 5, 
in this study with the restriction that parents were not allowed to help in 
completion of the CDLQl. The children were asked to complete the CDLQl at 
first quality of life assessment visit (March 1999) and then again after 6 
months (October 1999), to assess the impact of having atopic dermatitis on 
their quality of life. 
The questionnaire was developed by Lewis-Jones and Finlay (1995) as 
speciality-specific one-page questionnaire to measure the impact of any 
dermatological disease on children's quality of life over the previous 7 days 
and was chosen because it was potentially of value in measuring the impact 
of the same skin disease in varied subjects relative to each other (Lewis- 
Jones and Finlay 1995). It consists of 10 items about different aspects of life: 
symptoms and feeling (questions 1 and 2), leisure activities (questions 4,5 
and 6), school or holidays (question number 7), personal relationship 
(questions 3 and 8), sleep (question number 9) and treatment (question 
number 10). Each question of the CDLQl has four answers (not at all = Oý 
only a little =1, quite a lot = 2, or very much = 3). The sum of the 10 question 
scores forms the total score of CDLQl. The maximum score is 30 (the worst 
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score) and minimum is 0 (the best score). The lower the score, the less the 
impact on the child's life. 
The targeted population contained children age 5 to 10 years. and some of 
them may not be able to complete the questionnaire on their own. However, 
parents and children were told that the child must complete the questionnaire 
without the help of anybody. Any child who received any help from his/her 
parents in completing the CDLQl was excluded from the analysis. The 
investigator had made the decision to exclude those who received help after 
the subject had left the examination room immediately to avoid any potential 
observer bias. That was done for the following reasons. First; this hopefully 
will reflect the child's own view of the disease and not that of his/her parents, 
Second; to ensure data of the same quality. Third; this restriction may give an 
idea about the applicability of the CDLQl in this specific age group, despite 
the fact that the CDLQl was designed to be completed by the child, with the 
help of his/her parent. However, a comment on how this restriction may have 
influenced conclusion from the data is discussed in section 4.3.2.1. 
All these questionnaires (CDLQl and DFI) were suitable and tested 
questionnaires to quantify the impact of eczema on children and families' life 
respectively. Despite evidence, that there are no published data on the 
validity of these instruments from a community based-study (except one 
study published in an abstract form; Lewis-Jones, et al., 1998). Otherwise all 
the information was from hospital based-studies, 
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Family impact of childhood eczema questionnaire 
Child's Name: Mother/Father/Carer Date: Score 
The aim of this questionnaire is to measure how much your child's skin 
problem has affected you and your family OVER THE LAST WEEK. Please 
tick Vone box for each question. 
1. Over the last week, how much effect Very much 
has your child having eczema had on A lot 
housework, e. g. washing, cleaning. A little 
Not at all 
2. Over the last week, how much effect Very much 13 
has your child having eczema had on A lot 0 
food preparation and feeding. A little 13 
Not at all C3 
3. Over the last week, how much effect has Very much [: ] 
your chilý having eczema had on the sleep A lot 17) 
of others in the family. A little 13 
Not at all [I 
4. Over the last week, how much effect has Very much [3 
your child having eczema had on A lot 
family leisure activities, eg swimming. A little 
Not at all 
5. Over the last week, how much effect has Very much 
your chili having eczema had on time spent A lot 
on shopping for the family. A little 
Not at all 
6. Over the last week, how much effect has your Very much [3 
child having eczema had on your expenditure, A lot 17) 
eg costs related to treatment, clothes, etc. A little 13 
Not at all 13 
7. Over the last week, how much effect has your Very much (: ) 
child having eczema had on causing tiredness A lot 13 
or exhaustion in your child's parents/carers. A little 13 
Not at all C3 
8. Over the last week, how much effect has your very much C] 
child having eczema had on causing emotional A lot 13 
distress such as depression, frustration or A little C3 
guilt in your child's parents/carers. Not at all C] 
9. Over the last week, how much effect has your Very much 
child having eczema had on relationships A lot 
between the main carer and partner or A little C3 
between the main carer and other children Not at all 
in the family. 
10. Over the last week, how much effect has helping Very much 
with your child's treatment had on the A lot 
main carer's life. A little 
Not at all 
Figure 4. The DFI questionnaire 
Permission to copy and use the CDLOI and DFI was obtained from Professor Andrew Finlay 
and Dr Sue Lewis-Jones 
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H(^pital No. 
CHILDREN'S DERMATOLOGY LIFE QUALITY INDEX 
Name- Diagnosis: CDLQI 
Age- SCORE- 
Addrewi- Dare: 
The aim of this questionnaire to to measure how much your skin problem has 
affected you OVER THE LAST WEEK. Please tick V one box for each question. 
1. Over the last week. how itchy, "scratchy". Very much 0 
sore or painful has your skin been? Quite a lot 0 
Onlv a little 
Not at all 
2. Ovrr the last week. how embarrassed Very much 
or self conscious, upset or sad have you Quiteza lot been because of your skin? Only a little 
Not at all 0 
3. Over the last week. how much has your Very much 0 
skin affected youT friendships? Quite a lot 13 
Only a little C3 
Not at all n 
4. Over the Inst weelt. how much have you changed Very much 0 
or worn different or special clothes/shoes Quite a lot 0 
because of your sidn? Only a little 0 
Not at all 
5. Over the last week, how much has vour Verv much 
skin trouble affected going out, pliying, Quite a lot 
or doing hobbles? Only a little 
Not at all 
6. Over the last week. how much ha%-e you Very much 
avoided swimming or other sports because Quite a lot 71 
of your skin trouble? Ovdy a little -1 
Not at all 71 
7. Last week, If school time: Over the Prevented school 
was It last week, how much did Very much. 
school time? your skin affect your Quite a lot 
school work? Only a little 
OR Not at all 
Was It If holiday time: How much Very much 
holiday time? -x over the last week, has your uite a lot 8 
skin problem interfered with nly a little 
your enjoyment of the holiday? Not at all 
a. Over the last week, how much trouble %'cry much 
have you had because of your skin with Quite a lot 
other people calting you names, teasing, 01dya littlC C3 
buUying, asking questions or avoiding you? Not at aU 71 
9. Over the hIst week, how much has your sleep Verv much 0 
been affected byr yow skin problew. ý gufte a lot :1 Only a tittle 
Not at all 
10. Over the last week. how rauch of a Very much 
probIrm has thr treatment for your Q11tte a lot C3 
skin been? 0111V a little 1-1 Not at all 
Please check that you have answered EVERY question. Thank you. 
Figure S. The CDLQI questionnaire 
Permission to copy and use the CDLQl and DFI was obtained from Professor Andrew Finlay 
and Dr Sue Lewis-Jones 
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2.5 Section 5: Analysis strategy 
2.5.1 Sample size calculation 
One of the principal factors which influences the standard error (SE), and 
therefore the width of the confidence interval, is the sample size: generally, 
the larger the sample, the smaller the SE, and thus the narrower will be the 
confidence interval (Barker and Rose,, 1995). 
A statistician helped to calculate the sample size required for studying the 
risk factors for atopic dermatitis using the Stata software (Stata corp. 1999). 
Standard deviation (SID) of SCORAD was taken as equal to 10 (Schafer, et 
al., 1997), in which experience with SCORAD in pre-school children was 
achieved. So for a risk factor to which 10% of the patients are exposed, and 
which leads to a 10 point increase in SCORAD, for example 10 to 20 points 
in SCORAD, 120 patients are needed to give a 90% chance of detecting a 
difference at the 5% level. 
2.5.2 Possible confounding factors 
Confounding is a key concept in epidemiology and controlling for it in 
observational studies is the basis for most designs and statistical methods. A 
potential confounder must be, by definition, independently related to outcome 
and the exposure under study (Barker and Rose., 1995). In the design it was 
possible to control for age where it was restricted to the age group between 5 
and 10 years and the multiple regression analyses was used to control for 
other potential confounders including predictors. 
Collection of information about potential confounding factors is a crucial fact 
that should be taken into account before starting the study. With this 
information, any statistical analysis can be carried out with and without 
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adjustment for these potential confounders. The literature provides little 
information about factors related to the severity of atopic dermatitis and 
therefore selection of potentiaý confounders cannot be based on hard 
evidence. However, it was decided in this study that any factor, which has 
been related to the prevalence of AD could be a potential confounder and 
controlled for in that particular exposure. Including many confounding factors 
could confound the results even if they have no real effect what so ever. The 
following 6 factors were treated as potential confounders and controlled for in 
ail multiple regression analyses (sex, age, area of residency, social class, 
family size and ethnic background). Other factors treated as potential 
confounders, when necessary, such as breast-feeding and early onset AD 
and or any other confounding factor necessitating control in the analysis will 
be mentioned specifically in that particular exposure. 
Nevertheless, no observational design or analytic method can absolutely 
guarantee that an effect is not confounded to some extent and proof of 
causality or an effect on the basis of observational research will always have 
its detractors. 
2.5.3 Statistical analysis 
2.5.3.1 General 
After the study had finished, data were entered in Epi-Info version 6.04b 
statistical software (Dean A, Dean J, Burton, Dicker., 1997) and edited for 
any human errors. The observer remained blind to results of the 
questionnaires by not entering the data till the data collection had finished. 
Therefore the observer was unaware of the exposure under investigation 
such as age at onset and breast-feeding when the severity assessment was 
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carried out. This has eliminated any potential measurement bias, except 
where sex, ethnic group, and area of residence were the exposure. In these 
factors bias was inevitable and its potential effect on the results will be 
discussed later in each of these factors. In a simple term, the observer did 
not know about the risk factors under study apart from those three factors 
mentioned earlier. 
The data then were transferred to Stata statistical software version 6.0 for 
analysis (Stata Corp. 1999). Descriptive statistics means that results will be 
presented in the form of tables, figures or percentages, while statistical 
analysis means presenting results after using statistical tests such as ordered 
logistic regression, or Wilcoxon test. Statistical tests were carried out at the 
5% level (95% confidence interval and exact p value). Missing data were 
included in the descriptive statistics when risk of information bias was high, 
but were otherwise excluded from that particular analysis. Generally "Don't 
know" answers were also considered as missing data and excluded from the 
analysis. Chi-square (x2) test was used to test for any significant difference 
between two independent proportions such as sex and visible flexural 
dermatitis. The Wilcoxon's Signed Ranks test was used to detect any 
significant difference in the scores between two paired observations. 
2.5.3.2 Atopic dermatitis severity as the outcome 
Eczema severity was measured using the SCORAD Index, which produces a 
continuous variable. Ranking it into a categorical variable (for example, 
reducing these to a two-point scale indicating presence or absence) can 
sacrifice much of the information in the data - information that has been 
obtained with considerable effort, expense, and patient co-operation. Often, 
ordered categories are the best available way to capture important 
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information, such as the stage of disease or the severity of symptoms. 
Efficient statistical methods for analysing such data have considerable value. 
The outcome of interest is a continuous variable (the SCORAD scores) 
skewed to the right, which was expected in a community-based study with 
mostly mild disease. So non-parametric tests were used for statistical 
significance, the most powerful of these being ordered logistic regression 
(Anderson., 1984). The "svyolog" command in the Stata software (Stata 
Corp. 1999) estimates an ordered logistic regression for complex survey data 
and "psu" adjust for repeated measurements on each subject using the 
actual values at each visit. 
It means that, the individual remained the unit of analysis by using the simple 
mean of the observation. This method uses the response for each individual 
to form a single mean score that summarises the response curve of that 
single individual. In simple terms, the individual has remained the unit of the 
analysis despite using the total number of observations. Summary scores 
give greater power and less chance of false positive results (Matthews, 
Altman, Campbell, Royston., 1990). 
In this study the outcome of interest was infrequent (severe disease) and the 
odds ratio with 95% ýconfidence interval and p values will be used to present 
the magnitude of the difference. It should be emphasised that the study is 
looking at many factors that may affect disease severity without any pdor 
hypothesis. This may come, however, under the categories of testing multiple 
hypotheses in which there is a high chance that statistical significance may 
occur by chance alone and without any real effect. An increase in the number 
of factors studied in the same study means increasing the chances of getting 
significant results just by chance (Altman, Gore, Gardner, Pocock., 1995). It 
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was, therefore, decided prior to starting the study that any results that have a 
p value of more than 0.05 will be considered as happening by chance and 
would not be considered as significant findings. 
2.5.3.3 Family and children's quality of life as the outcome 
When families or children's quality of life was the outcome of 'interest and 
atopic dermatitis severity was the exposure under study, Spearman 
correlation Coefficient was used to test for any association between disease 
severity and QOL at each visit. It was also used to correlate each component 
of the quality of life questionnaire with disease severity on each visit. Tobit 
regression was used to examine the effect of any potential confounder on the 
association between OOL and disease severity scores at each visit 
(Arnemiya., 1973; Arnerniya., 1984). This assumes that OOL scores has a 
censored-normal distribution, censored at zero. And values recorded as zero, 
are regarded as being not exactly known but could be anywhere in the range 
[minus-infinity to 0]. Interval regression, controlling for potential confounders 
(black skin, child's age, social class, family size, sex, and location) was used 
to investigate the relationship between changes in severity assessment and 
quality of life measures (Amemiya., 1973; Amemiya., 1984). 
There were 34 body areas examined and recorded on the examination sheet 
(Table 3). To make a relevant clinically meaningful comparison, the 34 areas 
were grouped into 5 major areas (Face and neck, chest and abdomen, upper 
limb, back, and lower limb). In this way, it was possible to make a sensible 
comparison of the OOL scores between areas with visible eczema and those 
free of eczema and between each other. 
110 
3 CHAPTER 3 RESULTS 
ill 
3.1 Section 1: General results 
Recruitment and response rate 
General practitioners (GPs) from 9 practices in south London and mid Wales 
provided names and addresses of 377 subjects, who were contacted by post. 
The response rate in the urban area (35%) was significantly lower than in 
the rural area (78%), Table 4. Information about the non-responders is not 
available. These are subjects who failed to respond after contacting them up 
to three times and it was not feasible to gather any further information from 
these subjects. 







Number (RR, %) Number included in 
the study from those 
who responded 
One 150 52(35) 45(87) 
Two 19 5(26) 4(80) 
U Three 27 8(30) 2(25) 
R Four 36 13(36) 11 (85) 
B Five 38 12(32) 9(75) 
A Six 33 17(52) 11 (65) 
N _ 
Total 303 107(35) 82(77) 
R Seven 21 21 (100) 21 (100) 
U Eight 29 23(79) 21 (91) 
R Nine 24 14(58) 13(93) 
A 
L Total 74 58(78) 55(95) 
Nine practices 1 377 1 165 (44) _137 
(83) 
RR; Response Rate 
3.1.2 Clinical examination 
Of 165 subjects who responded, 21 children were excluded from the study 
before clinical examination. Of these 21,7/165 (4%) did not turn up for three 
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different appointments, 4/165 (3%) had moved out of the area, and 1 &165 
(6%) were excluded before examination because they had never had 
eczema (they answered "No" to the last question in the UK diagnostic criteria 
one-page-postal questionnaire (see question number 6 in Appendix 6.1). 
Of 144 children who were clinically examined, 137 were eligible to be 
included in the study. The reasons for excluding 7/144 (5%) children, with 
their UK diagnostic criteria characteristics, are summarised in Table 5. 






1 One Had a rash oniy once 0 2 
2 One Vitiligo around the mouth 1 1 
3 Two Anaernia and pruritus 1 1 
4* Three Angular stornatitis only 1 4 
5* Three Has AD but her father was interested in receiving 
treatment and not just observation 
1 3 
6 Three Lichen Nitidus 0 1 
7 Nine Young age (Date of Birth 1994) 
*Has fulfilled the UK diagnostic criteria 
3.1.3 Inclusion criteria 
The UK diagnostic criteria for AD were used to define cases of atopic 
dermatitis. These contain one major criterion and 5 minor criteria (Williams, 
et al., 1994a; 1994b; and 1994c). A subject must have one major criterion 
and three minor criteria to fulfil the criteria and qualify as a case of AD. 
Description of each criterion for this population is as follows: 
3.1.3.1 Itchy skin condition in the last 12 months 
Itching in the last 12 months is the only major criterion in the UK diagnostic 
criteria for atopic dermatitis (Williams, et al, 1994a). One hundred and thirty- 
five (98.5%) children had an itchy skin condition in the last 12 months, and 2 
(1.50, o) children were not itchy in the last 12 months. 
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3.1.3.2 Onset below the age of two 
Eczema starting before 2 years of age is one of the 5 minor criteria in the UK 
diagnostic criteria for AD. One hundred and eleven (820o) patients had 
eczema before the age of 2 and the rest (18%) their eczema started when 
they were older than 2 years. The late onset population included 14 children 
whose eczema started between the age of 3 to 4, and 10 children who's 
eczema started between the age of 5 to 10. 
3.1.3.3 Skin crease involvement 
In 119 (87%) children, the eczema had affected the skin creases in the past, 
14 (10%) never had affected the skin creases and data were missing in 4 
chiidren (3%). 
3.1.3.4 Personal history of other atopic disease 
The answer was yes to the question "has your child ever suffered from any 
atopic disease (asthma and/or hay fever)" in 87 (64%) children, and no in 50 
(36%) children. There was a positive history of asthma in 59 (43%) and hay 
fever in 62 (45%) children before joining the study. 
3.1.3.5 History of generally dry skin in the last 12 months 
One hundred and seventeen patients (87%) had suffered from generally dry 
skin in the last 12 months. Three missing values were not included in this 
percentage. 
3.1.3.6 Visible flexural dermatitis 
Flexural dermatitis is the oniy sign in the UK diagnostic criteria. It was seen in 
74 (54%) children on the day of clinical examination. The analysis revealed 
no significant difference in frequency of flexural dermatitis between 39 (53%) 
girls and 35 (471o) boys (p = 0.97, x2 test) . 
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3.1.3.7 Fulfilling the UK diagnostic criteria for atopic dermatitis 
After clinical examination and assessment of flexural dermatitis, 123 (90', o) 
children fulfilled the UK diagnostic criteria (Williams, et aL, 1994a; 1994b: and 
1994c). Of 123 children who satisfied the criteria, 34 (25%), 42(31%) and 
47(34%) had five, four and three minor criteria respectively. Fourteen (10%) 
children did not fulfil the criteria; 11 (8%) of these had one major and two 
minor criteria. Three (2%) children had the following: the first had no major 
and one minor; the second, one major and no minor; and the third, had a 
positive history of eczema but did not have any of the criteria. Table 6 shows 
the descriptions of the 14 subjects who did not fulfil the criteria. 
Table 6. Description of children who did not fulfil the UK diagnostic criteria for atopic 
Ut: FtlldLitib. UUt LFJUV lldU Ul IIOU lldU Lilt: Ulbrldbt: 
Description of 11 (8%) children who had one major 
and two minors criteria 
Description of three 
(2%) children who did 
not fulfil the criteria 
1. Eczema has cleared now. The minors were hay fever 1. One major and the 
and early onset. one minor was dry skin. 
2. Late onset eczema 5-10 years. The minors were skin Age of onset was 5 to 
creases and dry skin. On examination there is 10 years. 
hype rpig m entation below the buttocks, which might 2. No major and the two 
indicate active eczema before. minors were dry skin 
3. Late onset eczema and has cleared now. Minors and flexural dermatitis. 
were hay fever and dry skin. He has MC*. 
4. Age of onset was 3-4 years. Minors were hay fever 3. No major neither any 
and dry skin. of the minors, but 
5. Late onset 5-10 years. The minors were dry skin and positive history of 
flexural dermatitis. eczema that probably 
6. Age of onset was 3-4 years. The minors are asthma has cleared now. Data 
and dry skin. about age of onset and 
7. Onset at 3-4 years. The minors were dry skin and skin creases 
flexural dermatitis. involvement were 
8. Eczema has cleared. The minors are onset under 2 missing. 
years and dry skin. 
9. Eczema cleared now, but it never affected the skin 
creases (extensor eczema). The minors are onset 
under 2 years and dry skin. 
10. Eczema has cleared now. The minors are skin 
creases and dry skin. On follow-up excoriation was 
seen on the back of his forearms. He has MC*. 
11. Eczema has cleared. The minors are onset under 2 
years and dry skin 
*IVIC: Molluscum Contniosum 
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A decision had to be made as to whether to include these 14 children or 
exclude them from the analysis. However, prior to making such decision 
sensitivity tests were carried out before and after excluding this group of 
patients (14 children) to investigate any significant difference in the outcome 
between these two groups. 
For instance, when the urban area was compared with the rural area, the risk 
of severe disease was 1.87 higher in the urban area than rural area when the 
14 patients were included. However, the risk remained significant and almost 
the same (1.93 higher) even after excluding these 14 children (see Table 7). 
Table 7. Odds ratio for severe disease in children who live in the urban area by those 
who fulfilled the criteria. who did not and the total sample included 
Subjects included in the analysis 
(Number of children) OR 95%Cl P value 
Total sample (137) 1.87 1.12 to 3.11 0.017 
Fulfilled the criteria (123 1.93 1.13 to 3.3 0.016 
Did not fulfil the criteria (14) 2.95 0.56 to 15.56 0.18 
OR, Odds Ratio. Cl; Confidence Interval 
Table 7 showed that the risk of severe disease in those who lived in an urban 
area and did not fulfil the criteria (14 children) was still higher, but statistically 
insignificant. Although the risk was statistically insignificant, the odds ratio 
value still lies within the 95% confidence interval of those who fulfil the 
criteria. This could represent a type 11 error by accepting that there were no 
differences, when in fact there were true differences. A type 11 error could 
have happened because of the small number of subjects reflected by a very 
wide confidence interval. 
The results shown in Table 7 suggest that there were no systematic 
differences between these two populations (who fulfilled or did not fulfil the 
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UK diagnostic criteria for AD), and therefore the sample should include both 
as they represent subjects with similar behaviour. 
Another example was the relationship between disease severity and the 
children's quality of life. There was no significant difference in the outcome 
before and after excluding those children who did not fulfil the criteria as 
shown in Table 8. It was almost the same. 
Table 8. Correlation between CDLQl and SCORAD before and after excluding those 
children who did not fulfil the UK diaanostic criteria for AD 
QOL Visit 1 (March 99) QOL Visit 2 (October 99) 
Total sample After exclusion Total sample After exclusion 
r=0.42 
(p < 0.001) 
r=0.44 
(p < 0.001) 
r=0.46 
(p < 0.001) 
r=0.47 
(p < 0.001 
r, correlation coetticient. UOL; Uuality ot lite. P; p-value 
When the relationships between changes in DFI and the SCORAD-D were 
investigated using multiple regression analysis, each unit change in 
SCORAD-D was associated with a 0.17 (95%Cl, 0.06 to 0.29, p=0.002) 
units change in family quality of life. The outcome has remained the same 
and was also statistically significant (Regression Coefficient (R) = 0.16, 
95%Cl, 0.05 to 0.28, p=0.004) after excluding cases that did not fulfil the 
criteria. 
It was clear that there were no substantial differences before and after 
excluding the 14 children who did not fulfil the UK diagnostic criteria for AD, 
Based on the previous finding, the high percentage (90%) of those fulfilled 
the criteria and the prospective design of the study, it was decided to include 
these children in the study and carry out all the analyses with these subjects 
being included. 
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3.1.4 Subjects Included 
The number recruited during the three visits was 137 children, 82 (60%) and 
55 (40%) children from the rural and urban areas respectively. The gender 
ratio was almost balanced in the total population (see Table 9). The age 
range was 5 to 12 years and the mean age was 8 (SD: 1.6) years. The 137 
children included in the study were primarily interviewed and examined 
during the following dates; 40 (29%) in March 1998,70 (51 %) in October 
1998, and 27 (20%) in March 1999. Details of recruitment and follow-up are 
shown in Table 10. No more new subjects were recruited after the third visit. 
Table 9. Sex distribution of newlv recruited children bv each visit 
Time Number of children newly 
recruited at each visi 
Male Female (%) 
_March 
98 40(29) 17 (43) 23 (57) 
_October 
98 70(51) 38 (54) 32 (46) 
_March 
99 27(20) 10 (37) 17 63 
- 
Total 137 65 (48) 72 52 
Table 10. Number of oatients on recruitment and follow ur) 
Frequency* March 98 October 98 March 99 October 99 
_Four 
times 40 34/40(85%) 33/40(83%) 35/40(88%) 
Three times ------------------ 70 56/70(80%) 65/70 ý93%) 
_Two 
times ------------------ ------------------ 27 20/27 
Total seen 






Shaded number represent newly recruited patients at Mat time 
Trequency of severity assessment per each group of patients 
In all, 29 (21%) children attended the four visits, 84 (61%) attended the last 
three visits and 106 (77%) were seen in both March 1999 and October 1999 
(see Table 10). By the end of the study, 17 (12%) children did not turn up for 
their last appointments and this led to an 88% follow-up rate. With this high 
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follow up rate any potential substantial difference between these two groups 
would be less likely to have any significant effect on the outcome. 
3.1.5 Course of AD 
3.1-5.1 Severity of eczema when first started and at each visit 
Parents were asked retrospectively to grade their children's eczema at onset 
on a0 to 10 scale. Parents of 132 (96%) children rated their children's 
eczema and data were missing for 5 children. The mean severity score at 
onset was 5.02 (SD 2.8, range 0 to 10) and median 5 (95%Cl, 4 to 5). At 
each visit parents were asked to rate the child's eczema on the same scale. 
The mean score at the final visit was 2.1 (SID 2.2) and median 1 (95%Cl, 1 to 
2) representing highly significant improvement in disease severity as rated by 
the parents (p < 0.001). It appears that parents had seen a significant 
improvement in their children's eczema severity between the time when the 
eczema first started and the date of the final visit. 
3.1.5.2 Best season in the year for eczema 
Parents of 28 (20%), 12 (9%), 52 (38%), and 4 (3%) children felt that their 
children's eczema was at its best condition during winter, spring, summer, 
and autumn respectively. In 41 (30%) children there was no difference 
between the four seasons. In general, summer was the best season for 
eczema while 30% showed no seasonal variation. 
3.1.5.3 Apply or ever applied steroid cream/ointment 
Parents of 123 (90%) children applied or had ever applied steroid 
cream/ointment to their children's skin before joining the study; 11 (8%) 
children had never applied topical steroids, with no data for 3 (2"o) children. 
There was no sianificant differpnre between males and females In steroid 
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usage (P = 0.9,4. However the mean SCORAD was higher in those who 
used topical steroids 11.2 (SID 11.5) than those who did not apply topical 
steroids 5.8 (SID 5.8). Although the difference was statistically significant (OR 
= 1.86,95%Cl, 1.03 to 3.36, p=0.038), it does not have any significant 
clinical implication because topical steroid was more likely to be used in 
children with severe disease, but this statistically significant finding validates 
the usage of the SCORAD index in severity assessment. It suggests that the 
system was able to give high scores for those with more severe disease. 
3.1.5.4 Frequency of topical steroid application 
Parents were asked about the frequency of topical steroid application in the 
time preceding each visit. The figures from the fourth visit were more 
consistent as this represents the frequency of topical steroid ýusage in the last 
6 months only, yet figures from first, second and third visits represent a 
mixture of 6 and 12 months recall times; question number 34 in the 
recruitment questionnaire (Appendix 6.2) and question number 20 in the 
follow-up questionnaire (Appendix 6.3). 
Answers from the fourth visit (October 1999) have the same recall time, and 
therefore, these were reported. Parents of 10 (9%), 5 (4%), 11 (9%), and 48 
(41 %) children had applied topical steroids twice a day, once a day, every 
other day, and less frequently respectively. However, parents of 43 (37%) 
children had never applied topical steroids to their children's skin before the 
fourth visit. Parents of three children did not answer this question. These 
figures are consistent with the fact that most cases were in mild form and did 
not necessitate topical steroids. Nevertheless, "steroid phobia" cannot be 
excluded from the data available. 
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As answers from the fourth visit were more consistent (all parents answered 
the same question with 6 months recall time), they were used to investigate if 
there was a trend in the objective severity scores with increased topical 
steroid frequency. 
The mean observer's score (SCORAD-D) was higher at any frequency of 
topical steroid application (9.3) than the no category (4.7). The observer was 
able to give higher scores for those who applied steroids than those who 
never used topical steroids in the last 6 months. A small number of 
observations indicating once a day application (5 children, 4%) might explain 
the low main score in that category. The low number of children in a once a 
day category may have affected the trend in the parent's grading of the 
child's eczema, see Table 11. 
It is also quite clear from Table 11 that the parents were able to give higher 
scores when the application of topical steroids became more frequent. This 
suggests that the questionnaire used in this study has an internal 
consistency. 
Table 11. Mean (SD) and median (95%Cl) of the SCORAD-D and the mean (SD) parents 
grading of child's eczema at the fourth visit for each frequency of topical steroid 
arwlied before this visit 
SCORAD-D 
Frequency of 
application Mean (SD) Median (95%Cl) 
Mean scores of the 
parents' grading of the 
child's eczema (SD) 
None 4.7( 7.2 0 (0 to 7) 1.7(1.4) 
Less frequently 9.04( 9.2) 8 (O, to 12) 2.1 (2.0) 
Every other day 12.4( 8.8) 11 (5.7 to 19.7) 3.1 (2.7) 
Once a day 5.2( 7-3) 0 (0 to 15) 1.8 2.5) 
Twice a day 12.2( 13.6) 9 (0 to 29.9) 4.2(3.1) 
Missing values 0 0 S 
S In this category, data were missing for two children and parents scored 8 for the third child. 
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3.1.5.5 Admission to hospital 
Before the first visit only one patient was admitted to the hospital because of 
eczema. Before the third visit two patients were admitted to the hospital 
because of their eczema. No one was admitted to the hospital before the 
second and fourth visits. 
3.1.5.6 Systemic treatment 
Again the recall time was different at the first three visits regarding the usage 
of systemic remedies. Therefore, information from the final visit was more 
consistent as parents completed the same question with a6 months recall 
time. Before the final visit, 20 (17%) children had taken systemic antibiotics 
for their eczema, 22 (19%) children had taken oral antihistamines because of 
their eczema, while systemic steroids were used in 2 (1.7%) children for their 
eczema. In this study no child had used systemic cyclosporin or azathioprine 
at any time. 
The mean scores of the SCORAD-D at the fourth visit were looked at to 
assess the internal consistency and validity of the question. It was clear that 
children who received antibiotics and/or prednisolone had higher mean 
scores than those who did not. However, there was no difference in the mean 
score between those who were receiving oral antihistamines and those who 
did not (see Table 12). But the subjective symptom scores were higher 3.6 
(SD 3.2) for those receiving oral antihistamines than those who did not 2.8 
(SD 3.4). 
Table 12. Mean SCORAD-D per each systemic treatment taken in the last 6 months 
Precedinq the final visit 
Mean SCORAD-D (SD) 
Systemic treatment Yes No 
Antihistamine 7.9 7.9(9.1) 
Antibiotic 9.4(10.0) 7.6(8.9) 
- Prednisolone 26.5 (10.6) 7.5(8.8) 
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3.2 Section 2: Atopic Dermatitis Severity 
3.2.1 Description of the atopic dermatitis severity 
3.2.1.1 Total number of observations 
The total number included 137 subjects, each seen on up to 4 occasions, 
which represented 380 observations (69% out of an expected 548). There 
was no data for 168 (31 %) observations, and of these, 124 (23%) 
observations were "missing" due to the fact that the required number were 
not interviewed during the first and second visits. The remaining 44 (8%) 
observations were unavailable because subjects had not attended the follow 
up appointments on visits 2,3 or 4. The SCORAD Index was used to assess 
atopic dermatitis severity and as mentioned earlier, it has two components 
(signs and symptom evaluation). 
3.2-1.2 The total SCORAD 
When the total SCORAD from the four visits was considered, the minimum 
and maximum scores were 0 and 66 respectively and the mean and median 
of the total SCORAD with numbers of patients per each visit are shown in 
Table 13. The mean SCORAD improved at the second (October 98) and 
fourth (October 99) visits, which took place in autumn, one year apart and 
deteriorated in March 1998 and 1999. 
Table 13. Mean (SD) and median (95%Cl) of the SCORAD with number of subjects per 
visit 
Visit Number* Mean SCORAD (SD) Median (95CI%) 
One (Mar. 98) 40 9.8 (8.4) .3 to 12. Two (Oct. 98) 104 9.4 (10.4) 7.5 (6 to 8) 
Three (Mar. 99) 116 12.1 (12'. 6) 9 (7 to 11) 
_Four 
(Oct. 99) 120 10.7 (11.4) 7 (4 to 11) 
b D, Standard deviation. ", I otal number ot su0jects seen per visit. GI: Uonfidence Interval 
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Figures presented in Table 13 may have been contaminated by the subjects 
newly recruited at the first three visits. Looking at each individual group of 
patients separately was important in order to evaluate if these subjects had 
similar patterns compared with the total number shown in Table 13 or the 
inclusion of new subjects had deviated the scores at each visit. It also will 
show the changes of severity for each of these subgroups. 
Figure 6 shows that the 29 children attending all the four visits, 55 attending 
the last three visits but not the first, and 20 children attending the last two 
visits only had a similar SCORAD pattern compared with the mean SCORAD 
for the total number at each visit. The mean SCORAD, for the total number 
attending each visit, shown in Figure 6, is a duplicate of the mean SCORAD 
shown in Table 13. The repetition was used for comparison between the total 
number and the three subgroups. It is therefore quite clear that the inclusion 
of new subjects at visits two and three did not contaminate the data and the 
pattern of AD severity got worse in March and improved in October but 
remained the same for each of these subgroups as well as for the total 
sample. 
Figure 6 shows also disease fluctuation over time, a finding that was to be 
expected in a chronic relapsing disease such as AD (Rajka., 1989a). 
Preliminary analysis of the data could not explain the changes between visits 
on the basis of the information available from questionnaire about the 
potential risk factors. However, the changes in disease severity might be 
explained by the seasonal variation as the second visit came after winter 
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3.2.1.3 Objective score 
The objective SCORAD (SCORAD-D) included only the intensity and extent 
components of the SCORAD index. The highest and lowest observer scores 
over the four visits were 0 and 56 respectively. Severity scores from visit 
three were used to rank the severity distribution because the required 
number of subjects was recruited and more new subjects were recruited after 
the third visit. The SCORAD-D, from the third visit, was ranked into three 
categories; mild, moderate and severe, according to guidelines suggested by 
Kunz et al (1997), 80% of patients were rated as having mild eczema 
(SCORAD-D : 515), 18% as moderate (SCORAD-D >15:! AO), and 2% as 
severe eczema (SCORAD-D > 40) (see Table 14). There were no significant 
statistical differences in the SCORAD-D scores between the visits, for 
example in the third and fourth visits p=0.74. 
Table 14. Severity (Ranked SCORAD-D) distribution per visits for the total number and 
each subarour) 
Number of child ren per vi sit 
Severity Distribution Mar. 98 Oct. 98 Mar. 99 Oct. 99 
Mild 
Total number per visit 37(93) 92(88) 93(80) 98(82) 
29 attended all the four visits 27(93) 28(97) 24(83) 23(79) 
55 attended the last 3 visits only --------- 49(89) 43(78) 47(85) 
20 attended the last 2 visits only ----- --- --------- 17(85) 17(85) 
Moderate 
Total number per visit 3 (7) 11 (11) 21 (18) 22(18) 
29 attended all the four visits 2(7) 1 (3) 5(17) 6(21) 
55 attended the last 3 visits only --------- 5(9) 11 (20) 8(15) 
20 attended the last 2 visits only --------- --------- 2(10) 3(15) 
Severe 
Total number per visit 0(0) 1 (1) 2 (2) 0(0) 
29 attended all the four visits 0(0) 0(0) 0(0) 0(0) 
55 attended the last 3 visits only --------- 1 (2) 1 (2) 0(0) 
20 attended the last 2 visits only --------- --------- 1 (5) 0(0) 
126 
It can be concluded from Table 14 that the vast majority of children have 
atopic dermatitis in its mild form. The table also shows that inclusion of new 
subjects did not deviate the severity distribution with the majority being mild 
for any subgroup. 
Another way of looking at this group of patients, to avoid the effect that might 
be introduced by new subjects each time, is to rank the disease severity for 
the 137 children included in this study. These are subjects recruited on three 
occasions over one year. The severity distribution was similar to those who 
attended the third visit (mild 87%, moderate 11 %, and severe 2%). 
3.2-1.4 Subjective symptoms scores 
Observer's scores were excluded and parents' scores only were used to look 
at the trend of parents' assessment of itching and sleep loss (subjective 
symptoms). Parents' score of subjective symptoms produces the same trend 
as for the observer scores (see Table 15), except for the 29 children who 
attended all the four visits. They tend to have higher mean scores and do not 
follow a similar trend. This can be explained by the origin of these subjects as 
all of them were from the urban area. 
Table 15. Number of children and the mean (SD) subjective symptoms scores per 
each visit for the total sample and each subgroup 
Mean (SD) * per visit 
Number of children seen Mar. 98 Oct. 98 Mar. 99 Oct. 99 
Total number included 3.7(4.0) 3.1 (3.9) 3.7(3.8) 3.0(3.6) 
29 attended all the four visits 3.4(4.0) 4.6(4.4) 4.7(4.5) 3.5(3.9) 
55 attended the last 3 visits only --------- 2.2(3.2) 3.0(3.1) 2.1 (2.5) 
20 attended the last 2 visits only 4.7(4-2) 3.5(3.9) 
Mean (SD) of Subjective symptoms scores 
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However, there was statistically significant improvement in the subjective 
symptom scores between the third and fourth visits (p = 0.008). The summer 
holiday preceding the fourth visit could be the real factor that had led to 
improvement, or there might be a subtle clinical improvement that the 
observer was unable to detect it. But generally the scores showed significant 
correlation with the observer's scores, which reflects the internal consistency 
of the SCORAD (see Table 16). 
Table 16. Correlation between the SCORAD-D (Observer scores) and the subjective 
svmt)toms scores (Darents score) in each visit 
Visit One Visit Two Visit three 
I 
Visit four 
r ---0.2 9 (p = 0.07) 
r= 0.45 
(p < 0.001) 
r=0.56 
(p < 0.001) 
r=0.53 
(p < 0.001) 
r, Correlation coefficient. P, p-value 
3.2.1.5 Parents grading of disease severity 
In the recruitment and follow-up questionnaires parents were given the 
opportunity to grade their child's eczema on a0 to 10 scale at that time (0 no 
eczema and 10 the worst eczema the child ever had). Number and the mean 
scores of parental grading are shown in Table 17. 
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Table 17. Number of children and the mean (SD) score of parental grading of the 
child's eczema ner each visit for total number and subarouDs 
Mean (SD )* per visit 
Number of children seen Mar. 98 Oct. 98 Mar. 99 Oct. 99 
Total number included 2.3(2.1) 2.0(2.0) 2.5(2.3) 2.1 (2.2) 
26 attended all the four visits 2.0(1.6) 2.8(1.9) 3.2(2.8) 2.6(2.6) 
(no data for 3 children) 
53 attended the last 3 visits only --------- 1.3(l. 7) 2.2(2.2) 1.7(1.8) 
(no data for 2 children) 
18 attended the last 2 visits only --------- --------- 2.8(2.2) 2.4(2.3) 
(no data for 2 children) 
*Mean (SD) ot severity grading by the parents 
Parents' grading of disease severity was significantly correlated to the 
investigator assessment (SCORAD-D) of disease severity using the 
SCORAD index (sign scores only). Table 18 shows this is a highly significant 
and consistent correlation during the four visits. 
Table 18. Correlation between the SCORAD-D (Observer scores) and the parents 
assessment of disease severitv (in the questionnaire) at each visit 




(P < 0.001) 
r=0.57 
(p < 0.001) 
r=0.56 
(p < 0.001) 
r uorrelation coetticient. H; p-vatue 
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3.2.1.6 Summary of severity description 
* The total SCORAD, SCORAD-D, subjective symptom scores, and global 
assessment have the same trend, except at visit one. 
9 In most cases (80%) the eczema was in its mild form, a finding that had 
been expected in community-based study. 
9 The total SCORAD, sign scores and global assessment showed 
insignificant fluctuation in disease severity between the visits. This was 
expected in an observational study without any active interventions. There 
was however a significant improvement in the subjective symptom scores 
between the third and fourth visits. 
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3.2.2 Atopic dermatitis severity over time as the outcome 
This is a longitudinal study and the outcome was disease severity over time. 
The total number of observations over the four visits was used in the 
statistical analysis controlling for each repeated measure as mentioned 
earlier. In other words, the subject remained the unit of analysis, despite 
using the total number of observations (Matthews, Altman, Campbell, 
Royston., 1990). 
Figure 6 shows that there are three subgroups of subjects with similar 
severity changes over time. However, sub-analysis of each group should be 
carried out to evaluate if these subjects have a similar increased risk of 
severe disease over time or whether a substantial difference did exist. 
The first was accomplished by looking at the description of these groups. 
Table 19 shows that the mean scores of SCORAD for those who attended 
one follow-up visit and who attended more than one follow-up are almost the 
same. The lower severity scores in the two follow-up subgroups could be 
explained by the high percentage of new subjects recruited from the rural 
area (80, %), who always showed low scores, and high severity scores in the 
one follow-up subgroup could be explained by the high percentage of 
subjects from the urban area (90%). Table 19 also shows that there were no 
substantial differences in the demographic characteristic of these groups, 
except for those who attended three follow-ups where there was more 
unemployment. These subjects were recruited from one practice in an urban 
area, where there is large number of council houses. 
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Table 19. Follow-up characteristic of the study population per number of follow visits 
for each subaroun 
V 
Number of follow-up visits 
ariables name One 
(n = 20) 
Two 
(n = 55) 
Three 
(n = 29) 
Age in years (mean) 8.0 7.1 7.5 
_Sex, 
%Male 40 58 41 
SCORAD, mean (SD) 13.9(15.4) 8.8(10.0) 9.2(7.8, ) 
_SCORAD-D, 
mean (SD) 9.3(12.7) 6.6(7.8) 5.8(5.8) 
_Subjective 
Symptoms, mean (SD) 4.7(4.2) 2.2(3.2) 3.8(4.1) 
Ethnic group 
White 13(65%) 51(93%) 15(52%) 
Black skin 4(20%) 3(5%) 9(31%) 
Otherraces 3(15%) 1 (2%) 5(17%) 
Social class 
_ One 5(15%) 
. 
8(15%) 3 (10 
Two 5(25%) 15(27%) 5 (17%) 
Three non-manual 3(15%) 12 (22%) 8 (28%) 
Three manual 0 2 (4%) 0 
Four 3(15%) 9 (16%) 3 (10%) 
Five 1 (5%) 6 (11%) 0 
Unemployed 5(25%) 3 (5%) 10 
Area of residence 
Urban 18 (90%) 11 (10%) 29 (100%) ý 
Rural 2(10%) 44(80%) 0 
t 
n; number ot children seen 
Secondly, data analysis was carried out using Stata's -svy- commands for 
repeated measures (in particular -svyolog-), the primary sampling unit being 
the subject. All values are used to produce appropriate estimates and the 
standard errors then adjusted using the Huber sandwich estimator. This 
approach ensures that all information is fully used, but that the standard 
errors are appropriate. The net effect is a modest, but entirely appropriate 
increase in power and decrease in standard error. To confirm the robustness 
of the findings, the analysis was repeated in a number of ways for the one 
most important risk factor (onset during first year of life): 
For 3 subgroups: those with complete data from 2 visits, 3 visits and 
all 4 visits, results were similar for the 3 subgroups. The 3 subgroups 
have similar tendency of increased risk for severe disease with an 
odds ratio around 2 lying within the 95% confidence interval of the 
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total group without reaching the statistical significance in the 2 visits 
subgroup. Although not significant, it was not possible to say that there 
was no association because this may present a type 11 error. Type 11 
error could have happened due to the small number of subjects 
included in the sub-analysis which was reflected by relatively wider 
95% confidence interval, see Table 20. Urban area as an exposure 
has a similar outcome when the sub-analysis was carried out, see 
Table 21. It should be explained here that the 29 children attending all 
the four visits were not included in this analysis because they were all 
recruited from the urban area, and not because they different in other 
ways from the other two groups. 
2. With adjustments for a main effect of visit, there was no significant 
main effect of time (F3,135= 092, p=0.43). 
3. With a visit onset interaction term, there was no significant main effect 
of time by onset interaction (F3,135 = 0.45, p=0.72). 
However, the analysis is mentioned for other risk factors only where there is 
evidence of a complication. 
Table 20. Risk for severe disease (exposure onset during the first year) per each 
aroup of patients 
Number of children seen OR 95%Cl P value 
Total number included 2.1 1.2 to 3.3 0.006 
29 children who attended all the four visits 2.56 1.03 to 6.33 0.043 
55 children who attended the last 3 visits only 2.67 0.99 to 7.09 0.05 
20 children who attended the last 2 visits only 1.3 0.34 to 5.2 0.67 
uH,, uaaS Hatio. u: LonTloence imervai 
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Table 21. Risk for severe disease (exDosure urban area) per each qroup of patients 
Number of children seen OR 95%Cl P value 
Total number included 1.87 1.12 to 3.11 0.017 
55 children attended the last 3 visits only 3.5 0.9 to 13.4 0.06 
20 children attended the last 2 visits only 1.2 0.3 to 4.3 0.79 
OR; Odds Ratio. Cl; Confidence Interval 
It can be concluded from the results shown in Tables 19,20, and 21 and the 
sub-analysis that these three subgroups and the total number included follow 
similar disease patterns over time. Therefore, the total number of observation 
per visit is a valid grouping and will be included in the longitudinal analysis 
controlling for each observation, In other words, the subject remained the unit 
of analysis and was not a duplicate number of observations. 
12.2.1 Intrinsic factors as the exposure 
3.2.2.1.1 Age at onset 
Parents of 93 (68%) children reported onset of eczema during the first year of 
life, 21 (15%) at the age of 2,18 (13%) at 2-6 years and 4 (3%) at 7 years or 
more. Table 22 shows the distribution by area of residency. There was not 
any marked sex difference in children whose eczema started during the first 
year of life, 49 (53%) females and 44 males, p=0.93 (X2). 
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Table 22. Distribution of age at onset of eczema of the whole, urban and rural 
Doi)ulation 
Age of onset Whole population Urban (%) Rural (%) 
_6 
months or less 64(47) 40(49) 24(44) 
7-12 months 29(21) 19 10(18) 
13-24 months 21 (15) 10 12) 11 (20) 
2-6 years 18(13) 9(11) 9(16) 
7 years or more 4(3) 3 (4) 1 (2) 
_ Missing 1 (1) _ 1 (1) Nil (0) 
Total 137 82 1 55 
The odds of having severe disease was almost two times more in children 
with eczema that started during the first year of life (OR = 2.1; 95% C1,1.2 to 
3.3, p=0.006). Onset during the first year remained as an independent 
predictor for disease severity after adjusting for potential confounders, which 
included breast-feeding for any duration (OR = 2.1; 95%Cl, 1.2 to 3.5, p= 
0.008). This remained significant even after exclusion of the parents' score 
from the SCORAD, (OR = 1.9; 95%Cl, 1.15 to 3.22, p= 0.013). Therefore, 
children with eczema starting during the first year of life are almost two times 
more likely to have severe disease than those with eczema that started later. 
3.2.2.1.2 Ethnic group 
The ethnic group of the child was defined according to the parents' response 
to question number 5 in the recruitment questionnaire (see Appendix 6.2). 
One hundred and thirty-three children were born in the UK, and of the 
remaining 4 children; one was born in the USA, one in Canada, one in West 
Germany, and the country of birth was missing in one child. The parents of 
the last child considered him to be in the "oth&' ethnic group. All these 4 
children had been living in the UK for 5 years or more. 
The urban population contained 42 (51 %) Caucasians. This is because the 
population of the area studied contained a high proportion of patients from 
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minority groups e. g. 26 (32%) black. All black children were bome in the UK. 
The rural population were 100% Caucasian (Table 23). 
Table 23. Ethnic backaround distribution of the whole. urban and rural DoDulations 
Ethnic group Whole sample Urban (%) Rural (%) 
White 97 (70.8) 42(51) 55(100) 
_ Black African 11 (8) 11 (13) None 
Black Caribbean 13 (9.5) 13(16) None 
_ 
_Black 
Other 2 (1.5) 2(3) None 
Indian 1 (0.7) 1 (1) None 
_Bangladeshi 
1, (0.7) 1 (1) None 
_Other 
group 10(7.3) 1 None 
Not applicable 2(1.5) 2(3) None 
Total 137 82 55 
3.2.2.1.2.1 Black Skin 
In the total population parents of 26 (19%) children considered their children 
of black origin. On a crude analysis, children with black skin are at a non- 
significant risk of severe disease (OR = 1.06; 95%Cl, 0.56 to 2.00 p=0.84). 
This risk became highly significant after adjusting for erythema score (OR = 
7.52; 95%Cl, 2.56 to 22.62, p<0.001) with relatively wide confidence 
interval. Erythema can be very difficult, if nearly impossible, to see on black 
skin. Erythema scores also form nearly 10% of the total SCORAD and 12.5% 
of SCORAD-D. It is therefore independently associated with the exposure 
(black skin) and the outcome (atopic dermatitis severity), thus erythema 
score is a true confounder. 
This relationships stayed highly significant when subjects with erythema 
score equal to zero were only included (OR = 6.21; 95%Cl, 2.76 to 13.96, p 
0.001). The risk remained high and statistically significant even after 
controlling for other potential confounders (social class, area of residence, 
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sex, child's age, and family size) (OR = 5.56; 95%Cl. 1.91 to 16.18, p= 
0.002). 
To determine whether other source of bias had perhaps affected the outcome 
other than erythema scores, the SCORAD index was excluded and parents' 
grading of disease severity on a0 to 10 scale was used as the outcome of 
interest. It was found to be completely independent of the SCORAD index 
and the investigator had no influence on it but it was significantly correlated 
to his scores (Table 18). Children with black skin were at a significant higher 
risk of having severe disease than their white counterparts (OR = 3.66; 
95%Cl, 2.04 to 6.55, p<0.001). This risk remained highly significant after 
controlling for area of residence, social class, family size, sex, and child's age 
(OR = 2.55; 95%Cl, 1.28 to 5.11, p=0.008). Exclusion of children from the 
rural area had no effect on the outcome (OR = 2.39; 95%Cl, 1.24 to 4.61, p= 
o. ol). 
In summary, children with black skin who have AD are about six times more 
likely to have severe disease than their white counterparts. This risk 
remained highly significant when parents assessed disease severity and after 
adjusting for potential confounders. Reliance on erythema scores in severity 
assessment system can mask severe disease in black children. 
3.2.2.1.2.2 Other Ethnic groups 
As shown in Table 23, the number of children with AD from "other" ethnic 
groups was very small. Also they have differing genetic backgrounds, thus, 
they were not considered for further analysis. 
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3.2.2.1.3 Child's atopy (asthma/hay fever) 
The data described here was collected from the one-page questionnaire of 
the UK diagnostic criteria for AD. Sixty-two (45%) and 59 (43%) children had 
a positive history of hay fever and asthma respectively. In total, 87 (64%) 
children had a history of atopy before joining the study. 
3.2.2.1.3.1 Child's hay fever 
Children who had ever had hay fever were 2.5 times more likely to have 
severe AD than those who did not (95%Cl, 1.44 to 4.3, p=0.001). Bronchial 
asthma in a child could be a potential confounder. Nevertheless, children with 
hay fever are still at higher risk of severe AD than those without hay fever, 
when asthma was included with other potential confounders in the analysis 
(OR = 2.42; 95%Cl, 1.39 to 4.2, p=0.002). 
3.2.2.1.3.2 Child's asthma 
Children who have had asthma have more severe disease than those who 
have never had asthma (OR = 1.95; 95%Cl, 1.34 to 3.34, p=0.016). This 
became statistically insignificant after adjusting for hay fever (OR = 1.67; 
95%Cl, 0.96 to 2.9, p=0.07). The independent effect, therefore, was due to 
hay fever and not bronchial asthma, but with a reasonably tight 95%Cl 
indicating that the data are consistent with the true odds ratio falling 
anywhere between these values. 
If hay fever was not included amongst other potential confounders, children 
with AD who had asthma were still at statistically significant high risk of 
having severe AD (OR = 2.0; 95%Cl, 1.1 to 3.6, p=0.021) than those who 
never had asthma. 
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3.2.2.1.3.3Any atopic disease in the child 
Children with any type of atopy, whether asthma or hay fever, were at a 
higher significant risk to have severe disease than those with no atopy at all 
(OR = 2.61; 95%Cl, 1.61 to 4.24, p<0.001). The relationships remained 
significant even after adjusting for potential confounders (OR = 2.86; 95%Cl, 
1.8 to 4.55, p<0.001). Food was not independently associated with the 
exposure and outcome, so it was not considered as potential confounders. 
3.2.2.1.4 Sex 
Although there were more females in the urban population, sex distribution in 
general was approximately the same 65 (47%) males and 72 (53%) females 
(Table 24). 
Table 24. Sex distribution by area of residence 
Region Male (%) Female (%) Total (%) 




Total 65(47) 72(53) 137 
Males are at a non-significant risk of severe disease than females (OR = 
1.19; 95%Cl, 0.72 to 1.97, p=0.49), with reasonably tight confidence 
interval. This non-significant relationship with disease severity persisted even 
after adjusting for potential confounders (OR = 1.41; 95%Cl, 0.83 to 2.42, p= 
0.2). Because of the potential observer's bias, parents' assessment of 
disease severity in the questionnaire was used as the outcome of interest, 
however the relationship between sex and disease severity remained 
insignificant (OR = 0.80-, 95%Cl, 0.48 to 1.39, p=0.45). Thus there was no 
evidence to suggest a significant difference in disease severity between 
males and females. 
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3.2.2.1.5 Birth weight 
The mean birth weight was 3368 grams (SID 601) and the lowest and highest 
birth weights were 1361 and 4423 grams respectively. In order to facilitate 
analysis, birth weight was ranked into three categories: low (below 2.5 
kilograms), average (between 2.5 and 4.0 kilograms), and more than average 
(more than 4.0 kilograms) as shown in Table 25. There were no data for 22 
(16%) children regarding birth weight which were not included in Table 25. 
Table 25. Ranked birth weiciht 
Birth weight ranking Number 
Less than 2500 grams (Low) 9( ) 
Between 2501 and 4000 grams (average) 92(80) 
More than 4000 grams (more than average) 14(12) 
Total 115 
An ordered logistic regression model revealed no significant association 
between disease severity and low birth weight (less than 2500 grams versus 
more) before (OR = 1.37; 95%Cl, 0.51 to 3.7, p=0.53) and after adjusting for 
breast-feeding, gestational age, mother's age when the child was born, social 
class, ethnic group, family size, area of residence, sex and age of onset (OR 
- 1.31; 95%Cl, 0.45 to 3.9, p=0.61). 
3.2.2.1.6 Gestational age 
The gestational ages of the premature group were 36 weeks 'in seven 
children, 35 weeks in one, 34 weeks in two, 33 weeks in two, and 32 weeks 
in one. Information about gestational age was missing in 14 (10%) children. 
The normal gestational age was taken as between 37 and 40 weeks 
inclusive. Premature and over dues were compared to this standard. Table 
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26 shows the ranked distribution of gestational age for 123 patients: 
premature, normal and over due. 
Table 26. Ranked distribution of aestational acie 
Ranked gestational age Number (%) 
Premature (32-36 weeks) 13(11) 
Normal (37-40 weeks) 73(59) 
Over due (41-42 weeks) 37(30) 
Total 123 
Premature children with eczema (36 weeks or less) have a slightly elevated 
risk of severe disease without reaching statistical significance (Table 27). 
Table 27. Odds ratio for severe disease bv ciestational acie 
Gestational age OR 95% CI P value 
Premature versus normal 1.26 0.4 to 3.96 0.69 
Over due versus normal 0.62 0.35 to 1.08 0.09 
Premature versus over due 2.0 T O. 62 to 6.54 0.24 
OR; Odds Ratio. Cl; Confidence Interval 
Adjusting for the following confounding factors: birth weight, family size, age 
of mother and gender did not affect the outcome. On the other hand, children 
with eczema who were born later than 40 weeks (41 weeks or more), are at a 
lower insignificant risk of severe disease. However, when children born 
prematurely (36 weeks or less) compared with over due children (41 weeks 
or more), premature children still have an insignificant risk of severe disease 
(see Table 27). 
Therefore neither birth weight nor gestational age was associated with 
severe disease, an association that remained insignificant after adjusting for 
potential confounders. 
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3.2.2.1.7 Family size 
Figure 7 shows that 57 (42%) children had one sibling (a brother or a sister), 
42 (31%) children had two brothers and/or sisters, 17 (12%) children had 
three or more brothers and/or sisters, and in 21 (15%) children the child was 
the only sibling in the family. As shown in the bar chart (Figure 71, the 
distribution in both areas was almost the same. The mean number of children 













One child only One sibling Two Three Four Five or more 
One child only means the patient was the only child in the family. One sibling means the patient and one 
brother or sister. Two means the patient and two bothers or sisters. Three means the patient and three 
bothers or sisters. Four means the patient and four bothers or sisters. Five or more means the patient and 
five bothers or sisters or more. 
Each bar represents the percentage of number of children 
Grossed bars = The total population 
Black bars = The urban population 
Grey bars = The rural population 
Figure 7. Percentage of sibling per area of residence and for the whole sample 
An increase in the number of children has not been significantly associated 
with disease severity over time (OR = 1.02; 95%Cl, 0.8 to 1.3, p=0.87) and 
remained insignificant after adjusting for potential confounders. A binary 
variable was created by dividing the number of children in the house into 
greater than two children and two or less. The number (2) was chosen based 
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on the national average of 2.4 children rather than using the results of 
multiple statistical testing and would hopefully be meaningful to the reader. 
There was a non-significant increase in the risk of having severe disease in 
families with 2 children or less (OR = 1.2; 95%Cl, 0.71 to 1.99, p=0.51) and 
this remained insignificant after adjusting for potential confounders (OR = 
95%Cl, 0.62 to 1.88, p=0.78). Thus family size had no significant 
association with disease severity. 
3.2.2.1.8 ChiI d's age 
The age range of this population was from 5 to 12 years, mean age 8.0 (SID 
years. Figure 8 and 9 show the mean SCORAD for each specific age 
group. Although the follow-up time was short, it was still possible to compare 
the different age group within this population. It is clear that disease severity 
remained almost the same in the different age groups, especially after 
excluding 37 (10%) observations in the upper and lower ages (5,11, and 12 
years) of this population (see Figures 8 and 9). The small number of 
observations in each age was the main reason for the exclusion, for example 
there was one observation only in the category 12 years and was not 
possible to have an error bar for it. 
In logistic regression, an increase in age had no significant effect on overall 
disease severity before (OR = 0.99; 95%Cl, 0.85 to 1.17, p=0.99) and after 
controlling for potential confounders (OR = 0.98; 95%Cl, 0.83 to 1.17, p= 
0.87). When child's age was ranked into two categories (5-7 vs. 8-12 years), 
regression analysis showed that the older age group were at non-significant 
lower risk of having severe disease than younger age group (OR = 0.79: 
950oCl, 0.49 to 1.25, p=0.31). Nevertheless, there was a non-significant 
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relationship between child's age and disease severity according to an 











Child's age in years 
Error bars = 95% Confidence interval 











Child's ar-ye in Years 
Error bars = 950o Confidence interval 
Figure 9. Mean SCORAD & 95%Cl for each age group after excluding 37 (10%) 
observations for children aged 5,11, and 12 years 
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3.2.2.1.9 Parental atopy 
Table 28 shows atopic diseases in the parents and in their families. It Is quite 
clear that there is more missing data about paternal than maternal atopy. 
Table 28. Atot)ic diseases in mother, father and their families 
Variable Eczema Asthma Hay fever (%) Atopy 
Maternal 
No 79 (58) 87 (63) 77 (56) 52 (38) 
Yes 31 (22) 23 (17) 33 (24) 58 (42) 
Missing 27 (20) 27 (20) 27 (20) 27 ( 
Paternal 
No 81 (59) 84 (61) 70 (51) 52 (38) 
Yes 18 (13) 15 (11) 29(21) 47 ( 4) 
Missing 38 (28) 38 (28) 38 (28) 38 (28) 
Mother's family 
No 67 (49) 61 (45) 67 (49) 40 (29) 
Yes 40 (29) 44 (32) 40 (29) 67 (49) 
Missing 30 (22) 32 (23) 30 (22) 30 (22) 
Father's family 
No 73 (53) 72 (53) 84 (61) 55 (40) 
Yes 27 (20) 28 (20) 16 (12) 45 (33) 
Missing 37 (27) 37 (27) 37 (27) 37 (27) 
3.2.2.1.9.1 Parents' Eczema 
Mothers and fathers who had suffered from eczema were identified in 31 
(22%) and 18 (13%) children respectively. In this population children with AD 
whose mother had suffered from eczema had a lower mean SCORAD than 
those whose mother had never suffered from eczema (Table 29). Paternal 
eczema produces an opposite trend. In an ordered logistic regression with 
the mean SCORAD as the outcome, children with a positive history of 
paternal eczema had a non-significantly higher risk of having severe disease 
than those whose father's had no eczema. On the other hand, children 
whose mother had eczema had a non-significant lower risk of severe disease 
than those whose mother's had no eczema (Table 29). This opposite 
parental effect remained insignificant after adjusting for breast-feeding, area 
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of residence, age at onset, ethnic group and social class (OR = 0.82; 95%Cl, 
0.43 to 1.58, p=0.56 for maternal eczema, and OR = 1.31; 95%Cl, 0.45 to 
3.76, p=0.5 for paternal eczema). However the number of children whom 
mothers had eczema (10 children) versus paternal eczema only (7 children) 
were too small to draw any conclusion. 
Table 29. Mean SCORAD and Odds Ratio bv Parental eczema, asthma, or hav fever 
Mean SCORAD 
Exposure Yes No OR 95% Cl P value 
Maternal eczema 8.7 10.7 0.78 0.42 to 1.47 0.44 
Paternal eczema 12.5 9.9 1.25 0.48 to 3.22 0.65 
Maternal asthma 10.4 10.1 1.5 0.6 to 2.2 0.67 
Paternal asthma 7.6 10.9 0.65 0.28 to 1.5 0.32 
Maternal hay fever 12.8 9.2 1.9 0.95 to 3.8 0.07 
Paternal hay fever 14.1 9.1 1.9 0.8 to 4.5 0.14 
Maternal atopy 10.6 9.7 1.3 0.75 to 2.25 0.35 
Paternal atopy 12.3 8.9 1.8 0.98 to 3.32 0.06 
OR; Odds Ratio. Cl; Conticlence Interval 
3.2.2.1.9.2 Parent's asthma and/or hay fever 
Parents' asthma and/ or hay fever had a non-significant predictive value for 
AD severity (see Table 29). However, maternal hay fever had a marginally 
insignificant effect. All these factors were not considered for further analysis 
such as controlling for confounding effects because information bias 
regarding these factors was potentially high. 
3.2.2.1-9.3 Paternal and maternal atopy 
Table 28 shows that 42% and 34% of children's mothers and fathers were 
reported to be atopic. Children with atopic fathers are at a marginally 
significant higher risk to have severe disease than those whose fathers were 
not atopic (asthma, hay fever or eczema). Atopy in the mother showed the 
same trend with overlapping 95% confidence intervals (see Table 29). 
However, the small number of atopic mothers only versus atopic fathers did 
not allow direct comparison between the two variables. 
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3.2.2.1.10 Atopic diseases in siblings (brothers and sisters) 
Siblings of 41 (30%), 29 (21%), and 20 (14%) children had suffered from 
eczema, asthma, and hay fever respectively. In ordered logistic regression, 
atopy in sibling has no significant association with disease severity (see 
Table 30). The statistically insignificant results and potential risk of bias due 
to high percentage (26%) of missing values made considering these finding 
for further statistical analysis inconclusive and will not be discussed further. 
Table 30. Number of sibling (brothers and sisters) with and without atopic disease and 
the odds ratio for severe AD with 95%Cl 
Exposure Number OR 95%Cl P value 
Yes No Missing 
Eczema 41 (30) 61 (44) 35(26) 0.84 1 0.45 to 1.54 0.56 
Asthma 29(21) 73(53) 35(26) 1.59 0.74 to 3.44 0.23 
Hay fever 20(14) 82(60 35(26) 1.78 0.83 to 3.73 0.14 
OR; Odds Ratio. Cl; Confidence Interval 
147 
3.2.2.1.11 Summary of intrinsic factors 
0 Children with atopic dermatitis starting during the first year of life are 
almost two times more likely to have severe disease than those with 
eczema starting later. Early onset AD is an important predictor of more 
severe disease later in life (5-12 years). 
* Children with black skin who have AD are about six times more likely to 
have severe disease. 
Reliance on erythema scores can mask severe disease in black children. 
A point that should always be considered in measuring disease severity in 
patients with pigmented skin 
* Children with atopic dermatitis who have other atopic diseases (asthma 
and/or hay fever) were at a higher significant risk of severe disease than 
those who had not had any atopic diseases. 
Family size, sex, birth weight, gestational age, child's age, any atopy (hay 
fever, asthma, or eczema) in parents, and any atopy in siblings have no 
significant association with disease severity. 
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3.2.2.2 Extrinsic factors as the exposure 
3.2.2.2.1 Area of residence 
The study included two populations from two different areas of residence 
(urban/rural) in the UK. Eighty-two (60%) children living in south London 
represented the urban population and 55 (40%) children resident in mid 
Wales represented the rural population. 
Children with atopic dermatitis in south London have a significantly higher 
risk of severe disease than their counterparts in mid Wales (OR = 1.87; 
95%Cl, 1.12 to 3.11, p value = 0.017). This difference remained statistically 
significant after adjusting for sex, family size, social class, ethnic group, and 
child's age (OR = 2.15; 95% Cl, 1.12 to 4.1, p value = 0.021). 
However, one should bear in mind observer bias, as the investigator was 
aware where the cases came from, urban or rural area. So, was there a 
chance that the urban patients could have been given a high score? To 
determine this, the observer scores (SCORAD-D) were excluded and 
parýents' scores (subjective symptoms) were used on their own, which was 
significantly correlated to observer's scores (SCORAD-D) at each visit (see 
Table 16). The odds ratio increased to 2.79 (95%Cl, 1.68 to 4.5, p<0.001) 
for the total subjective symptom score, 2.6 (95%Cl, 1.59 to 4.2, p<0.001) for 
pruntus, and 3.65 (95%Cl, 1.85 to 7.1, p<0.001) for sleep loss. The observer 
appeared to have no effect on this scoringas it was completely scored by the 
parents on a visual analogue scale. However, intra-observer variability 
cannot totally be excluded, as the investigator could not be blinded for area 
of residency. The risk of severe disease in the urban group remained highly 
significant even when the SCORAD and its components were excluded from 
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the analysis and parents' assessment of disease severity on 0 to 10 
analogue scale was used in its own (OR = 2.78-, 95%CL 1.65 to 4.69, p 
0.001). 
In summary, children who live in the urban area have more severe atopic 
dermatitis than their white counterparts living in a rural area. This significant 
difference remained the same when three different way of severity 
assessment were used. 
3.2.2.2.2 Social class 
Children were classified by the father's job on recruitment; the mother's job 
was used with single mothers or where the father was unemployed and she 
was employed. The social classes ranking was formed according to the 
Registrar General classification (Leete and Fox., 1977). For 75 (55%) 
children, parents were ranked in social classes 1,11 and 111-non-manual, and 
32 (23%) children ranked in social classes 111-manual, IV, and V. Parents of 
30 (22%) children were unemployed, of these 27 (20%) children were in the 
urban area (see Table 31). These figures represent a wide variation of social 
classes. In this population the unemployment rate was higher in the urban 
than rural areas (33% versus 5%). On the other hand there were more 
children from social class 11 in the rural area than the urban; 34% versus 13% 
respectively, because of the farming industry in the area. Apart from social 
class 11 and unemployment, the distributions of other social classes were 
almost the same in both areas. 
150 
Table 31. Social class distribution bv area of residencv and for the whole samole 
Social ciass Urban (%) Rural (%) Whole population 
One 9 (11) 7 (13) 16 (12) 
Two 11 (13) 19 (34) 30 (22) 
Three non-manual 17 (21) 12 (22) 29 (21) 
- manual 2 (3) 1 (2) 3 (2) 
Four 11 (13) 6 (11) 17 (12) 
Five 5 (6) 7 (13) 12 (9) 
Unemployed 33) 3( 5) 30 (22) 
Figure 10 shows no gradient trend in the mean SCORAD from high to low 
social classes. Children in social class four have the highest mean score and 
children in social class two have the lowest mean score. The small number of 
subjects in social class three-manual reflected by the wide confidence 







sc I SC2 SC3N SC 3M SC4 SCS 
Social Classes 
Writenk 
SC1 = Social class 1, SC2 = Social class 2, SC3N = Social class 3 Non-manual, SC31VI = Social class 3 
Manual, SC4 = Social class 4, SC5 = Social class 5, Unem = unemployment 
Error bars = 95% Confidence interval 
Figure 10. Mean SCORAD and 95%Cl per each social class 
SC4 
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Children in social classes one and two were compared with those from other 
social classes. There was no significant difference in disease severity 
between children in social class I and 11, and those in other social classes 
(OR = 1.02; 95%Cl, 0.57 to 1.8, p=0.95). The effect remained insignificant 
after adjusting for potential confounders and therefore social class had no 
significant association with disease severity. 
3.2.2.2.3 Food 
Parents of 36 (27%) children reported that some kind of food made their 
child's eczema worse and parents of 60 (44%) children reported no food 
effect, while parents of 39 (29%) children did not know whether food had an 
effect or not. Data were missing in 2 children (Table 32). 
Table 32. Eczema and food with severitv scores 
SCORAD SCOR AD-D 
Eczema gets Number (%) Mean Median Mean Median 
worse by (SD) (95%Cl) (SD) (95%Cl) 
food 
No 60(44) 110.0 8 7.2 5 
(10.3) (7 to 10) 0 03\ (0.01 (4 to 7) 
Yes 36(27) 15.2 12 10.4 8 
1 (13.3) (9 to 17) (10.8) (7 to 11) 
DK 39(29) 7.7 4 4.9 0 
1 (9.5) (3 to 7) (7.2) (0 to 
uK; uon i Know 
Those who reported food effects mentioned the following foods as being 
responsible for their children's eczema exacerbation; dairy products 
(including milk, cheese, yoghurt), eggs, fish (including sardines), chocolate, 
coloured drinks (including squash and cola), crisps and snacks, fresh fruit 
(includes apple, satsuma, citrus fruits, strawberries, banana, orange), 
sweets, and other (pork, yeast, fried food, porridge oats, raw potato). Most of 
the foods already mentioned have potential antigenic properties. 
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The mean SCORAD and SCORAD-D was higher for those who answered 
94 yes" than those who answered "no", and the lowest score was for those who 
answered "don't know". The median scores had the same trend (Table 32). 
Answering "yes" to the question about food (question number 32 in the 
recruitment questionnaire) was associated with a higher risk of severe atopic 
dermatitis than answering "no" (OR = 2.1; 95%Cl, 1.08 to 4.07, p=0.029). It 
became statistically insignificant after controlling for potential confounders 
(OR = 1.9; 95%Ci, 0.89 to 4.2, p=0.09). Therefore some kinds of food were 
associated with increased disease severity that became statistically 
insignificant after adjusting for potential confounders. 
3.2.2.2.4 Wool 
In this population 59 (43%) children had no reaction to wool and 68 (50%) 
children had reacted to wool and data were missing in 10 (7%) children who 
were not included in the previous descriptive statistics. Children with AD who 
reacted to wool were almost two times (OR = 1.8; 95%Cl, 1.06 to 2.98, p= 
0.03) more likely to have severe disease than those who do not. The 
relationships remained significant even after excluding subjective symptoms 
scores (OR = 1.73; 95%Cl, 1.02 to 2.95, p=0.043). However, this became 
statistically insignificant after adjusting for area of residence (OR = 1.45; 
95%C 1,0.83 to 2.54, p=0.19). 
Children who had reacted to wool were about two times more likely of having 
severe atopic dermatitis than those who had not reacted; an association that 
became statistically insignificant after adjusting for area of residence. 
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3.2.2.2.5 Breast feeding 
Forty (29.6%) children received no breastfeeding at all, 40 (29.6%) received 
breast-feeding for 3 months or less, 55 (40.8%) children were breast fed for 
more than three months, and data were missing in 2 children. There was no 
gradient trend in disease severity between the frequencies of breast-feeding, 
see Table 33. 
Table 33. Breast feedinq distribution and mean SCORAD 
Frequency of feeding Number (%) Mean SCORAD (SD) 
No feeding 40(29.6 9.6(11.6) 
3 months or less 40(29.6 a 11.9(11.9) 
More than 3 months -ý 55(40.83) 10.7(10.6) 
No significant association was seen between breast-feeding (expressed in 
the form of a yes/no binomial variable) and total severity score before and 
after adjusting for potential confounders (Table 34). Positive history of hay 
fever and/or asthma were not included in the adjustment because their 
effects could be part of the outcome and therefore were not independently 
related to exposure and outcome. 
When the duration of breast-feeding was divided into two categories (Breast 
feeding for 3 months or less versus more than 3 months), no significant 
association was detected between the duration of breast-feeding and disease 
severity, before and after adjusting for potential confounders (Table 34). 
Table 34. Odds ratio (OR) of severe disease for breast feeding before and after 
adiustino for notential confounders 
Breast feeding for ... Crude 
OR p Adjusted OR P 
(95%CI) ('95%Cl) 
3 months or less versus none 1.36 0.28 1.39 0.31 
(Yes/No) (0.78 to 2.4) 1 (0.73 to 2.65) 
More than 3 months versus 0.93 0.82 0.96 0.91 
3 months or less ý0.51 to 1.7) 
1 
(0.52 to 1.78) 
P: p-value. OR; Odds Ratio. (A Gontidence interval 
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3.2.2.2.6 Other extrinsic factors 
Frequency of household vacuuming, frequency of mattress vacuuming, 
presence of fitted carpets, type of heating, having pets, site of the house, 
distance of the house from the main road, or trees in the front of the house all 
had no significant effect on disease severity and therefore this will not be 
discussed any further. 
3.2.2.2.7 Summary of extrinsic factors 
9 Children who live in the urban area had a higher significant risk of severe 
disease than their counterparts who live in the rural area. 
e Children who had reacted to wool were at a significant higher risk of 
severe disease than those who had not reacted and this became 
insignificant after adjusting for the area of residence. 
9 Children whom their parents reported that food had made the eczema 
worse had the same trend as reaction to wool. 
9 Social class and breastfeeding were not significantly associated with 
disease severity. 
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3.2.3 Independent risk factors for AD severity over time 
When urban area, age at onset, asthma and hay fever were only included in 
ordered logistic regression, the effect of each of these factors remained 
independently and significantly related to disease severity (Table 35). 
Table 35. Odds ratio for severe atopic dermatitis by area of residence, age at onset, 
asthma. hav fever. child's atoDv. and black skin 
Risk factor OR 95% Cl P value 
Urban area 1.95 1.17 to 3.23 0.01 
Onset during the first year of life 1.9 1.15 to 3.13 0.013 
Child's asthma 1.8 1.02 to 3.18 0.042 
Child's hay fever 2.2 1.24 to 3.83 0.009 
Child's atopy 2.7 1.66 to 4.4 0.000 
Black skin 5.2 1.75 to 15.2 0.003 
OH; Odds ratio: Cl; Conticlence Interval 
The risk remained independently significant for all these factors when history 
of asthma and/or hay fever considered as positive history of atopy in the 
children and when black children, atopy in child, urban area, and age of 
onset were included and adjusting for erythema scores. These factors 
retained their significant and independent association with disease severity 
over time. 
156 
3.3 Section 3: Quality of life 
Quality of life in the child and family was quantified by two different 
questionnaires on two occasions (March and October 1999). Social class, 
ethnic background, child's age, family size, area of residence (urban/rural) 
and sex were controlled for and referred to as potential confounders. 
3.3.1 The family's quality of life 
The DFI was used to assess the impact of children's eczema on their family 
and the higher the score the worse the impact (Lawson, et al, 1998). 
3.3.1.1 The total DFI at visits one and two 
The numbers of children presented in the summary statistics are those who 
attended each quality of life visit. For instance 116 and 120 children attended 
the first and second QOL assessment visits respectively. Of 116 attending 
the first visit, 106 attended the second visit. The percentage and mean DFI 
score for the two groups are shown in Table 36. 
Table 36. Percentage and mean DFI scores for 106 children attending both visits and 
total number at each visit 
Number of childre seen per each visit 
DFI Visit one Visit two 
116 106 120 106 
Percentage affected 
(scored more then zero on DFI) 
45% 45% 33% 36% 
Mean score 2.32 2.39 1.88 
Table 36 shows clearly that the 14 chiidren who attended the second but not 
the first visit, did not have any substantial effect on the mean DFI score nor 
on the percentage of those who scored more than zero on DR. Therefore, 
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the total number will be included in the cross sectional description and 
excluded in comparison between the two visits. 
The DFI was filled in by the mother in 115 (99%) children and by the father in 
one child only during the first quality of life assessment visit (March 1999). 
On the final visit used to assess the family's quality of life (October 1999), the 
DFI was completed by the mother in 119 (99%) children and by the father in 
one child. Parents of 111 (96%) children with a mean DFI score 2.4 (SID 4.3) 
and parents of 118 (98%) children with a mean DFI score of 1.8 (SID 4.3) had 
answered all the 10 questions of the DFI at visits one and two respectively. 
The initial mean of DFI for the total number of 116 subjects was 2.3 (SID 4.3) 
and six months later the mean final DFI for 120 subjects was 1.9 (SID 4.3). It 
was clear that there were no significant differences between those who 
answered all the questions and those who did not complete the whole 
questionnaire. It was therefore decided to include the scores for the total 
number and giving zero scores for missing answers. 
The medians of DFI for the first and second visits were 0 (upper quartile 3, 
lower quartile 0) and 0 (upper quartile 1, lower quartile 0) respectively, 
representing a non-significant improvement perceived by the parents (p= 
0.1) 
Although the maximum score of the DFI is 30, in this study the maximum 
scores were 21 and 25 at the first and second visit respectively. Families) 
quality of life was affected in the household of 52 (45%) and 40 (33%) 
children during the first and final visits respectively. In other words, these 
figures show the percentage for those who scored more than zero on the DFI 
at each visit. Figure 11 shows the percentage per aspect of families' life 
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affected by the children's eczema for 116 and 120 children attending visits 
one and two respectively. 
The total DFI scores were significantly correlated with SCORAD-D at visits 
one (rý-- 0.19, p=0.042) and two (r%-- 0.32, p<0.001). In multiple regression 
analysis and after controlling for potential confounders, each unit increase in 
SCORAD-D led to a 0.21 unit increase in DFI (95%Cl, 0.07 to 0.36, 
0.004) during the initial visit. On the final visit each unit increase in 
SCORAD-D was significantly associated with a 0.38 unit increase in DFI 
(95%Cl, 0.16 to 0.59, p=0.001). In other word this mean that a 10 units 
increase in the SCORAD-D was associated with 3.8 units increase in the DFI 
at visit two. 
The DFI was also significantly correlated to the parents' grading of diseases 
status on a0 to 10 scale at the first (rý-- 0.51, p<0.001) and second (r= 0.49, 
p<0.001) visits. This shows that AD severity had a direct impact on family's 









c >% U) 
E 
m 1- 4-d «a 
U) %6- 3. - cu 4-0 0 
m CL) 0 (D 0 m Q ii a) 1- . (L) L- 





0 m r_ r_ 
. 
0 0 . c M 
« 0 r a (n C 0 r 0 L 0 4-1 CL m m Fn :. 0 
E 0 E 












































Z-- a5 E-L 
-u 0 



















3.3.1.2 Each aspect of the DFI on visit one and two 
The 10 items shown in Figure 11 form the total DFI scores. During the first 
visit for example, the highest impact was on the main carer's life (22%) and 
family leisure activities such as swimming (22%). The lowest impact was on 
time spent on shopping by the family (9%) and on the relationships between 
the main carer and partner or between the main carer and other children in 
the family (10%). It was apparent that eczema in 24 (21%) children had 
affected the sleep of others in the family and in 23 (20%) children the 
expenditure of family such as costs related to treatment or clothes had been 
affected by their eczerna. 
On the second visit the same trend was seen except that the highest impact 
was on housework (18%) and causing emotional distress (18%) (see Figure 
11). There was also a marked drop in the impact on family leisure activities, 
from 22% on the first visit to 12% on the second visit, which was statistically 
significant (p = 0.013). 
Table 37 shows the relationship between the objective scores and each of 
the DFI components. Although the highest score of SCORAD-D was about 
20 times more than the highest score of each component of the DFI, an 
increased eczema severity in the children assessed by the observer had led 
to significant impact and high scores on the family's house work, sleep in the 
family, emotional distress, and the main carer's life at each visit. The 
relationship between eczema severity and causing tiredness was significant 
at the first visit but not at the second visit. 
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Table 37. Relationships between disease severity (SCORAD-D) and the DFI 
components 
Visit One Visit Two 
The DFI components 
R* 95%Cl P value R* 95%Cl P value 
House work 0.06 0.01 to 0.11 0.023 0.08 0.001 to 0.15 0.043 
Food preparation 0.01 -0.05 to 0.06 0.75 0.07 1 -0.05 to 
0.19 0.23 
Sleep in the family 0.05 0.004 to 0.089 0.032 0.09 0.02 to 0.17 0.017 
Family leisure 
activities 
0.04 -0.01 to 0.08 0.09 0.07 -0.0 1 to 0.15 0.09 
Time spent on 
shopping 
0.02 -0.06 to 0.09 0.59 0.05 -0.05 to 0.15 0.3 
Costs related to 
treatment 
0.001 -0.05 to 0.05 0.96 0.06 -0.004 to 0.13 0.07 
Causing tiredness 0.09 0.2 to 0.15 0.015 0.08 -0.02 to 0.17 0.1 
Causing emotional 
distress 
0.05 0.003 to 0.1 0.037 0.11 0.05 to 0.17 0.001 
Relationships in the 
family 
0.06 -0.01 to 0.12 0.09 0.11 -0.01 to 0.23 0.07 
Main carer's life 0.06 0.01 to . 011 0.017 0.1 0.04 to 0.17 0.003 
Bold; Statistically significant results (p value less than 0.05). 
Cl; Confidence Interval. R*; Regression coefficient 
3.3.1.3 The DFI at visits one and two by site 
The following findings are for all children seen in visits one and two (116 and 
120 children), in which the mean DFI scores for 5 body regions (Face and 
neck, chest and abdomen, upper limb, back, and lower limb) were 
considered. The mean and median DFI scores were compared between sites 
with visible eczema and those free of eczema and between each other. 
Tables 38 and 39 show quite clearly that visible eczema at any site of the 
body had more impact on family's quality of life than areas free of eczema at 
any visit. For instance, the mean DFI at visit one was about three times more 
in children with visible eczema on the back than those without any visible 
eczema. Eczema on the back had the highest impact on family's quality of 
life 4.9 (SD 5.7), which perhaps due to large surface area of the back. Visible 
eczema on the other sites of the body had a lower mean score than visible 
eczema on the back [chest and abdomen 4.5 (SD 6.0), face and neck 3.3 
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(SD 5.2), upper limb 3.1 (SID 4.5) and lower limb 2.9 (SID 4-5)]. Visible 
eczema during the second visit nearly had the same trend, except eczema 
on the chest and abdomen that had a higher impact than on the back (see 
Table 39). This reflects the crude sensitivity of the DFI to visible eczema and 
the ability of DFI to pick up a higher score when there was visible eczema. 
Statistical tests were not carried out because it was very difficult to control for 
the effect of other areas involved. 
Table 38. Number of site involved with median and mean values for the DFI score 
(95%Cl) per each visible eczema on each site of the body at the first quality of life 
assessment's visit for 116 children 
Site involved 
Number of children 
with visible eczema 
(Median DF11) 
Mean DF11 (95%Cl) according to 
visible eczema per site 
Yes No Yes (95%Cl) No (95%Cl) 
Back 18(2.5) 98(0) 4.9 (2.1 to 7-8) 1. (1.1 to 2.6 
Chest and abdomen_ 14(2) 102(0) 4.5 (1.0 to 8.0) 2.0 (1.3 to 2.8) 
Face and neck 23(l) 93(0) 3.3 (1.0 to 5.5) 2.1 (1.3 to 2.9) 
Upper limb 56(l) 60(0) 3.1 (1.9 to 4.3) 1.6 (0.6 to 2.6) 
Lower limb 42(l) 74(0) 
- 
2.9 (1.9 to 4.3) 2.0 (1.1 to 3.0) 
Cl; Conticience Interval 
Table 39. Number of site involved with median and mean values for the DFI score 
(95%Cl) per each visible eczema on each site of the body at the second quality of life 
assessment's visit for 120 children 
Site involved 
Number of children 
with visible eczema 
(Median DF12) 
Mean DF12 (95%Cl) according to 
visible eczema per site 
Yes No Yes (95%C No (95%Cl) 
Chest and abdomen 1 101 (0) 
- 
5.0 ( 1.3 to 8.7) 1.3 (0.7 to 1.9) 
_ Back 23 97(0) to 7.9) 1.2 (0.6 to 1.8) 
Face and neck 18(l) 102(0) 3.8, ( 0.6 to7.1) 1.5 (0.8 to 2.3) 
Lower limb 38(l) 82(0) .7 to5.4) 1.1 0.4 to 1.8) 
Upper limb 44(l) 76 .4 to 4.9) 1.1 (0'. 4 to 1.9) Cl: Confidence Interval 
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3.3.1.4 Changes in DFI and SCORAD-D scores over 6 months 
The results from parents of 106 children (53 females) who completed the DFI 
in both visits are reported here. The children mean age was 7.9 and 8.4 
years at the initial and final visits respectively. Family quality of life was 
affected in 54 (51%) children on at least one visit - 48 (45%) at the first visit 
and 38 (36%) six months latter. The initial mean of DFI for 106 subjects was 
2.4 (SID 4.4). Six months later the mean final DFI was 1.9 (SID 4.2)9 
representing a non-significant improvement perceived by the parents (p= 
0.1). Age, sex, family size, location and social class were not significantly 
related to changes in DFI, The initial mean of SCORAD-D for 106 children 
was 8.2 (SID 10.2) and six months later the mean final SCORAD-D was 7.7 
(SD 8.7), representing a non-significant improvement documented by the 
study investigator (p = 0.74), which was expected in an observational study 
of mostly mild eczema cases. 
The mean change in DFI was -0.5 (SD: 3.55), range -21 to 11 and in 
SCORAD-D was -0.5 (SID: 8.6), range -22 to 21. Of 106 children who 
attended both visits, 54 (51%) children were included in interval regression 
analysis because their eczema had affected their families' life. In other 
words, the parents scored more than zero on the DFI on at least one 
occasion. In multiple regression analysis, each unit change in SCORAD-D 
was associated with a 0.17 (95%Cl, 0.06 to 0.29, p=0.002) unit change in 
family quality of life. After adjusting for potential confounders each unit 
change in SCORAD-D led to a 0.16 (95%Cl, 0.04 to 0.27, p=0.008) unit 
change in DFI. Therefore, change in the DFI was significantly associated with 
change in the SCORAD-D. 
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3.3.1.5 Changes in the DFI Components and SCORAD-D over 6 months 
Figure 11 shows the percentage per aspect of family's life affected by their 
children's eczema at each visit for all children who attending visit one and 
two. Changes in SCORAD-D were investigated for relation to each 
component of the DFI for those who attended both visits. 
Examination of the relation between changes in each of the DFI components 
and in SCORAD-D revealed that the strongest and significant associations, 
although small, were seen in changes in the impact of eczema on family 
leisure activities such as swimming (p = 0.002) and causing tiredness or 
exhaustion on the child's parents (p < 0.001), see Table 40. The significant 
relation between changes in disease severity and changes in the impact of 
eczema on family leisure activities persisted after controlling for potential 
confounders (R = 0.04; 95%Cl, 0.01 to 0.06, p=0.002). Change in "causing 
tiredness or exhaustion" also remain significantly related to changes in 
SCORAD-D after adjusting for potential confounders with narrower 95% 
confidence interval (R = 0.03; 95%Cl, 0.03 to 0.04, p<0.001). Relation 
between change in SCORAD-D and other components of the DFI were weak 
and not significant (Table 40). 
Table 40. Relation between change in SCORAD-D scores and change in each 
components of the DFI 
Change in SCORAD-D 
Change in the ............. R 95%Cl P value 
House work -0.01 -0.05 to 0.03 0.57 
Food preparation -0.01 -0.07 to 0.05 0.82 
Sleep in the family 0.01 -0.03 to 0.05 0.73 
Family leisure activities 0.04 0.02 to 0.07 0.002 
Time spent on shopping* *96 and 98 of the 106 scored zero 
Costs related to treatment 0.01 -0.01 to 0.04 0.21 
Causing tiredness 0.04 0.03 to 0.05 < 0.001 
Causing emotional distress 0.03 1 -0-01 to 0.06 0.12 
Relationshi s in the f *94 and 99 of the 106 scored zero 
Main carer's life 0.01 1 -0.02 to 0.04 1 0.37 
*Large number ot zero scores eacn wsit so interval regression analysis was not possible 
Bold: statistical significant. R. Regression coefficient. Cl; Confidence Interval 
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3.3.1.6 Summary of the family's quality of life 
* Family's quality of life was affected in the household of 45% and 33% of 
children on the first and second visits respectively, a finding that provide 
an evidence for the burden caused by mostly mild AD. 
e There is a positive effect of increased disease severity on DFI scores. It 
implies that increased severity can lead to impairment in family's quality of 
life. The ultimate outcome of this provides a construct validity of the DFI in 
a community-based study. 
9 Changes in DFI scores were significantly correlated with changes in 
disease severity scores before and after adjusting for potential 
confounders. 
9 The DFI as a tool for assessing the impact of childhood atopic dermatitis 
on the family's quality of life was able to detect higher scores for the DFI 
when there is visible eczema than when there is no eczema seen. 
finding that reflects the DFI crude validity. 
* Scores in the questions concerning the main carer's life, house worký 
sleep in the family, and causing emotional distress were significantly 
correlated to the observer's scores of diseases severity at each visit. 
9 In conclusion, increased atopic dermatitis severity in children had led to 
increased impairment of their families' quality of life. The DFI was a 
practical tool to assess the impact of children's eczema on their family in 
a community-based study with mostly mild disease. 
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3.3.2 The children's quality of life 
3.3.2.1 Age and completion of the CDLQI on visits one and two 
The CDLQl was used to quantify the impact of AD on the children's life 
(Lewis-Jones and Finlay., 1995). In total 116 and 120 children attended the 
first and second quality of life assessment visits respectively. At visit one 
(March 1999), 78 (67%) children were able to complete the CDLOI, mean 
age 8.6 years, [44 (56%) females and 34 males], while 38 (33%) were unable 
to complete the CDLQl mean age 6.5 years, [16 (42%) females and 22 
males]. On the final visit (October 1999), 90 (75%) children were able to 
complete the CDLQl, mean age 9.0 years, [52 (58%) females and 38 males], 
while 30 (25%) children were unable to complete the CDLQl mean age 7.1 
years, [10 (33%) females and 20 males]. Seven children of the 38, who did 
not complete the CDLQl on the first visit, had completed it on the final visit. 
These 7 children were not included in the analysis. 
On the first visit, the mean age of children who were unable to complete the 
CDLQI (6.5 years) was lower than those who completed the questionnaire 
(8.6 years), and on the second visit, the same trend was seen (7.1 and 8.9 
years). There were also more males among those who were unaUe to 
complete the CDLQl (16 female and 22 male), despite higher number of 
females on each visit. Inability of the child to read without the help of parents 
was the main reason for not completing the CDLQII, even though other 
reasons cannot totally be excluded. Table 41 shows that all children aged 9 
or more were able to complete the CDLQI, except one child who was unable 
to complete it. He was unable to read according to his mother. He fulfilled the 
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UK diagnostic criteria, had a visible eczema on visit one, and had cleared on 
the final visit. 
Table 41. Children acie and completion of the CDLQl on visits one and two 
Visit One Visit Two 
Children's age 
Completing the CDLQl Completing the CDLQl 
Yes (%) No (%) Yes (%) No (%) 
6 years 5(18) 23(82) 1 (20) 4 (80) 
7 years 16(62) 10(38) 16 (44) 20(56) 
8 years 16(80) 4(20) 17 (77) 5(23) 
9 years 18(100) 0_(O) 21 (100) . 0(0) 
10 years 14(93) 1 (7) 17 (94 1 (6) 
11 years 9(100) 0(0) 17 (100 0(0) 
12 years _ None None 1 (100) 0(0) 
Total 78 38 90 30 
Results that were shown in Table 41 raise a question about applicability of 
the CDLQI in assessment of quality of life in children aged 7 years or less. 
The literacy level varies from one child to another and social class may have 
an effect as well. However, there was insignificant difference between those 
who completed the CDLQl and those who did not in factors such as social 
class, ethnic background, and family size. 
3.3.2.2 The CDLQI on both visits by gender 
Males had a higher mean score than females on the first visit (4.66 vs 4.26), 
but on the second visit males and females almost had the same mean score 
(3.15 vs 3.16). The differences in the total CDLQl between males and 
females was not statistically significant on both visits (p = 0.35 and 0.3 
respectively), as well as in each component of the CDLQI, except teasing 
scores on visit two. 
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Figures 12 and 13 show the mean scores of each component of the CDLQI 
for 71 males and females attending both visits. There was no significant 
difference between each components of the CDLQI except for teasing 
scores. During the second visit, males had a higher mean score for teasing 
(0.31) than females (0.13), which was statistically significant (p = 0.021). 
While on the first visit, the mean score for teasing was higher in females 
(0.26) than males (0.24), but was statistically insignificant (p = 0.41). Also, 
there was no evidence of any significant correlation between teasing scores 
of both sex and any components of the objective SCORAD (extent, total 
intensity, erythema, oozing, oedema/papulation, excoriation, and 
lichenification) on any visit. However, male scores on the CDLQl had a 
stronger association with disease severity than females (see Table 42). 
Table 42. Correlation between the CDLQl and SCORAD bv sex 
Sex Visit One Visit Two 
R P value r P value 
Male 0.56 < 0.001 0.66 < 0.001 
Fernale 0.39 0.002 0.45 < 0.001 
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3.3-2.3 The total CDLQl on visits one and two 
Children's quality of life was affected in 72 (92%) and 71 (79%) children 
during the first and final visits respectively. The previous figures were for the 
78 and 90 children who completed the CDLQl at the first and second visits 
respectively. However, of the 78 children who had completed the CDLQl 
during the first visit, 71 (91%) attended the second visit. Data for the 71 
children attending both visits were included in the analysis in order to 
compare the two visits for the same group of children. Table 43 shows the 
number, mean age, sex, and ethnic distribution of these children. The 
children's quality of life was markedly affected in 65 (92%) and 55 (77%) in 
the 71 children attending both visits, a similar figure to the total number of 
children attending each visit. These percentages represent those children 
who scored more than a zero on the CDLQI. 
Table 43. Number, mean age, sex and ethnic distribution of children with AD who were 
able to comi: )Iete the auestionnaire on both visits 
Visit One Visit Two 
Total number 78 children 71 children 
Mean age 8.6 years 
8.5 years for 71 
8.9 years 
Felmale 44(56%) 38(54%) 
Male 34(44%) 33(46%) 
African skin 17 (22%)_ 13(18%) 
White 55(70%) _ 52(73%) 
Otherraces 6(8%) 6(9%) 
Of the 71 children attending both visits 38 (53%) showed an improvement, 12 
(17%) remained unchanged, and (21) 30% showed an increase in the CDLQI 
scores. The initial mean of CDLQl for 71 children was 4.5 (SID 4.2), and 6 
months later the final mean CDLQl was 3.2 (SD 3.7), representing a 
significant improvement perceived by the children (p= 0.007). 
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The CDLOI was significantly correlated with the SCORAD on the first and 
second visits (r = 0.52, p<0.00 1) and (r = 0.59, p<0.00 1) respectively. This 
remained significant even after controlling for potential confounders on visits 
one (R = 0.13; 95%Cl, 0.05 to 0.2, p=0.002) and two (R = 0.18; 95%Cl, 
0.08 to 0.3, p=0.001). That is each unit increase in SCORAD had led to an 
average 0.15 unit increase in the CDLQI. 
When the subjective scores were excluded from the SCORAD Index, the 
CDLQl remained significantly related to severity scores on the first and 
second visits (r = 0.46, p<0.001) and (r = 0.53, p<0.001) respectively. 
There was a direct positive correlation between the CDLQl and total 
SCORAD, which reflects the construct validity of the CDLQl. However, 
observer scores explained only 21% and 28% of the children's score at the 
first and second visits respectively. 
Although the strength of eczema impact on the families and children was 
different, the CDLQl was significantly correlated to the DFI scores; r= 0.37, 
= 0.001 and r= 051, p<0.001 at visits one and two respectively. This means 
that parents and children evaluated the same problem with different attitude. 
3.3.2.4 Changes in the CDLQI and disease severity over time 
The mean change in CDLQI was -1.3 (S D: 3.8) with range of -13 to 10 and 
in SCORAD was -1.06 (SID: 10.7) with range of -30 to 33. In multiple 
regression anaiysis, each unit change in SCORAD was associated with 0.12 
(95%Cl, 0.04 to 0.19, p=0.004) units change in CDLQI. After adjusting for 
potential confounders (black skin, social class, sex, child's age, family size 
and region of residency), each unit change in SCORAD led to a 0.12 (95%Cl, 
0.04 to 0.2, p=0.003) unit change in CDLQI. This finding shows the 
relationship between quality of Ve and disease severity over a6 months 
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time. The differences in these two scoring systems are related despite the 
fact that the improvement in the CDLQl was statistically significant and 
minimal improvement in the SCORAD was insignificant. 
3.3-2.5 Individual aspect of the CDLQI on visits one and two 
Figures 14 and 15 show the percentage and mean scores for each aspect of 
children's life respectively for 71 children attending both visits. On visit one 
the highest mean score was in the question related to symptoms (itching) 
1.17 and the lowest (0.19) was for friendships. These scores showed almost 
the same trend on the second visit. 
3.3.2.5.1 Itchy "scratchy" or painful skin 
Fifty-six (79%) and 46 (65%) children had an itchy "scratchy" or painful skin 
during the first and second visits respectively. This question had the highest 
impact on children's quality of life and also produced the highest over all 
mean score (see Figure 15). The initial mean score was 1.17 and after six 
months the mean final score was 0.82 representing a significant 
improvement perceived by the children (p = 0.008). Itching mean scores 
formed 23% and 25% of the total CDLQl scores during the first and second 
visits respectively (see Figures 16 and 17). 
There was a highly significant direct but not linear relationship between 
itching scores and the observer's assessment of excoriation on visits one (r= 
0.36, p=0.002) and two (r = 0.3 1, p=0.008). It happens that the value of r2 
(the square of the correlation coefficient - sometimes called the coefficient of 
determination) has a readily understandable interpretation in terms of the 
strength of a relationship between two variables (Daly and Bourke., 2000). 
Calculation of the coefficient of determination (rý was possible to evaluate 
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the effect of excoriation assessment on scratching scores. In the scratching 
and excoriation scores for example, r equals 0.36 and 0.31, so that t2 equals 
0.1296 and 0.0961 on the first and second visits respectively. Thus, the 
variation in the excoriation scores made by the observer explains only 13% 
and 10%, on visit one and two respectively, of the total variation in scratching 
scores by the child. The other 87% and 90% variation is unexplained and 
must be due to other factors not considered in this analysis. 
There was also a highly significant direct but not linear relationship between 
itching scores and the observer's assessment of lichenification on visit one (r 
= 0.37, p=0.001) and two (r = 0.28, p=0.019). Calculation of the r2 was 
possible in order to evaluate the effect of the assessment of lichenification on 
scratching scores. The r2was 0.1369 and 0.0784 for visits one and two 
respectively. Thus, the variation in the lichenification scores made by the 
observer explains only 14% and 8%, on visit one and two respectively, of the 
total variation in scratching scores by the child. The other 86% and 92% 
variation is unexplained and must be due to other factors not included in this 
analysis such as geographic area, social class, ability to cope with the 
disease and customs 
3.3.2.5.2 Effect on child's sleep 
Eczema had affected the child's sleep in 27 (39%) and 34 (48%) children on 
the first and second visits respectively (see Figure 14). This question had the 
second highest mean score (0.6 and 0.66 on the first and second visits 
respectively) after itching scores (see Figure 15). Scores on this question 
formed about 121o and 19% of the total CDLQl scores on the first and 
second visits respectively that constitutes the second major component of the 
CDLQI after itching (see Figures 16 and 17). 
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The effect on sleep was significantly correlated with the SCORAD-D (r = 
0.39, p=0.001) and (r = 038, p=0.001) on the first and second visits 
respectively. By calculating the ?, variation in severity scores made by the 
observer explains only 15% and 14% on visits one and two respectively, of 
the total variation in sleep scores by the child. The other 85% and 86% 
variations are unexplained and must be due to other factors such as other 
illness, child's behaviour, not considered in this analysis. 
3.3.2.5.3 Effect of treatment on the child 
Twenty (31%) and 17 (25%) children were troubled by the treatment of their 
eczema at visits one and two respectively. However, the mean score for this 
question decreased from 0.43 to 0.38 representing a non-significant 
improvement recognised by the child (p = 0.8). There was a highly significant 
direct but not linear relationship between treatment scores and the observer's 
assessment of erythema on visits one (r = 0.29, p=0.021) and two (r = 0.35, 
p=0.003). When the r2was calculated to evaluate the strength of the effect 
of erythema assessment on treatment scores, it showed that the variation in 
the erytherna scores by the observer explains only 8% and 12%, on visits 
one and two respectively, of the total variation in treatment scores by the 
child. The other 92% and 88% variation is unexplained and may be due to 
other factors such as personality and child's behaviour, not considered in this 
analysis. 
3.3.2-5.4 Other components of the CDLQI 
Twenty (30%) and 11 (16%) children were embarrassed or self conscious, 
upset or sad because of their AD during visits one and two respectively. The 
child being embarrassed or self-conscious, upset or sad because of her/his 
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skin, was significantly correlated to disease severity (SCORAD) on visits one 
(r = 0.36, p=0.003) and two (r = 0.37, p=0.002). 
Atopic Dermatitis had affected a child's playing and doing hobbies in 20 
(29%) and 11 (16%) children during the week before the first and second 
visits respectively. Childhood eczema had led to changing or wearing 
different or special clothes/shoes in 17 (29%) and 8 (12%) children during the 
week before the first and second visits respectively. While 18 (26%) and 7 
(10%) children had avoided swimming or doing other sports during the week 
before the first and second visits respectively because of eczema. Eczema 
had troubled personal relationships in 12 (17%) and 13 (19%) children on 
first and second visits respectively. It also produced the lowest mean score 
0.19 and 0.08 during the first and second visits respectiveiy. No significant 
correlation with disease severity was found. And friendship was affected by 
AD in 10 (15%) and 4 (6%) children during the first and second visits 
respectively. Question about friendships had the lowest mean score 0.19 (SID 
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3.3.2.6 Percentage "weight" of each item in forming the total CDLQI 
score 
Figures 16 and 17 illustrate the percentage "weight" of the mean score of 
each item in forming the total CDLQl scores, in this population, on visits one 
and two respectively. These figures illustrate the weight exerted by the mean 
score of each item, answered by the children in the current study, in forming 
the total mean CDLQI scores. For instance, the maximum mean score of 
scratching (3) forms only 10% of the maximum score of the CDLQl (30), 
providing each of the CDLQI has the same score (3 each). However, in the 
current study, the question relating to scratching forms more than 10% of the 
total CDLQl. The mean score for scratching forms almost one quarter of the 
total CDLQl scores at each visit. This demonstrates the important of itching in 
this stressful disease and highlights the importance of including such 
information in documenting the impact of eczema on quality of life. Despite 
that most cases in this study had mild disease. 
The second item that played a major rule in forming the total CDLQl score 
was the question related to an impact of eczema on child's sleep. The 
question formed 12% of the total score during the first visit and 19% of the 
total score during the second visit. Again it shows the importance of including 
information about sleep in quantifying an impact on children's quality of life. 
The third item was the question related to treatment where it forms 9% and 
11% of the total mean CDLQl score during the first and second visits 
respectively. 
In this study with mostly mild cases, the mean score of the other 7 items in 
the CDLQI forms 56 O, o and 45% of the total mean CDLQl scores during the 




























































































3.3.2.7 Collated scores of groupings of the questions at each visit 
The impact of AD on three different aspects of QOL was analysed by 
grouping answers to those questions related to that particular aspect, i. e. 
symptoms and feeling (questions 1& 2), leisure activities (questions 4,5 & 
6), and personal relationships (questions 3& 8). On initial visit, symptoms 
and feeling were affected in 59 (83%) children and personal relationships 
















Symptoms & feeling Leisure activities Personal 
relationships 
Each bar represents the percentage of that aspect of the child's life affected by eczema 
Black bars = Visit one 
Grey bars = Visit two 
Figure 18. Percentage of three areas of children's QOL on visit one and two for 71 
children 
The mean score of each aspect score is shown in Table 44, which was 
calculated using the "egen" command in the Stata software (Stata Corp, 
1999). 
Table 44. Mean (SD) of the collated CDLQl scores for 71 children 
Collated CDLQl Mean scores (SD) 
Visit One 
Mean scores (SD) 
Visit Two 
Symptoms and feeling 0.82(0.69) 0.541.053) 
Leisure activities 0.42(0.59) 0.22 (0.52) 
Personal relationships 0.23(0.47) . 0-22ý0.41) 
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Symptoms and feelings also scored the highest 0.82 (SD 0.69) and personal 
relationships scored the lowest 0.23 (SID 0.47). On the second visit, the same 
trend was observed. Symptoms and feeling had shown a significant positive 
and marginally strong correlation with disease severity measured by 
SCORAD on both visits. Personal relationships did not show any significant 
correlation with disease severity, while leisure activities showed inconsistent 
correlation, see Table 45. 
Table 45. Correlation between the collated CDLQl and SCORAD scores 
Collated CDLQl 
Visit One Visit Two 
r P value r P value 
Symptoms and feeling 0.49 < 0.001 0.55 < 0.001 
Leisure activities 0.23 0.52 0.33 0.005 
Personal relationships 0.1 0.52 0.21 0.08 
r, correlation coefficient. CDLQI; Children Dermatology Life Quality Index 
3.3.2.8 Summary of the children's quality of life 
Children of different age groups were able to complete the CDLQl, 
however the mean age tended to be lower in those who were unable to 
complete than those who completed the CDLQl. 
* Most children aged 9 years or more were able to complete the CDLQl. 
This may imply that 9 years should be the lower age limit for using the 
CDLQl. The data suggested that all children with atopic dermatitis aged 9 
years or more were able to complete the CDLQl without parents' help, 
except one child who was unable to. 
9 Inability to complete the CDLQI was not significantly related to social 
class, ethnic background, or family size. 
* Ninety-two per cent and 771o of children were affected by their atopic 
dermatitis on the first and second visits respectively. This highlights the 
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disability in children caused by eczema despite the fact that 80% of cases 
were graded as mild in severity. 
9 Disease severity had a positive and significant correlation with children's 
quality of life. This reflects the construct validity of the CDLQl, and may 
imply that the CDLQl can be used, within limited age groups, in a 
community-based study to evaluate the impact of eczema on children's 
life. 
* There was an insignificant difference in the CDLQl scores as well as in its 
components between males and females. 
Male scores in the CDLQl have a stronger correlation than female scores 
with the SCORAD. 
In this study, children with atopic dermatitis provided information 
concerning their health-related OOL that was not typically available from 
their parents. 
9 Asking children directly and independently about their QOL has an 
important implication in obtaining information for patient management and 
evaluation of medical intervention in a paediatric setting. An experience 
that is both relevant and important to children with AD. Asking children 
directly about emotional burden, leisure activities, friendships, and 
treatment side effects can reveal this experience. Such information is 
valuable for a better understanding of atopic dermatitis burden and 
therefore to design a better intervention to reduce these burdens. 
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4 CHAPTER 4 DISCUSSION AND 
CONCLUSION 
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4.1 Section 1: General discussion 
The study has revealed new findings in relation to the severity of childhood 
atopic dermatitis over time and the impact of this disease on children and the 
family's quality of life. It is the first time that eczema severity and impact on 
quality of life have been studied in a systematic way and in a community- 
based setting. The study has provided evidence that; 
9 Atopic dermatifis starting during the first year of life was a predictor of 
severe disease later on. 
e Children with other atopic diseases (asthma and/or hay fever) have 
more severe disease then those who had no atopic diseases. 
* Children with black skin who have AD are at higher risk of severe 
disease than their white counter parts and reliance on erytherna 
scores can mask this disparity. 
* Children with atopic dermatitis who live in an urban area were at 
higher risk of severe disease than their counterparts in a rural area. 
9 Family size, sex, birth weight, gestational age, child's age, parental 
atopy (hay fever, asthma, or eczema), and any atopy in siblings have 
no significant association with disease severity. 
* Reaction to wool and some kinds of food was associated with severe 
disease, but their associations became statistically insignificant after 
adjusting for potential confounders. 
9 Social class and breastfeeding were not significantly associated with 
disease severity. 
* Atopic dermatitis has affected both children ard family's quality of life 
at different levels. 
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9 Children's quality of life scores were significantly correlated to their 
atopic dermatitis severity as assessed by the observer. 
* Family's quality of life scores were significantly related to eczema 
severity scores in their children as assessed by the observer. 
Changes in quality of life scores in both family and children were 
significantly related to changes in atopic dermatitis severity scores. 
All these findings are important for a better understanding of atopic 
dermatitis. However, there are general points related to study design that 
should be discussed in this section before focussing on the main findings. 
These points are important for establishing the validity of this study's findings. 
For example any evidence of selection, information or measurement bias 
would make any conclusions drawn from this study debatable. 
Study design 
A longitudinal study design was implemented in this study to document the 
course of disease over a period of time because very little information about 
factors that may affect disease severity and the impact of AD on quality of life 
was available from a prospective design. Atopic dermatitis is a chronic 
relapsing disease and it's course may vary over time. The longitudinal design 
enabled the documentation of disease severity over time and also factors 
that affect severity over time. The design allowed documentation of the 
impact of disease that comprised mostly mild atopic dermatitis, on children 
and family's quality of life at a single point in time and over a period of time. 
Because of this design, it was also possbe to show that changes in quality 
of life scores were related to changes in severity scores. However, 
longitudinal studies may suffer from a high drop out rate due to different 
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reasons. If the rate is high, subjects may have a substantial difference in the 
main outcome. Fortunately, this study had a low drop out rate (12%) and this 
would make any potential substantial difference in these subjects from those 
attended the last follow up less likely to have a significant effect on the 
outcome. 
A retrospective study design is easy to carry out and is less expensive, but it 
is associated with problems in the collection of data from patients' notes. 
Another disadvantage is that it is not possible to assess disease severity in a 
systematic way. A study with a cross-sectional design provides information 
regarding the effect of factors at one point in time and not over time. In a 
chronic relapsing disease such as AD, exploring factors that may affect 
disease severity over time is more important than exploring their effect at just 
a single point in time. Therefore the longitudinal design implemented in this 
study was ideal for investigating factors that may affect disease severity over 
time and the impact of AD on quality of life. 
4.1.2 Bias 
4.1.2.1 Selection bias 
The most crucial problem in carrying out this epidemiological study was to 
select appropriate subjects representing the targeted population; thus a 
representative sample of children with AD was needed. It is important to 
consider whether there was a selection bias due to the selection of GP's in 
this sample. This is a community study and general practices were not 
selected randomly, even though they were representative of the general 
practices in both areas studied. Generally, subjects, whether they have 
disease or not, register with the nearest GP group in the area, and there is no 
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evidence to suggest that patients with eczema have a tendency to register 
with one GP rather than another. 
Another point of concern was the low response rate, which was generally 
low, in particular from the urban area (35%). For example, practice number 
two, in the urban area, had the lowest response rate (26%). One explanation 
might be the way the GP had coded the cases of AD, which had led to 
confusion with other diseases. This speculation was supported by data from 
this study in which 3% of parents who responded had moved from the area 
and another 6% denied that their children had ever had eczema. 
On the other hand, practice number seven from the rural area had the 
highest response rate (100%). The GP in this practice said "They were the 
only cases with atopic dermatitis registered with our practice in this age 
group. All of them were happy to help and, in fact, other parents were upset 
that their children were not included (from a different age group) in the study". 
One explanation is that in a very small community where everybody knows 
everybody, the relationship between doctor and patient is often closer. 
Another reason that could be a potential source of bias is that the GP in this 
practice has a special interest in dermatology and is a leading member of the 
Primary Care Dermatology Group. These two practices represent two ends of 
the spectrum in this study. This queries the way in which GPs had chosen 
the list and may explain the low response rate in some situations. Another 
explanation is that GPs may have included many cases with very mild 
eczema, which can be treated by an emollient or patients with just dry skin. 
Therefore parents might have thought that these cases were not of any help. 
This speculation is supported by the fact that some GPs did use repeat 
prescriptions for emollient to create the list of potential patients. It was 
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impossible to investigate the latter speculation because access to patients' 
notes was not part of the study protocol. 
In general, the response rate per individual practice was quite low in the 
urban area compared with the rural area. This raises three questions: First, 
are patients from the urban area less motivated to participate in such 
studies? Second, was there any bias in the way that GPs had created the list 
of potential patients? Thirdly, if one GP is more interested in dermatology 
research than another does this have an effect on recruitment? Unfortunately 
it is not possible to answer these questions directly; although the design is 
supported by indirect evidence when the children with visible eczema only 
were ranked into three categories. The severity distribution of this population 
was the same as in other studies (Dotterud, Kvammen, Lund, Falk., 1995; 
Berth-Jones et al., 1997; Emerson, et al., 1998). All this information suggests 
that there was no intrinsic bias towards disease of low severity and therefore 
selection bias, due to GPs preference, is less likely to have occurred. 
A potential way to rule out selection bias in cases of low response rate is to 
contact the non-respondents and investigate if their disease state was 
substantially different to those who responded. Unfortunately, it was 
generally impossible to contact the non-responders. Even if it had been 
possible, it would have required an examination and assessment of their 
eczema severity and documenting the ratio of the impact on their quality of 
life in order to rule out any substantial differences. As they had shown no 
interest in the study at all, it was deemed unacceptable on ethical grounds to 
proceed further. 
Another potential source of selection bias was the way subjects themselves 
participated. The responders who had volunteered to help could have been 
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either healthier (no disease) or sicker (having severe disease). The total low 
response rate could have led to selection of a certain group of patients with 
specific characters. However, it is believed that this form of selection bias is 
less likely for the following reasons; 
1. When the SCORAD-D was ranked into three categories (mild, moderate, 
and severe), the severity distribution of this population had approximately 
the same severity distribution as in Nottingham, UK, the study with a 
higher response rate (84%) than this study (Emerson, et al., 1998). 
Another community study in Leicester with high response rate (83%) 
compared with this study found that 82% of children had mild eczema 
(Berth-Jones, et aL, 1997). This suggests that there was no intrinsic bias 
to disease of low severity and no overrepresentation of mild cases. 
2. When children's QOL was the outcome of interest, the mean scores of the 
CDLQI at each visit were similar to the mean scores found in other 
community-based studies (Emerson, Williams, Allen, et aL, 1997; Lewis- 
Jones, et aL, 1998). The mean score in Emerson's study (1997) was 3.8 
(SD 4.2) using an instrument designed to measure the impact of any 
disease on children (This questionnaire has not been published yet). In 
Lewis-Jones' study (1998) the mean score of the CDLQI was 2.93 (Lewis- 
Jones and Finlay., 1995). Both of these studies, by Emerson et al (1997) 
and Lewis-Jones et al (1998), were published in abstract form and have 
different study designs. A further critical approach to these studies was 
not feasible because of the limited data provided in the abstract. 
However, it suggests that intrinsic bias to children with a low impact on 
quality of life is unlikely. 
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I When the family's quality of life was the outcome of interest, the mean 
scores of DFI at each visit were similar to the reported DFI scores from a 
study in rural practice (Lewis-Jones, et al., 1998). This suggests that 
intrinsic bias towards parents, for whom there was a low impact on quality 
of life, was unlikely to have occurred. 
4. Other exposure factors such as age of onset and ethnic group have 
similar distributions to those seen in other studies (Balarajan and 
Raleigh., 1992; Queille-Roussel, Raynaud, Saurat., 1985). 
It is maintained, therefore, that the cases in this study are representative, 
although an overall underestimation cannot be excluded completely. Finally, 
this is a longitudinal study with a relatively good total follow-up rate (88%) 
and there was no substantial difference in disease severity between those 
who dropped out and those who continued in the study. In addition an 88% 
follow rate would make any substantial difference between those who 
attended the last follow up and those who drop out, less likely to affect the 
outcome. 
4.1.2.2 Information bias 
It is clear in this study, as well as in any other studies that rely on maternal 
reporting of events, that the problems of definition and recall could not be 
entirely avoided. The clinician in a paediatric population depends completely 
on the history taken from the parents. In this study however, information 
about risk factors was gathered by a piloted and structured questionnaire that 
depended, in most questions, on recall from the last 6 to 12 months. Few 
questions had a longer recall time such as age at onset, breast-feeding, birth 
weight, and severity at onset. The piloted and structured questionnaire would 
have made information bias less likely to occur and any potential source of 
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information bias regarding exposure will be discussed specifically in relation 
to that particular factor. 
4.1.2.3 Measurement bias 
It was impossible to make the observer blind to some exposures (area of 
residence, sex and skin colour) in this population. He was the only observer 
who assessed disease severity all the time. However, during the study the 
observer did not know the results of the questionnaires (exposure) and was 
completely blind to these exposures, except area of residence, sex and skin 
colour. This is an inevitable drawback of this study regarding these factors 
and carried a potential risk of bias. To investigate the effect of measurement 
bias on this study finding, a parental score on a0 to 10 analogue scale was 
used. To avoid repetition when discussing these factors (ethnic background, 
sex, or area of residence), it should be emphasised here that the finding 
remained the same, whether it was significant or insignificant, when the 
parents' scores were used in their own. Also, when quality of life was the 
outcome of interest the observer remained blind to the questionnaire (the DFI 
and CDLQl) results. 
During assessment of severity the dependence on a single observer may 
have removed the inter-observer variability but left the study with intra- 
observer variability, a feature that could not be avoided. Hence observer bias 
cannot be totally excluded. This may take the form of detection bias and can 
be partially eliminated by double-blind controlled trials in an experimental 
design, but in epidemiology it is nearly impossible to eliminate. One should 
always be open to consider alternative explanations (bias and/or confounding 
effect) when interpreting results because randomisation and blinding is 
usually impossible in population studies. 
194 
4.1.3 Inclusion criteria 
Comparison is at the heart of clinical epidemiology and subjects compared 
should have similar behaviour. The UK diagnostic criteria for AD were used 
to ensure that subjects included had the same disease (Williams, et al., 
1994a, 1994b, and 1994c). There is only one sign (flexural dermatitis) in 
these criteria, which was documented by a previously trained observer 
according to the guidelines suggested by Williams and others (1995b). All 
these were implemented to select patients in the same entity. The criteria 
have a sensitivity of 80% and a specificity of 97% when validated in a 
community study (Williams, et al., 1996) but it is possible to speculate that 
there will be atopic dermatitis cases that do not fulfil the criteria. 
Unfortunately the study demonstrated this obstacle in that 14 (10%) children 
whom the investigator felt had or had had AD, but they did not fulfil the UK 
diagnostic criteria. An ideal way to deal with this problem is to carry out the 
analysis for each factor, with and without inclusion of these children. This 
would have been both complicated and impractical to implement and possibly 
confusing to the reader. Simple exclusion would have had the potential to 
introduce bias in the study as these subjects potentially might relapse and 
then fulfil the criteria. Against exclusion therefore are the following points; 
1. Some of these children had flexural postinflammatory hype rpi gm entation , 
which indicated previously active eczema - but only if they were to 
relapse would they fulfil the criteria. 
2. A survey of childhood atopic dermatitis in London found that only about 
half of children with a history of this condition had identifiable dermatitis 
during the survey (Williams, Pembroke, Forsclyke, et al., 1995a). There 
was similar finding in the current study where 54% had visible flexural 
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dermatitis at recruitment. Williams' and this study's findings suggest that 
atopic ermatitis has a relapsing nature and it is possible that this would 
underestimate the prevalence if one was to rely on visible dermatitis only. 
In these two studies about half of the patients did not have visible 
eczema. 
3. Eleven (79%) children of the 14 had one major and two minor criteria. For 
instance if they were to develop asthma and/or hay fever and they would 
then satisfy the criteria. Asthma and hay fever are unstable diseases with 
unpredictable prevalence, yet atopic dermatitis patients have a higher risk 
of developing both (Gustafsson, Sjoberg, Foucard., 2000). The 
longitudinal design of this study allows the previous possibility to occur 
and the absence of any predictive information on the disease outcome 
(Williams and Strachan., 1998) would make excluding them unjustifiable. 
However, when the sensitivity analysis was carried out before and after 
excluding these 14 patients, the outcome was the same, and it was therefore 
deemed justifiable to include them. It also should be emphasised here that 
this inclusion was not to increase the number of observations and therefore 
the statistical power. It was carried out to make sure that all subjects with the 
same disease were included. 
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4.1.4 Disease severity assessment 
4.1.4.1 The SCORAD index 
The SCORAD Index was developed to assess disease severity in a standard 
way (European Task Force on Atopic Dermatitis., 1993). A recent review by 
Charman and Williams (2000b) concluded that the SCORAD was the most 
tested instrument but there was significant inter-observer variability. The 
latter had no effect on the results of this study because only one observer 
assessed disease severity all the time. This would therefore add strength to 
the study result and misclassification seems unlikely to have influenced the 
results. Nevertheless intra-observer variability cannot totally be excluded in 
this study as it often occurs in epidemiological studies. 
Another weakness of the SCORAD index was the usage of the rule of nines 
to assess disease extent. It has been reported to have very poor inter- 
observer agreement when it was used to assess disease extent in 6 patients 
with AD, and also showed low intra-observer variation with perfect 
agreement, in only 4 of 6 cases (Charman, Venn, Williams., 1999). However 
in this study, the same observer assessed disease extent all the time, which 
should satisfy the suggestion made by Charman et al (1999) in which a 
single observer should be used. Memory recall bias could not have 
happened because subjects were re-examined after 6 months that was long 
enough for the previous assessment to bias the next. The observer in this 
study also was previously trained while in Charman's study (1999) the 
investigators were not trained before hand. In the absence of objective 
markers for disease severity, using the rule of nines, even with it's limitation, 
still provides systematic information about disease extent. Therefore 
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substantial effects were unlikely to occur because subjects had nearly the 
same severity distribution as in other studies (Berth-Jones, et al., 1997; 
Emerson, et al., 1998). 
A comprehensive severity instrument should measure signs and symptoms. 
The first of these reflect the physician's assessment of any visible sign and 
the second reflects patient's assessment of their disease. Although symptom 
assessment is more subjective, it should be included because it evaluates an 
outcome of the visible sign, as perceived by the patient. Combining 
subjective and objective assessments could be a source of bias in disease 
severity assessment because there are at least two different observers 
involved in this process. However, it is also the only way of obtaining a 
comprehensive view of the disease status. For example in atopic dermatitis, 
itching and sleep loss, probably in most cases, are the immediate outcomes 
of disease and a cause of major concern to the patient (Lewis-Jones and 
Finlay., 1995). Itching and sleep loss can be encountered even in the 
absence of visible eczema. Any scoring system that does not include them 
would not provide a comprehensive view of disease status. 
The observational design of the study did not permit any interference with the 
patients' activities including self -medication. Ideally in order to score dryness 
the parents would have been told not to apply emollient before clinical 
examination. Therefore the dryness score was excluded from the SCORAD. 
This may have affected the internal consistency of the SCORAD index and 
therefore could be a source of bias. However, it has been documented that 
the SCORAD remains a valid instrument of severity assessment even after 
exclusion of dryness and subjective symptoms when a group used 
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photographs to train 98 investigators from different disciplines (Oranje, 
Stalder, Ta'feb, et al., 1997). 
Another inadequate validation of the objective scores was the positive and 
significant correlation to the global severity assessment by the parent on a0 
to 10 scale. Although the former is rather weak validation of the observer 
scores, it seems a reasonable approach in the absence of any 'gold' 
standard marker for atopic dermatitis severity. Thus exclusion of dryness is 
unlikely to have underestimated the disease severity in this population. 
4.1.4.2 Practical meaning of the units used in the SCORAD 
It is well know that a subject with blood pressure of 190/150 has 
hypertension, as it is clear from this study and other studies that a patient 
with SCORAD of 60 or more definitely has severe disease. But what does a 
one unit or 10 units increase in the SCORAID meant clinically? If one could 
explain what a one unit increase in the SCORAD means clinically, one also 
could explain what a one-millimetre increase in assessment of blood 
pressure by a sphygmomanometer means clinically, a more objective scale 
used to assess blood pressure. These two techniques represent two ends of 
the spectrum, the sphygmomanometer with its objectivity validated using 
physics produces an objective gold standard, but the SCORAD with less 
objectivity measures a disease state for which there is no pre-existing gold 
standard. However, these two techniques (Sphygmomanometer and 
SCORAD) are used to assess an outcome in a systematic and repeatable 
way. So what is really matter, at the current level of knowledge of the subject, 
is the validity, reliability and applicability of the technique. It has been 
reported that the SCORAD, used in the current study, proved to be the most 
tested technique for vali6ty and reliability (Charman C, Williams., 2000b). 
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What a one or 10 unit increase in the SCORAD means to the patient is a task 
that has not been achieved yet. Scoring atopic dermatitis is still in its early 
days and may be improved by time. 
4.1.4.3 Suggestions that may improve the SCORAD 
The SCORAD was an easy instrument to use in the assessment of AD 
severity in this study, and it is recommended for usage in other observational 
studies. Nevertheless, it is possible to suggest a few points that may improve 
the SCORAD, bearing in mind that designing a new instrument was outside 
the originalgoal of this study. 
1. Using the rule of nines in the SCORAD. It would be easy to divide the 
body areas into several areas similar to those used in the NESS 
(Emerson, et al., 2000) because of the difficulty in precisely marking 
the end of the lesion. This may improve the accuracy and decrease 
the time needed to score the disease severity in a patient. 
2. Usage of the SCORAD in an observational study necessitated 
exclusion of the dryness score from the total SCORAD. In this study, 
the exclusion of dryness did not affect the SCORAD and therefore it is 
possible to use this scale without this sign. 
3. SCORAD users should be aware of the difficulties in scoring erythema 
in pigmented skin and treat its score as a confounder and control for it 
in the analysis. An alternative suggestion would be to exclude the 
erythema score from the SCORAD index. But it should be emphasised 
here that using hype rpigmentation instead of erythema is not good 
alternative. 
4. The SCORAD is a point measure of disease severity and does not 
reflect the disease status in the time prior to that point. Theoretically 
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one may suggest that assessment of disease sevedty everyday and 
taking the average score may give an average of disease activities 
over this time of measurements, but there are practical constraints. 
Even if it was possible to find cooperative subjects, the variation in the 
observer assessments and the fluctuation in the disease course on a 
day to day basis inevitably make these more complicated. On the 
basis of practicality, the SOCRAD cannot truly be used in this way. 
Also the effect of each measurement on the subsequent one may be 
significant because 24 hours is a short time and this may bias the next 
measurement, if the same observer is used. 
This study got around this by taking average disease activities over a 
period of two years. However at this point, it is not possible to provide 
an objective way of measuring disease fluctuation over a short period. 
One might suggest a subjective measurement of disease fluctuation 
by asking the subject about number of flares in the last week, month 
or even longer, bearing in mind that the longer the recall time, the less 
the precision of the answers. However, asking the subject would 
decrease the objectivity and increase the subjectivity. The issue of 
disease fluctuation in this study is dealt with later in the discussion on 
AD course, and in the current state of knowledge of AD it is not 
possible to assess 'average' activities of AD objectively without asking 
the subject. 
In summary, the SCORAID proved to be an easy and valid technique 
to assess AD severity in the current knowledge of the disease. 
However, the suggestions made may improve its validity and 
practicality. 
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4.1.5 Quality of life assessment 
The design of some general health quality of life instruments may 
underestimate the magnitude of the problems caused by skin diseases. In 
this study two different (speciality and disease specific) instruments were 
used to quantify the impact of atopic dermatitis in children on themselves and 
their families' quality of life. The DFI was used to assess families' quality of 
life without any restriction and in accordance with the guidelines suggested 
by the authors (Lawson, et al, 1998). 
The CDLQl, however, was used with some slight restriction. The impact on 
the parents was quantified by the DR. Thus, asking parents to help in 
completing the CDLQI would have provided information on the impact on 
parents and not on the children, a variable that already has been measured. 
It was therefore decided to prevent parents from helping with completion of 
the CDLQl, a restriction that might make one question the validity of the 
CDLOI as used here because the parents, according to the instrument 
design, were allowed to help children to complete the CDLQl (Lewis-Jones 
and Finlay., 1995). While this concern is understandable the method used 
was the only way that the impact of eczema on children's quality of life, 
without parental influence, could be quantified in the absence of any other 
reliable and valid instrument. However, there are two findings, from this 
study, that lend support to the validity of using the CDLQl in this way. First, 
the significant positive correlation between quality of life and disease severity 
established the construct validity of the CDLQI in this group. Second, 98% of 
children aged 9 years or more were able to complete the CDLQI, when only 
50% of children aged 8 years or less were able to complete the CDLQl. This 
finding suggests that older children can complete the questionnaire without 
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parental help, which perhaps reflects the fact that the CDLQI can be used in 
this age group. The first finding showed the construct validity and the second 
showed the applicability of the CDLQl and taken together these confirm that 
the CDLQI is still a valid instrument for quantifying QOL in children with AD 
and the restriction implemented did not affect the outcome. 
4.1.5.1 Lessons learned from using the DFI 
It should be emphasised here that it is neither the aim of study to validate the 
quality of life scale nor to develop a new scale to measure quality of life in 
atopic dermatitis. But what was important was the justification of using these 
scales in this study. Design and validation of a new scale requires a different 
study design that would allow examining the validity, reliability and 
applicability of the scale. However, there are some points to suggest that 
should be taken in consideration when designing or using such scale. 
The DFI was easy to use in this study, which was reflected by the high 
percentage of parents who were able to complete it. Therefore, the DFI was 
easy to use. On the other hand the DFI was positively correlated with the 
children's AD severity, which reflects its construct validity. And finally the 
crude validity was shown by the ability of the DFI to give higher scores for 
visible than non-visible eczema on the same site. 
However, it was not possible to speculate or test what a one unit increase in 
the DFI means to the parents in practical terms. Quality of life assessment in 
dermatology is still in its early days and in the current state of knowledge, it is 
not possible to assume that a DFI score of 20 means that parents were 
affected twice as much as parents who scored 10 on the DFI. It was possible 
to show that a 10 unit increase in the SCORAD was associated with a 3.8 
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unit increase in the DFI, but what was not possible was to give any biological 
meaning for each unit increase in the DFI. 
One suggestion one may add by increasing the recall time from one week to 
an average last 12 months. However, this may affect the precision of the 
information. 
4.1.5.2 Lessons learned from using the CDLQl 
The CDLQI was designed to quantify the impact of any skin disease on the 
QOL (Lewis-Jones and Finlay., 1995). Apart from the reading ability that 
improved as the children get older, the CDLQl was an easy instrument to use 
for assessing the impact of eczema on children quality of life. The positive 
correlation between the CDLQl and disease severity demonstrated its 
construct validity. The questionnaire focuses on items of special concern to 
the children with skin disease such as itching and sleep loss that are 
conceptually less demanding and therefore more valid. However there are a 
few suggestions that may improve the CDLQI in the future: 
1. Increasing the recall time might give an average impact on the last 
year for example aithough this might lead to decrease in data 
precision. 
2. The CDLQl completion by young children might be improved by 
change the wording of the questionnaire. It is a hypothetical 
suggestion based on assumption that those who did not complete the 
CDLQ1 were unable to understand the questions. It shouid be stressed 
here it is assumed that the CDLQI is going to be used without any help 
from anybody including parents. 
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3. Question 7 can be made easy to read by dividing it into A and B. Also 
its current position might be confusing. To keep the same style 
question number 7 could be moved to be the last question. 
4. The completion might be improved by asking the observer to read the 
questionnaire and explain it to the children (face-to-face interviews). 
This would avoid the parents' input but the child might be 
embarrassed and then would not give a precise answer. 
5. In this study, answers to question numbers 1,9 and 10 accounted for 
nearly half the CDLQl scores. This may make one speculate about 
changing scores given for each item in the CDLOI so that 1,9 and 10 
would have 15 units out of the 30, the rest being shared between the 
remaining questions. This would provide a greater degree of 
differentiation based on the present study. But this study population 
comprised subjects with AD only where, itching and sleep loss were 
the most important symptoms. However, this may lead to 
underestimation of the impact of non-itchy skin conditions such as 
acne, warts as the CDLQI was designed to measure the impact of any 
skin disease on quality of life and not only eczema. 
Nevertheless, the CDLQl appeared to be practical, valid and easy to use in 
children aged 9 years or more. 
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4.2 Section 2: Atopic Dermatitis Severity 
4.2.1 Course of AD 
4.2.1 .1 Severity of eczema when first started 
Parents gave higher scores for their children's eczema severity when it first 
started than the scores given at the final visit in the study. This means that 
eczema severity had improved in parallel with an increase in the child's age, 
according to the parents' evaluation. They rated disease severity when it first 
started, but this involved varying recall times. This could be a source of bias 
because the assessment was documented at the time of recruitment in 
respect of something that had happened some years previously. 
Also, the presence of visible eczema on recruitment may have affected the 
reliability of this assessment and therefore could be a source of bias (Kulig, 
Bergman, Edenharter, Whan, and the Multicenter Allergy Study Group., 
2000). However, the child's eczema had improved from when it first started 
according to parental evaluation, which was demonstrated by a highly 
significant decrease in mean severity scores. Although this was a subjective 
assessment, it represented a highly significant improvement from the 
parents' point of view from the time of disease onset to the day of the final 
visit. These findings supported the previously reported improvement of AD 
with age (Williams and Strachan., 1998), despite the limitations of both 
studies (William's and the current study). This is an important finding but note 
should be made of the subjectivity of severity assessment by parents and the 
potential information bias. 
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4.2.1.2 Best season in the year for eczema 
With 38% of children parents felt that summer was the best season for their 
children's eczema. This may indicate a subtype of eczema that gets better 
during a warm environment. Hot weather, no central heating and exposure to 
more ultra violet light might also explain eczema improvement during this 
season. The effect of other factors such as holiday time and exposure to 
other aeroallergens cannot be excluded from the available data. 
4.2.1.3 Topical steroids 
The study showed that 90% of parents were applying or had applied steroid 
cream or ointment to the child's skin. Although the question about topical 
steroids (cream s/ointm e nt) was straightforward, the unlimited recall time 
might have affected the reliability of this question (see question number 33 in 
Appendix 6.2 and question number 20 in Appendix 6.3). Also, it may have 
been interpreted as including the usage of topical treatment in general, i. e. 
for other conditions. However, when parents were asked about the frequency 
of steroid application in the last 6 months preceding the final visit, 63% of 
parents had applied topical steroids at different frequencies (i. e. less 
frequent, every other day, once a day, or twice a day). The pattern of 
answers was therefore consistent as all the parents answered exactly the 
same question with a6 months recall time. Another observation that supports 
the construct validity of the question, about topical steroid frequency, was 
that observer assessment of eczema severity had increased with an 
increased in the frequency of topical steroid applicatior. There is also 
evidence that support the internal consistency of the questionnaire where 
parents were able to give high scores in accordance with more frequent 
application of topical steroid. 
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Although the term 'steroid cream/ointment' used in this study's question 
about topical steroid usage was similar to the term used by Charman et al 
(2000a), the outcome of these two studies was different. In this study the 
information gathered was about the usage and frequency, but in Charman's 
study (2000a) the outcome was worry about using steroids. This explains 
why in the latter study 72.5% of those asked were worried about using topical 
steroids while in this study parents of 37% of children did not apply steroid in 
the last 6 months. 
Although there was a significant statistical difference in disease severity 
between those who applied topical steroids and those who did not, this 
finding was not considered for further analysis. It is more likely that patients 
with severe disease were more likely to use topical steroids and not that 
usage of topical steroids had lead to severe disease. This finding represent a 
result that is statistically significant but not necessary clinically relevant. 
Researchers should be aware of such finding. Allergy to any of the 
cream/ointment components, though, cannot be ruled out in the current study 
design. 
The main reason for including questions about topical steroids was to 
document the usage and to check the internal consistency of the 
questionnaire. It also helped to validate the observer's scores, whIch had 
shown a trend to an increase in the severity score for question 20 (Appendix 
6.3) with an increased frequency of topical steroid use, except for the once a 
day category which is probably due to the low number of subjects in that 
group. 
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4.2.1.4 Admission to hospital 
Less than 2% of children had been admitted to hospital, which reflects the 
fact that most cases were mild and did not warrant hospital treatment. Again 
this finding adds strength to the study results and makes selection bias less 
likely and in agreement with the finding of Emerson and colleagues that the 
majority of AD cases were managed in primary care (Emerson, et al., 1998). 
4.2.1.5 Systemic treatment 
This study showed that less than 4% of children had used systemic steroids, 
an expected finding in a community-based study where most of patients have 
mild disease. It indicates that the majority of cases in this study were mild, a 
finding that has been documented in other studies (Berth-Jones, et al., 1997; 
Emerson, et al., 1998). Oral antibiotics were used more frequently than oral 
steroids. The range of those receiving oral antibiotics varied from 50% before 
the first visit to 17% before the fourth visit. The latter is more reliable as all 
parents answered exactly the same question while during the first three visits 
answering the same question involved different recall times. The same 
applied to other systemic treatments. 
When disease severity from the fourth (final) visit was examined, the 
observer was able to give higher severity scores for those who used 
antibiotics and prednisolone than who did not. Both drugs tend to be used in 
I infectious and severe eczema. The observer could not be biased by the 
exposure because the information about the iatter was only revealed after the 
study had finished. Therefore the SCORAD used by the observer to assess 
AD severity, was able to detect (although not statistically tested) higher 
scores for those with, presumably, more severe disease. 
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Oral antihistamines were taken in the last 6 months preceding the final visit in 
19% of children. The mean SCORAD-D was similar in those who used and 
did not use oral antihistamines. However, the mean subjective symptoms' 
scores were higher in children who received oral antihistamine than those 
who did not. This may indicate that itching and/or sleep loss were 
encountered even when the eczema got better. 
4.2.1.6 Atopic dermatitis severity fluctuation over time 
Atopic dermatitis is a chronic relapsing disease with an unpredictable course 
over time. Information on short-to-medium term fluctuation and factors that 
may affect this is scanty (Williams and Wuthrich., 2000b), information that is 
needed for everyday practice and evaluating any new treatments. In this 
study, it was clear from the observer assessment that signs did fluctuate over 
time. However, the problem was to find a marker or a surrogate that could 
represent quantification for instability in disease severity. Theoretically 
standard deviation (SD) of the objective scores (SCORAD-D) could be used 
as a surrogate to represent severity fluctuation. But at each time point SID 
may also reflect intrinsic "inaccuracy" of measurement by the observer, even, 
if there was no change in disease severity at all. Therefore, it was decided 
that SID would be an inappropriate surrogate to assess severity fluctuation. 
The 6 months period between each visit may also not be ideal for the 
assessment of severity fluctuations. 
Objective and systematic evaluation of severity fluctuation remains a difficult 
task. However, history of disease duration or frequency of exacerbation in the 
last 6 months before clinical assessment may provide information about the 
severity fluctuation, but this still remains subjective, as a different observer 
would assess disease severity. This therefore might underestimate or 
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overestimate the actual disease course. It, therefore, was not possible to 
investigate those factors that may affect severity fluctuations. 
4.2.2 Severity over time as the outcome 
The summary measures and statistical analysis used in the current study had 
calculated the odd ratio for severe disease using 'average' disease activities 
over a period of time per subject and not at a single point in time. By using 
this approach it was possible to get around the problem of the SCORAD 
being a point measurement. Nevertheless, an individual remained the unit of 
analysis despite using the total number of observations from the four visits. 
4.2.2.1 Intrinsic factors 
4.2.2.1.1 Age at onset 
Eczema starting during the first year of life was a predictor of severe disease 
later in life. This holds true after adjusting for important potential confounders 
such as location of residence and the presence of atopic diseases, although 
these proved to have a significant association with disease severity. The 
exposure status regarding the age of onset in this study was not biased and 
was consistent with other data found in the literature in which most cases 
were found to occur during the first year of life (Schmied and Saurat., 1991). 
From another study with a similar distribution of disease onset, the majority 
starting during the first year of life, 0 ueille- Roussel, et al (1985) reported no 
association between age of onset and disease severity. The latter study 
recruited subjects from both in and out-patient populations of a specialised 
paediatric dermatology unit and the investigator used a locally constructed 
system to assess disease severity. The dissimilarity in study design and 
severity assessment may explain the contrasting findings. 
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Eczema in the mother may be considered as a potential confounder; so is it 
appropriate to adjust for the mother's eczema? A mother with experience of 
eczema may recognise the disease sooner in her child than a mother without 
such experience and so cause it to be diagnosed earlier. She may also give 
a higher score to the same symptoms because she can imagine more easily 
what her child may be suffering. So eczema in the mother could be a true 
confounder if she scored eczema severity. However, the outcome (SCORAD) 
consists of maternal score (SYMPTOMS) and observer's score (SIGNS 
SCORE). Therefore the maternal eczema would not be independently related 
to disease severity in children. However, the child's eczema severity could be 
a consequence of the fact that the mother had eczema. The latter, therefore, 
is not a real confounding factor because it was not independently related to 
both the exposure (onset during the first year) and outcome (disease 
severity). Onset of eczema during the first year of life was a predictor of 
severe disease, which may imply that factors acting in utero or during the first 
year of life had affected disease severity. Longer follow-up studies are 
needed in order to measure the association over a longer period, for example 
the effect on adulthood eczema and to answer the question, does this 
association remain the same or does it change? 
4.2.2.1.2 Ethnic group 
4.2.2.1.2.1 Black skin 
This study showed that black children who lived in London were at higher risk 
of severe atopic dermatitis than their white counterparts. It also showed that 
the significant difference in disease severity could be masked by reliance on 
erytherna scores. 
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The proportion of white children in this sample was slightly lower than 
reported in the 1991 Census. For example, the percentage of white children 
in Lambeth, Southwark, and Lewisham was 69.7%, 75.6%, and 78"o 
respectively (Balarajan and Raleigh, 1992) compared with 51% in the urban 
population recruited from the same areas. White children may be 
underrep resented in this population, but in the Lambeth area for example, AD 
is more common in black Caribbean children borne in the United Kingdom 
(16.3%) than their white (8.7%) counterparts (Williams, et al., 1995a). 
Therefore, in a representative sample of children with atopic dermatitis one 
would expect a slightly higher proportion of black children than that reported 
in the 1991 Census. Thus the sample appears to be representative of the 
studied population and bias toward overrepresentation of black children was 
less likely to affect this finding. 
One drawback of this study was observer bias. The investigator could have 
given children with black skin a high score, an outcome that was inevitable in 
such a study design. However, when parents' grading of disease severity on 
a0 to 10 scale was used, black children remained at significant risk of having 
more severe disease than their white counterparts. This suggests that 
observer bias was less likely to have happened. 
Parents' assessment of eczema severity may have eliminated observer bias 
but one should also think of a different source of bias in which parents of 
black children may have given higher scores to their children's eczema than 
white parents. Also, atopic dermatifis has some different clinical 
presentations in black children where extensor and papular lesions more 
common, but all the parents were aware that the study was looking at tactors 
that might affect disease severity and there was no reasor why parents of 
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black children would have been more likely to give high scores. Thus the 
chance of giving high scores among black and white would be the same. This 
can be supported by the observation that the risk remained highly significant 
even after controlling for potential confounders such as social class and area 
of residence. Another observation from this data supporting this interpretation 
was that parents' scores were significantly correlated with the observer's 
score at each visit (Table 18). This positive significant correlation means that 
parents and investigator agreed on disease assessment, which validated the 
parental score despite the difference in ethnic background. Measurement 
bias, therefore, was unlikely to have occurred and the finding was real and 
not biased, but it contradicts the finding of Williams et al (1995a). They 
reported no difference in the disease severity between black Caribbean and 
white children. Direct comparison cannot be made because the authors did 
not mention specific details about how the dermatologist assessed disease 
severity. Also the cross-sectional design of Williams' study cannot be 
compared with the longitudinal design implemented in this study. 
Although it has been reported that the prevalence of flexural eczema or a 
history of this condition was lower in the Caribbean countries than in the UK 
(Pearson., 1973), data about disease severity were also lacking, therefore 
direct comparisons are not possible. 
Factors associated with urbanisation may be important in AD prevalence and 
severity, but it cannot explain the difference in disease severity between 
black and white children who were born and lived in the same area. Genetic 
factors are more likely to play an important role in this disparity than 
environmental factors. It is probable that the latter acting together with 
genetic factors. This could mean for example, that black children are 
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genetically capable of making large amounts of IgE. This view could be 
supported by observations of an inverse relationship between helminth 
infestation and allergic diseases in the Gambia (Godfrey., 1975). 
The literature provides little information about atopic dermatitis severity. 
However, the ethnic difference in disease severity has been documented in 
patients with asthma where blacks had much higher mortality rates than 
whites (Sly and O'Donnell., 1997). Although the exposure and outcome are 
different, Sly's finding is similar to this study. These authors found that 
uncontrolled and severe asthma had led to an increased mortality rate in 
blacks compared to whites. 
Other social factors such as degree of exposure to pet allergens and 
differences in access to medical care may also explain this trend. In the 
current study, the fact that 50% of black children's parents were unemployed 
compared with 10% of parents in white children would rank most of the black 
children in a lower social class. Unemployment may have subjected children 
to inadequate medical care. In the United States, it has been reported that 
higher asthma morbidity and mortality were observed in the African American 
population. The higher risk was related to higher exposure and sensitisation 
to allergens from cockroaches, which are more prevalent in a lower social 
class environment (Togias, Horowitz, Joyner, et aL, 1997). 
In the current study of AD though controlling for social class did not affect the 
outcome. Data on the potential difference in feeding habits, breast-feeding, 
type of heating, fitted carpets in the house and pets in the house could not 
explain the significant association between black skin and severe atopic 
dermatitis. The finding from this study adds strength to the need for further 
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genetic and epidemiological studies to confirm these results and thereafter a 
better understanding of atopic dermatitis. 
The other aspect related to black skin was erythema scoring. The study has 
shown that reliance on erythema scores can mask severe atopic dermatitis in 
black chiidren. Erythema is one of the components in almost all the scoring 
systems used to measure atopic dermatitis severity. Atopic dermatitis 
severity scores in clinical trials or observational studies, especially in areas 
inhabited with high percentages of ethnic minority groups, should be 
interpreted with caution because erythema scores can mask severe disease 
in black children. Thus GPs and dermatologists should note that the use of 
erythema in any severity system could be misleading in black children. 
Difficulties of assessment due to skin pigmentation might mean that severe 
cases are not being detected and appropriately treated. 
Although it has been suggested that skin darkening should be used instead 
of erythema in pigmented skin (Kunz, et aL, 1997), the differences in healing 
time and pathophysiological process (erythema vs. hype rpigmentation) would 
make clinical comparison meaningless. Berth-Jones (1996a) suggested 
omitting erythema from the SASSAD in pigmented skin and reported that he 
was able to score erythema in Asian skin. The recent scoring system (NESS) 
from Nottingham (Emerson, et al., 2000) has got around this problem in 
intensity assessment, but erythema scoring would meet the same problem 
when it comes to assessment of the extent of the examined eczema on the 
proposed 45 areas. Lichenification and papulation can be easily scored in 
pigmented as well as in white skin. Therefore these signs may be of help in 
clinical trials where the studied population contains a high proportion of those 
with pigmented skin. Further studies are needed to find an objective marker 
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for disease severity that does not depend on erythema scores and is valid in 
different ethnic groups. 
4.2.2.1.2.2 Other Ethnic groups 
There was small number of children from Asian and other ethnic groups. 
According to the 1991 Census, however, Asian and other ethnic groups 
represent a small percentage compared to blacks in the area studied 
(Balarajan and Raleigh., 1992). Therefore the sample is representative of the 
group living in the area studies and the small number of other ethnic groups 
was not due to selection bias and too small to allow any conclusion. 
However, in Leicester, it was reported that there was no significant difference 
in the prevalence of atopic dermatitis between Asian and 'white children 
(Neame, Berth-Jones, Kurinczuk, Graham-Brown., 1995). Areas with large 
Asian communities such as Brent, Tower Hamlets, Birmingham or Leicester 
(Balarajan and Raleigh., 1992) might be ideal places to study the difference 
in disease severity between white and Asian children. Studying different 
groups may help in exploring unidentifiable beneficial factors that may help in 
disease prevention. However, the lack of genetic markers for atopy, atopic 
dermatitis, and disease severity is an obstacle that needs to be overcome 
before more progress can be made in this field. Thereafter, comparing 
different ethnic groups can be a powerful indicator of the contribution of 
genetic versus environmental factors in AD aetiology. 
4.2.2.1.3 Child's atopy 
The study had shown that children with any atopic disease (asthma and/or 
hay fever) were at increased risk of having severe disease. But was there a 
chance that children with AD who had asthma and/or hay fever were more 
likely to participate in this study? This was unlikely to occur because the 
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frequency of atopic diseases (45% for hay fever, 43% for asthma, and 641o 
for any atopy) in this study was similar to the frequency of atopic diseases in 
atopic eczema documented in other studies. It has been shown that around 
50% of patients with AD have other atopic diseases (Rystedt., 1985; Rajka., 
1989a; Aberg and Engstrom., 1990; Williams, et al, 1996). A recent study 
from Sweden where children with AD were followed up, it has been reported 
that 43% developed asthma and 45% allergic rhinitis (Gustafsson, et al., 
2000). Therefore information bias was unlikely to have occured. 
Nevertheless, in an individual patient the course of atopic cutaneous or 
respiratory manifestation may be alternating, simultaneous, or independent 
(Rajka., 1989a). 
Therefore this finding confirms that any atopic disease (asthma and/or hay 
fever) in a child was significantly associated with more severe AD, with hay 
fever as the dominant significant effect. However, the risk of severe disease 
in children with asthma became marginally statistically insignificant (p = 0.07) 
after adjusting for hay fever, compared with those without asthma. So is hay 
fever a true confounder or not? It Is part of exposure (atopy; eczema, hay 
fever and asthma) and may be associated with the outcome (AD severity). 
Hay fever does not appear to be a true confounder because it forms part of 
the exposure and is not independently associated with the exposure. 
Therefore the adjustment for hay fever cannot be justified, and asthma had a 
real association with disease severity. The findings are in accordance with 
those of Musgrove and Morgan (1976) from a historical cohort study, in which 
they showed that the persistence of eczema was greater in those who had 
asthma and/or hay fever. Rystedt (1985) has found that associated allergic 
rhinitis, and/or bronchial asthma were unfavourable prognostic factors for 
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healing of AD. The finding that hay fever had an independent effect on 
disease severity is in agreement with Rystedt's findings that allergic rhinitis 
had the dominant effect of these two factors (Rystedt., 1985). However, she 
used the number of sites as a measure of dermatitis severity. Vickers (1980) 
has shown that the prognosis appeared to be slightly worse when the patient 
had classical bronchial asthma but hay fever and urticaria, when present, did 
not influence the prognosis at 10 years. Most of these studies looked at the 
prognosis of AD using a completely different design and were mainly based 
in a hospital setting. Although, these findings are in agreement with that of 
the current study, direct comparison would not be sensible because of the 
differences in inclusion criteria and assessment of outcome. 
This is an important clinical finding for clinicians and researchers. First, 
clinicians should be aware that children with hay fever and/or asthma tend to 
have severe atopic dermatitis. This may help them in managing such cases 
and may explain why the usual remedies may not work. Second, in clinical 
trials these subjects should be analysed separately. The observation that hay 
fever and/or asthma were predictors of severe disease necessitate 
controlling for them and carrying out a sub-analysis of the data before 
concluding whether a particular drug was effective or not. 
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4.2.2.1.4 Sex 
Sex and disease severity were not associated and this relationship remained 
insignificant after adjusting for potential confounders. Queille-Roussel et al 
(1985) also reported no difference in disease severity between males and 
females. On the other hand, Rystedt (1985) reported an increased risk of 
severe disease among female patients. Disease severity assessment in her 
study was based on an arbitrary scoring system that has never been 
validated, and which is less standardised than the system used in this study. 
The age difference and hospital origin in her study may explain the 
incongruity between this study and Rystedt's (1985) study. 
It is also possible that there was an observer bias. This highlights the need 
for objective markers of disease severity and further studies where the 
observer shouldn't be aware of the outcome of interest. In conclusion sex 
seems to have no significant association with disease severity. 
4.2.2.1.5 Birth Weight and Gestational age 
Birth weight has no significant predictive value for AD severity. Although the 
birth weight was not matched for gestational age, the latter was treated as a 
potential confounder and controlled for by regression analysis. Gestational 
age also seems to have no significant association with disease severity. One 
drawback is that information about gestational age and birth weight were 
obtained retrospectively from the parents with a minimum 5 years recall time, 
perhaps more, and not from the maternity records. This may have affected 
the accuracy of the information in which parents could not remember the 
exact gestational age or the birth weight. Such bias is possible, but for 
example the reported gestational age was 37 weeks or more in 90% of 
children, which was comparable with a study from Manchester where 97% of 
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children were born in the same gestational age group (David and Ewing., 
1988). This suggests that information bias was unlikely to have occurred. 
This study finding interestingly contradicts with Davis and Ewing's study 
(1988), in which they reported that the possible chances of the subsequent 
development of severe disease was reduced by preterm birth. Although the 
former study has a similar percentage of exposure, the outcome assessment 
"severe atopic eczema9l was not reported at all. They did not give any 
information about how they assessed disease severity nor how it was 
assessed. The study design was another drawback of David and Ewing's 
finding (1988) because it was not clear whether a retrospective or 
prospective design had been implemented, though it is likely to have been 
retrospective. In the current study the exposure and the outcome were both 
reported in detail and therefore neither birth weight nor gestational age had 
any significant predictive value for severe disease. Given the possible risk of 
information bias and the statistically insignificant associations, these factors 
will not be discussed any further. 
4.2.2.1.6 Child's age 
An increase in the child's age has a non-significant association with disease 
severity and remained the same after adjusting for potential confounders. 
However, the short follow-up time of this specific age group, within the 
studied sample, necessitate interpreting this finding with some caution. Thus 
it does not necessarily mean that AD severity does not change with age. This 
speculation is supported by the highly significant improvement in disease 
severity (p < 0.001) when the parents assessed atopic dermatitis in the 
children. This suggests that eczema does improve with age. Although the 
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parents' assessment was more subjective and retrospective with different 
recall times, it indicated real and significant improvement in disease severity. 
However, when the sample was divided into two groups, the study showed 
evidence of lower risk of disease severity in the older children but this was 
not statistically significant. Furthermore, this insignificant result does not 
mean that there is no real association of age with disease severity but only 
that the data are compatible with there being no association. 
Therefore, a longer follow-up time is needed before reaching a firm 
conclusion regarding the relationship between age and atopic dermatitis 
severity. Re-examining the same population after 10 years might give a 
better answer as to the association of age with disease severity. 
4.2.2.1.7 Family Size 
An increase in the number of children in the family was also not significantly 
associated with disease severity. Data on the age of siblings were not 
available and therefore it was not possible to investigate if older children in 
the house had different effects. The exposure status was not biased because 
the mean and median of the number of children were similar to the national 
average of 2.4 children per family. However, this finding cannot be directly 
compared with the inverse association between prevalence of reported AD 
and family size that was documented from the National Child Development 
Study (Strachan., 1989) because the former study looked at disease 
prevalence and disease severity was the outcome of interest in the present 
study. 
Therefore family size and disease severity were not significantly associated 
and in the absence of any study looking at the same outcome it will not be 
discussed further. 
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4.2.2.1.8 Parental atopy (eczema, asthma, or hay fever) 
The study showed no significant predictive value of parents' atopy for 
disease severity. This might be due to information bias because there were 
more data missing about paternal than maternal atopy, which can be 
explained by the fact that more mothers had completed the questionnaires. In 
general the mother may have been unlikely to know whether her husband or 
partner had had atopic disease as a child. 
Recall bias also cannot totally be excluded. It has been documented lately 
that recall bias should be considered for any association between parental 
and child's atopy. In simple terms parents would be more likely to report 
atopy when their children develop an atopic disease (Kulig, et aL, 2000). 
Information bias cannot be ruled out from the data available. The discussion 
of parent's atopy therefore will be brief. 
4.2.2.1.8.1 Parents' Eczema 
The study showed that children whose mother had eczema were at a non- 
significant lower risk of severe disease than those whose mothers never had 
eczema. However, information bias might have influenced this association 
and the data available cannot confirm whether the association is real or not. 
If information bias had no influence then the effect of the mothers' eczema on 
lowering disease severity was real. One potential explanation could be that 
the mother who had eczema has more experience of taking care of AD, in 
terms of avoiding irritants, applying moisturiser and early recognition of 
disease and the appropriate application of steroid creams. The mother may 
have modified the environment because of her awareness of her own 
eczema, and this ultimately would lead to the child living in a predetermined 
environment. Change in environment may explain the positive association 
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with disease severity, but it would have no effect on genetic predisposition. 
Another potential explanation that mothers may have intentionally or 
unintentionally blamed fathers for passing the disease to their children and, 
therefore, may have overestimated eczema in fathers. Further studies are 
needed to examine the association of maternal of eczema with disease 
severity. A valid definition such the UK diagnostic criteria could be used to 
identify eczema in potential mothers and then these could be followed-up 
prospectively to assess the association with their children's AD severity, if 
they developed AD. Such information is needed for a better understanding of 
AD and may help in treatment and prevention. It could mean that educating 
the mother might help in lowering disease severity. However, such a study 
would take many years to complete. 
4.2.2.1.8.2 Parents' asthma and/or hay fever 
There was no evidence from this data to support any association of parental 
asthma and/or hay fever with AD severity in their children. The high risk of 
information bias regarding these factors made further interpretation unhelpful. 
4.2.2.1.8.3 Paternal and maternal atopy 
The study showed a non-significant increase in the risk of severe AD in 
children when the mother or the father had any atopic disease. The high 
potential for information bias has limited any further conclusion, even though, 
in a study looking at disease expression, it was shown that maternal atopy 
resulted in a higher risk of infantile atopic dermatitis than paternal atopy. This 
group investigated disease prevalence during the first year of life and 
identified atopy in parents by skin test to common inhalant allergens (Ruiz, 
Kemeny, Price., 1992). The small amount of each exposure, in this study, did 
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not allow the investigator to determine whether maternal atopy had the same 
association with disease severity or not. 
With limitation in the knowledge about disease severity this finding should be 
taken with the above-mentioned restriction and attention should be directed 
to eliminating any information bias in future studies. 
4.2.2.2 Extrinsic factors 
4.2.2.2.1 Area of residence 
The study has shown that the risk of severe disease was about two times 
higher in children with atopic dermatitis who live in an urban area, than those 
who live in a rural environment. A recognised difficulty in such studies was to 
make the observer blind to the exposure, which was totally impossible in this 
study design. This did not affect the outcome because the risk remained 
significant even when three different ways of severity assessment were used. 
Observer bias therefore was less likely to have happened, even though it 
cannot totally be excluded. 
A potential reason for this difference in disease severity might be the 
differences in air quality or exposure to allergens or infection in the rural 
environment. Another factor could be the differences in water supply between 
the two areas (McNally, Williams, S mallman- Raynor, et aL, 1998). Certainly 
life styles in the cities have changed dramatically in the last 50 years. Double 
glazing, fitted carpets, heating and car pollution have changed and all are 
associated with urbanisation. This change in the cities may explain the 
increased prevalence in AD, but further studies are needed to quantify any 
difference in potential risk factors such as car emissions and water 
constituents. 
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The difference in ethnic background cannot explain this disparity because in 
the current study when all children from the rural area were excluded, black 
children with atopic dermatitis remained at higher risk of severe disease than 
their white counterparts live in the same (urban) area. On the other hand, 
when blacks were not included in the comparison between urban and rural 
areas, children living in the urban still have higher risk of severe disease than 
their white counterparts. 
Although Poysa et al (1991) reported an increased prevalence in the urban 
area, to the investigator's knowledge no one has reported an association of 
an urban area with atopic dermatitis severity. However, further studies that 
include information about water supply and air pollution might be needed 
before a valid explanation for this disparity can be achieved. Such a study 
should also be able to identify the differences in allergens such as house 
dust mite and pollens and therefore might have an important implication for a 
better understanding of this disease. 
4.2.2.2.2 Food 
Children were more likely to have severe disease when their parents were 
aware of a food source that made the children's eczema worse than those 
whose parents were unaware of any kind food effect, which became 
statistically insignificant after adjustment. This could represent a real effect of 
food in enhancing flare-up of the disease or just that parents of children with 
severe disease were more likely to provide a reason for eczema worsening. 
Information about the exposure was collected retrospectively. It was very 
probable that the parents of children with severe disease are more likely to 
be concerned with the cause of the disease, and therefore more likely 
provide a reason for the exposure to potential risk factors. It is difficult to 
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refute the possibility that the higher risk of severe disease after exposure to 
certain type of food is a result of recall bias. Although this finding is somehow 
similar to Guillet and Guillet's study (1992), the assessment of exposure in 
the former study was completely different. The current study used 
questionnaires while the other used skin test with fresh food allergens and 
standard extracts. Therefore these two studies cannot be compared but 
Guillet and Guillet's study (1992) seems to provide evidence for a role of food 
in atopic dermatitis especially the severe form where all the children were 
100% positive to food tests. 
The current study finding is based on an observational design, but blind 
systematic evaluation based on food challenge could confirm the relationship 
between food and eczema severity, and therefore a double-blind placebo- 
controlled oral food challenges (DBPCFC) might be an ideal way of looking at 
any food association with disease severity. Thereafter would be possible to 
identify those subjects who could benefit from diet restriction. Nevertheless, 
Atherton et al (1978) suggested, from a double-blind controlled crossover 
trial, that diet might have an effect in controlling atopic dermatitis (Atherton, et 
al., 1978), but a recent review on the role of diet in atopic dermatitis 
concluded that there is no evidence for the role of dietary elimination in the 
management of AD (David, et al., 2000). 
Therefore the effect of food on AD remains controversial and the current 
study approach seems to be practical and useful in exploring the 
relationships between food and eczema severity, and further studies such as 
(DBPCFC) are needed to confirm or refute this finding. 
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4.2.2.2.3 Wooi 
It was shown that children who had reacted to wool were about two times 
more likely to have severe atopic dermatitis than those who had not reacted. 
The association became statistically insignificant after adjustment for area of 
residence. It seems that the urban area still hold the statistically significant 
higher risk of severe disease. However, the information about reaction to 
wool was collected retrospectively, and a greater reporting of sensitivity to 
wool by parents of children with severe disease, compared with those with 
less severe disease as with diet, cannot be dismissed as a possible source of 
bias. It could be a real effect of wool in enhancing flare-up of the disease or 
just that parents of children with severe disease were more likely to answer 
yes. Collecting data about wool is subject to the same limitation as collecting 
data about food. Both factors have the same tendency to information bias. 
The potential information bias and the statistically insignificant higher risk 
after adjusting for area of residence would suggest that wool does not have 
real effect on disease severity and therefore its effect might be considered as 
happening by chance. Nevertheless, this finding could imply that wool 
contains antigenic material such as lanoline that triggers and exacerbates the 
disease. Prick and patch testing, in double-blind controlled study design, 
should be done to confirm this hypothesis. It would be interesting for instance 
to prick and patch test this population plus a control group with wool 
allergens and see if they have the same trend. 
4.2.2.2.4 Breast feeding 
Breast-feeding had no significant association with disease severity. The long 
recall may have affected the accuracy of the exposure. In this study about 
70% of children were breast-fed, similar to another study ýooking at predictors 
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of AD prevalence where 66% of children were breast-fed (Berth-Jones, 
George, Graham-Brown., 1997). Thus information bias was unlikely to have 
affected the outcome and therefore it is safe to conclude that breast-feeding 
had no significant effect on disease severity. 
4.2.2.2.5 Social class 
Social class seems to have had no significant association with disease 
severity, but was the exposure biased? Although direct comparisons cannot 
be made, the social class distribution in this population was similar to that 
reported in the 1971 census in which the majority were in social classes III 
and IV (Leete and Fox., 1977). However, the overrepresentation of, social 
classes I and 11 in this population could be explained by the increased 
prevalence of AD among these classes (Williams, et aL, 1994d). This 
suggests that the social classes in this population were representative and 
that exposure bias was less likely to affect the results. The finding that there 
no association between social class and disease severity should stand. 
Although data on AD severity is scarce, a recent study investigated the effect 
of social class on the severity of respiratory symptoms in asthmatics in a 
cross sectional survey of two general practices in Staffordshire (one urban 
and one rural). They showed that responders from social class V were more 
likely to report severe respiratory symptoms than those from social class 1, 
and that these were independently related. The location of the general 
practice was not independently associated with the severity of respiratory 
symptoms (Trinder, Croft, Lewis., 2000). 
Further research is needed to rule out an absence of effect or to exclude any 
clinically important difference in atopic dermatitis severity between higher and 
lower social classes. 
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4.3 Section 4: Quality of life 
At the time of writing, and to the best of the my knowledge, there are no other 
published clinical-epidemiological studies, which have related children and 
family's quality of life to atopic dermatitis severity in children in a systematic 
way, as a cross-section and over a time period, from a community-based 
study. 
4.3.1 Family' Quality of life 
4.3.1.1 The total DFI on visits one and two 
The study examines families' quality of life scores for children with atopic 
dermatitis in a community-based study at baseline (visit 1) and at 6 months 
(visit 2). Family Is QOL was affected in the households of 45% and 33% of 
children during the first and second visits respectively. This confirms the 
impact of mainly mild childhood atopic dermatitis on the family on each 
occasion. It was also shown that the family's quality of life was significantly 
correlated with atopic dermatitis severity in the children at a point in time and 
after 6 months. 
The DFI is an instrument constructed to evaluate the impact of AD on the 
family by the parents (Lawson, et al., 1998) and the SCORAD was developed 
to assess AD severity by objective means (European Task Force on Atopic 
Dermatitis., 1993). It is interesting though to see that in this study the two 
different systems scored by different observers produced parallel results. 
One negative point, relevant to this and other studies in atopic dermatitis, is 
that there is no other standard objective marker for disease severity, such as 
a serological response, which could be compared with the SCORAD-D. 
However, in the absence of such a marker, using a measure such as the 
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SCORAD, which has proven usage in the assessment of atopic dermatitis 
severity in a population -based study, seems to be a reasonable approach. 
This finding confirms the suggestion that stress and family environment are 
related to symptom severity in children with severe atopic dermatifis from a 
hospital-based study (Gil, Keefe, Sampson, et al., 1987). 
The current study's finding that the DFI is related to severity of the child's AD 
supports the construct validity of the DFI. It is also in agreement with 
Lawson's finding (1998) when the DFI was developed. They showed that the 
severity of the child's AD and the severity of disturbance in the family were 
related (r=0.55, P =0.002) (Lawson, et al., 1998). When the DFI was first 
tested, the mean DFI score was 9.6 (SD = 7.0, median = 9.5), and in our 
study the mean was 2 (SID = 4, median 0.5). This difference can be explained 
by selection of patients (hospital versus primary care). Also, Harper et al 
(2000) reported, using a different study design (a prospective, randomised, 
open, parallel group, multicentre oral cyclosporin study), significant 
improvement in family quality of life and disease severity after treating severe 
childhood atopic dermatitis with oral cyclosporin (Harper, et al., 2000). They 
did not report however whether these significant improvements are related or 
not. 
Although the proportion of disease impact differs between children and 
parents, there was significant correlation between children and family's 
quality of life scores. This may imply that they were assessing the same 
problem but had perceived it with varying intensity, a reasonable supposition. 
Another finding from this study, which supports the internal consistency of 
parents 9 assessment of quality of life, was the significant correlation between 
the DFI and parental assessment of disease severity. It shows that parents 
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were consistently able to evaluate disease status, despite the fact that they 
used two different approaches. This finding was also reported from a recent 
study to develop a new questionnaire to measure the impact of infantile 
eczema on the family (Lewis-Jones, Finlay, Dykes., 2001). The correlation 
coefficient was 0.50 and 95%Cl 0.32 to 0.64, which is obviously statistically 
significant and similar to the current study correlation coefficient. 
Finally, one important point that should be remembered is that the SCORAD- 
D represents disease severity at a certain point of time in that particular day 
and the DFI was designed to measure the impact of childhood eczema in the 
last week, but any effect before this week cannot totally be excluded. 
Therefore this may explain the weaker association. Theoretically the 
association could become stronger if the family's QOL could be measured at 
the same time as disease severity, a view supported by the slighfly stronger 
and highly significant relation between the CDLQl and DFI, in which both 
instruments have the same recall time. 
4.3.1.2 The DFI at visits one and two by site 
The DFI scores were, whether mean or median was used, higher when there 
was visible eczema on both visits. Although visible eczema was associated 
with non-significant higher scores on the DR, the results were not shown 
because it was thought that eczema at any site could confound this finding 
and it was not possible to provide a meaningful control. However, this is the 
first time, in childhood atopic dermatitis, that the impact of visible eczema on 
the family's quality of life has been demonstrated. The usefulness of the DFI 
was shown by its' ability to give higher scores to children with visible eczema 
than those without visible eczema at a particular site. The finding has 
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demonstrated the construct validity of the DFI and this may contribute to the 
estimation of power and calculation of sample size for clinical trials. 
4.3.1.3 Each aspect of the DFI on visit one and two 
Childhood eczema had affected different aspects of the family's life. It was 
very difficult to make any direct comparison between other instruments and 
the DFI because the latter is a disease specific measure. However some 
problems documented here have been reported by other studies, for 
example, sleep disturbance was reported by 86% of the parents with an 
average of parental sleep loss of 2.6 hours per night (Reid and Lewis-Jones., 
1995). The high percentage of parental sleep loss was perhaps due to 
inclusion of severe AD from the out-patient clinic. The lower percentage in 
this study (22% and 16% at visits, one and two respectively) could be 
explained by the inclusion of mild cases from a community setting. This was 
supported by data from this study, in which disease severity had a significant 
association with the score on the effect of eczema on the sleep of other 
members of the family at both visits. Differences in the specific outcome 
between this study and Reid's study (1995) could be the reason for the 
disparity. In Reid's study, the impact of eczema on parents' sleep only was 
measured, while in this study the question included the effect on the other 
members of the family. 
However, whether the study is based in hospital or the community, there is a 
clear impact of eczema on the families' sleep. It is necessary to document 
this impact and therefore to have a treatment strategy that takes into 
consideration improvement of the families' sleep patterns. It also may help in 
influence involvement of a psychiatrist and psychologist in the management 
of some cases of AD, mainly aiming at relieving the stress that originates 
233 
from sleep loss. Clinical trials should include assessment of family sleep loss 
in outcome measures because this will show disease improvement from a 
different point of view. 
In 20% and 17% of children with AD, the cost related to treatment and/or 
clothes had also been affected. This shows that even mild eczema can affect 
the expenditure of the family and cause an extra burden on household 
expenses. 
4.3.1.4 Changes in DFI and SCORAD-D scores over 6 months 
This is the first time in the study of childhood atopic dermatitis that changes 
in family quality of life can be related to changes in disease severity in a 
community-based epidemiological study. There was no significant difference 
in family's quality of life nor in disease severity between the two visits. It is to 
be expected that there would be no significant change in the average level of 
disease severity or impact on family quality of life, as this is a non- 
progressive disease with recurrent flare-ups. 
The interpretation of the regression coefficient should be explained here: The 
initial means of the DFI and SCORAD-D were 2.4 and 8.2 respectively and 
six months later the mean final DFI and SCORAD-D were 1.9 and 7.7 
respectively. The ratios of the mean DFI to the mean SCORAD-D are 3.4 and 
4 on the first and second visit respectively. The maximums are 30 for the 
DFI and 72.5 for the SCORAD-D, ratio 2.4. This means that 1 unit of DFI was 
related to more than one unit of SCORAD-D and the effect of SCORAD-D is 
therefore rather stronger than the regression coefficients imply. This serves 
to emphasise that these are substantial effects on the family's quality of life. 
However, individual patients experience flare-ups that come and go between 
the repeat assessments. It is the impact of these flare-ups on the life of the 
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families that is measured by the association between changes in SCORAD-D 
and DFI. Changes are harder to measure accurately than individual scores. 
The association between SCORAD-D and DFI is of a similar magnitude (0.21 
rising to 0.37 DFI points for each additional SCORAD-D point for each unit) 
as that between the changes (0.17 DFI per SCORAD-D unit), with broad and 
overlapping confidence intervals. The data therefore do not allow us to 
conclude that the association is weaker for changes over time than for single 
scores. The fact that the changes between the visits were not significant 
strengthens the finding rather than undermine it. 
Thus the study showed a non-significant improvement in disease severity 
and family's quality of life. There were mild changes toward improvement and 
these changes were significantly associated. In other word, it means that the 
two parameters changed in the same direction (getting better). This suggests 
that the DFI had the ability to detect minimal changes in disease severity. 
This approach could be used in clinical trails where the disease severity 
expected to drop sharply. 
Although this is the first community-based study on atopic dermatitis in 
children to relate changes in family quality of life to changes in disease 
severity, the study findings are consistent with another study in asthma that 
has shown that changes in Asthma Quality of Life (AQOL) correlated with 
changes in symptom score and bronchial hyperreactivity (Marks, Dunn, 
Woolcock., 1993). 
Nonetheless, it cannot be assumed that the ability of the DFI to detect 
decreasing scores (getting better) necessarily means a similar ability to 
detect increased scores (getting worst), although there is no real reason why 
the DFI should detect changes in one direction and not the other. Since it is 
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an observational study and only a small number had deteriorated, it was not 
possible to investigate the responsiveness of the DFI in the other direction. 
Nevertheless, this may not have fundamental implications against using the 
DR because the DFI would be used in clinical trials where the aim would be 
to detect decreases in the score rather than an increase. 
4.3.1.5 Changes in the DFI Components and SCORAD-D over 6 months 
There was evidence to suggest a significant relation between changes in 
disease severity and changes in the impact of eczema on family leisure 
activities. This implies that the effect on duration of leisure activities will vary 
with the changes in disease severity. But this finding may not be important 
clinically as it may represent seasonal variation because the final visit was 
preceded by the summer holiday. 
The weak strength for the association could be explained by the difference 
between the high scores for the SCORAD-D (72.5) and the DFI component 
The maximum score of the SCORAD-D is about 2.5 times higher than 
the total DFI and about 24 times more than each score of the DFI 
component. 
Changes in expenditure score were not significantly related to changes in 
disease severity. This might be explained by the observation that the 
expenses are still the same, or that parents are spending the same amount 
of money to keep eczema under control, even if the severity had improved 
slightly. Another explanation might be the high proportion of mild cases in this 
population. 
In general changes in the other DFI components were not significantly 
related to changes in SCORAD-D. The observational design of this study and 
short follow-up time (6months) could expiain the non-significant association. 
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The former perhaps did not allow a real relation to be shown to be significant. 
Therefore investigating the relationship between these variables such as cost 
and impact on carer's lives may need a longer time before a firm conclusion 
can be reached. 
4.3.2 Children's Quality of life 
The study has shown that children's OOL was affected in the majority of 
children. There are important reasons for asking the children about their 
health status and QOL, in order to provide information that is not generally 
available from a physician's assessment or by asking the parents. Such 
information is important in portraying the morbidity caused by atopic 
dermatitis and to evaluate the effectiveness of health and health-care 
interventions. It is therefore valuable to collect information, when possible, 
directly and independently from the children themselves. 
4.3.2.1 Completing the CDLQl 
Thirty-three per cent and 25% of children were unable to complete the 
CDLQl at visit one and two respectively. The mean age of those unable to 
complete the CDLQl was lower than those who completed the questionnaire. 
Potential reason for not completing the CDLQl might bedue to the restriction 
that was applied in the study design. When the questionnaire was first 
designed, an adult, preferably the child's parent was allowed to help the child 
in completion of the questionnaire (Lewis-Jones and Finlay 1995). In this 
study parents were not allowed to help their children in completing the CDLQl 
because the effect on children themselves ought to be quantified without any 
influence. Parents also had completed the DFI to document the 'impact on the 
family, which could affect their way in which they answered questions 
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regarding their children. The children who participated in this study aged 5 to 
12 years may also have had a different perception of life from their parents. 
This was supported by the different impact on the quality of life-, on the first 
visit for instance 45% of children's families were affected when assessed by 
the parents, while 92% of children were affected when assessed by the 
children themselves. The impact on quality of life was two times higher when 
children assessed quality of life than parents' assessment. Therefore children 
were able to recognise features that were seen by the parents as 
unimportant. 
It is quite clear that the restriction implemented in this study had affected the 
ability of the young children in completing the CDLQl than older children, 
which could have been improved by reading the questionnaire to young age 
group or allowing the parents to help in completion. This would have 
improved the number but would have introduced a different observer and 
ultimately could have introduced information bias. Therefore the data 
obtained by applying this restriction is of the same quality and justify the 
restriction. 
Nevertheless, one might speculate that this could have biased the results. 
The speculation would be that intelligent young children who completed the 
CDLQI had more severe disease than those who could not complete the 
CDLQl and therefore were more likely to complete the CDLQI- For instance, 
in this study, the youngest age group was 6 years old and there were 28 
children in this category, of these a high percentage (82%) was unable to 
complete the CDLQI. To evaluate if there was substantial difference in 
disease severity between these two groups, the objective severity scores for 
these children were compared. The mean SCORAD-D was 8.0 for the 5 
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children who completed the CDLQl and was similar to the mean SCORAD-D 
(8.4) for the 23 children who were unable to complete the CDLQl. This 
suggests that the speculation that children with more severe disease were 
more likely to complete the CDLQl is not true. The percentages of children 
who completed the CDLQl in the 7 and 8 years categories were higher and 
bias due those subjects being able to complete the CDLQl was less likely to 
influence the conclusion. 
It is also important to mention that the restriction was implemented before 
carrying out the analysis. This is in itself would exclude any potential bias as 
any child in that particular age group stand a same chance of completing the 
CDLQI. It can be concluded that the restriction implemented in this study did 
not have any substantial effect on the conclusion. 
The differing reading ability between children in different social classes, 
ethnic background or area of residence might be another potential reason for 
the children not completing the CDLQl. However, data from this study did not 
show any significant different in these factors between those who did and did 
not complete the CDLQl. 
4.3.2.2 The total CDLQl on visits one and two 
In this study 78 and 90 children from a primary care setting were included on 
the first and second visits respectively. This is nearly double the number of 
children with eczema (47) used in the preliminary validation of the CDLQl 
from a hospital based-setting (Lewis-Jones and Finlay 1995). In general, 
atopic dermatitis had affected the QOL and was scored at more than zero in 
92% and 79% of children during the first and second visits respectively, 
despite the fact that 44% and 48% of children were free of eczema during the 
same time. It can be concluded from this finding that children's quality of life 
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was affected even when there was no visible eczema, which is to be 
expected in a chronic relapsing disease such as atopic dermatitis. Another 
inference that can be drawn from the former finding was the difference in 
evaluating the significance of the problem by observer and children. 
Physicians should be aware that their assessment of signs does not 
necessary reflects a comprehensive evaluation of patients' quality of life. 
Therefore, doctors should always assess, value and consider the patients 
assessment during their consultation. 
The mean scores of the CDLQl in this study were lower than the mean 
scores in the initial validation of the CDLQl (Lewis-Jones and Finlay 1995). 
The latter findings were based on many different skin diseases from an out 
patients department. The mean score was 7.7 (SID = 5.6) for children with 
eczema (Lewis-Jones and Finlay 1995). The source of cases, hospital versus 
community, may explain the disparity in the mean score. It has been reported 
that AD severity was associated with an increased referral rate to the hospital 
from primary care and therefore more severe cases were expected to be 
seen in the hospital (Emerson, et al., 1998). 
Theoretically patients with severe disease would be expected to have a 
higher impact on their QOL. This was shown by the highly significant and 
positive association between children's QOL scores and severity scores, 
which remained the same after controlling for potential confounders. This 
suggests a consistent association between the two instruments, one disease- 
specific (the SCORAD) measuring signs and another special ity-specif ic (the 
CDLQl) measuring the impact on QOL. Although there was a highly 
statistically significant correlation between the scores of disease severity and 
those of children's quality of life, the severity scores accounts for only 21% 
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and 28% in the variation of the children's quality of life score at the first and 
second visits respectively. Quality of life is a concept that includes in its 
assessment many subjective elements. It is, therefore, perhaps not surprising 
that the observer's assessment of disease severity could explain about one 
quarter of the variability in quality of life measures. This may be due to the 
difference in the duration of assessment, in which severity assessment 
reflects disease status at a certain point of time while the CDLQl measures 
the effect in the last 7 days. But, the more likely explanation is that an 
assessment of signs does not necessarily explore the impact of the disease 
on quality of life. It is, therefore, necessary to include a quality of life measure 
plus an (severity) assessment of signs in clinical trials because doctors may 
not have the required knowledge of the children's feelings to evaluate their 
quality of life accurately. 
Some degree of caution should be exercised when interpreting the results of 
a study such as this. The population under investigation included those with 
wide range of eczema severities with a majority of mild cases. It is unlikely 
that the relationship between the CDLQi and disease severity will predictably 
remain the same in different disease severities. It may be strengthened or 
become weaker according to disease stage. However, part of the reason for 
such a study is to investigate if the quality of life instrument can add some 
information, which is 'useful, about the disease status that cannot be 
determined directly by the doctor. The CDLQI, therefore, proved to be useful 
in providing extra information about disease status as seen by the children 
themselves. Therefore quality of life instruments should be used as extra 
measures of assessing outcome in clinical practice, research and clinical 
trials. 
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Although the impact scored by the children was higher than by parents. the 
total CDLQI was significantly correlated with the DR. This highlights the 
agreement on reporting the stress caused by this stressful disease, despite 
the differences in the strength of disease perception. 
The study has shown that changes in children's quaiity of life can be 
predicted by changes in disease severity despite the difference in these two 
scores and despite the difference in these changes. The former finding 
highlights the important of including quality of life assessment as an extra 
measure of disease assessment in clinical trials. However, one should bear 
in mind the following question: 
Why was there a true significant improvement? 
The significant improvement in the CDLQl could be biased by the second 
visit being preceded by long summer holiday or seasonal fluctuation of AD. 
The observational design and length of time between the two visits (6 
months) may make any factor that had a statistically significant effect on a 
sense of well-being irrelevant clinically. The CDLQl reflects the child's own 
assessment of the disease whereas the SCORAD represents the observer's 
assessment of disease severity. This finding shows a significant 
improvement in quality of life and a non-significant one in disease severity. 
However, the 1.5 units decrease in the CDLQl that was statistically significant 
is not clinically important because by analogy this is similar to a statistically 
significant 5 millimetres mercury difference in blood pressure between right 
and left arm. These latter figures show a statistically significant difference but 
have no significant clinical implication. 
Another explanation that these discrepancies may be due to the summer 
holiday i. e. reduced stress, different attitude that preceded the second visit, 
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or that the investigator, using the SCORAD, was unable to detect a subtle 
improvement in disease severity that seemed to be significant for the 
children. Seasonal variation in the disease cannot be ruied out. 
4.12.3 The total CDLQl on visits one and two by gender 
This study has shown no significant difference In the CDLQI scores between 
males and females in childhood atopic dermatitis. This finding could perhaps 
be explained by the similarity in life perception in the age group (5-12 years) 
studied. Studying a different age group for example 12 to 16 years or adults 
may show significant differences in quality of life between females and 
males, a finding that has been shown when the Danish version of DLQl was 
used to assess the impact of any skin disease on quality of life (Zachariae, 
Zachaeiae C, Ibsen, et al., 2000). However, in studying adult populations with 
dermatological disorders recruited from a hospital outpatients department 
Finlay and Khan (1994) were unable to find any difference (Finlay and Khan., 
1994). It should be emphasised that the two studies previously-mentioned 
used a different quality of life measure (DLQI) and the patients included were 
adults with different dermatological conditions. Therefore direct comparison 
could not be made because this study included children with one skin 
disease (atopic dermatitis) only. Investigating the effect of atopic dermatitis 
on quality of life during the teenage period may show a different result. 
Male scores on the CDLQl had a stronger association with disease severity 
than female scores and severity scores could explain about 44% of the 
variation in male's quality of life score while disease severity could explain 
only 20% of variation in fernale scores. This may suggest that factors, such 
as impact on individual and body image, other than eczema severity may be 
important for females but not affect males. 
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There were no differences in the mean CDLQl scores between males and 
females except for teasing where it was significant during the second visit 
and not during the first. This inconsistent difference could not be explained by 
visible eczema. In theory, visible signs would be the main cause of the child 
being teased, called names, or bullied. Other factors such as a summer 
holiday and wearing different clothes and doing different activities between 
males and females may explain the inconsistent results. 
4.3.2.4 Individual aspect of the CDLQI on Visits One and Two 
Itching scores represented the highest proportion of the total CDLQI at each 
visit. About three quarters of children had an itchy "scratchy" or painful skin 
and this produced the highest overall mean score. This highlights how itchy 
AD is and the discomfort to the child from having this disease. Although 
direct comparison cannot be made between this finding and the original 
validation study, the trend was in accordance with the initial validation of the 
CDLQI. The highest mean score was for questions relating to symptoms 
(such as itching) and feeling, and the lowest for questions relating to 
friendships (Lewis-Jones and Finlay 1995). 
There was a significant correlation between itching scores and observer's 
scores of excoriation and lichen if ication. Although this association was 
statistically significant, the variation in observer's scores could not explain 
more than 15% of the variation in the itching scores. Excoriation and 
lichenification are physical signs that appears as consequences of scratching 
and rubbing respectively. The positive but weak correlation between 
scratching scores and the observer's assessment of excoriation and 
lichenification on each visit documented in this study is important. It means 
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that the observer was able to assess objectively a physical sign that has 
some effect on the child's life. 
About one third of children were embarrassed by their eczema. Scores on 
the question related to being embarrassed or self-conscious, upset or sad 
because of AD, were significantly correlated to severity scores on each visit. 
The positive and highly significant correlation suggests that an increase in 
disease severity could lead to the child being more embarrassed, upset or 
sad. However, one should bear in mind other factors such body image, 
customs and personality that may affect variation in embarrassment scores 
because variation in severity scores could account for 12% only. 
Finally, going out, playing or doing hobbies, buying special clothes/shoes, 
swimming or other sports, teasing, bullying, asking questions or avoidance by 
other people due to eczema, and an impact on friendships were not 
significantly associated with disease severity and will not be discussed 
further. 
4.3.2.5 Collated scores of groupings of the questions at each visit 
It was shown that the major impact of atopic dermatitis was on symptoms 
and on feelings, a finding in agreement with the original validation of the 
questionnaire (Lewis-Jones and Finlay., 1995). The CDLQI shows the same 
outcome in two different study setting (community versus hospital). This 
therefore provides evidence for the applicability and validity of using the 
CDLQI to assess quality of life to produce the systematic assessment of the 
effect of such a stressful disease on children' life and development. 
4.3.2.6 Generalisation and extrapolation 
Quality of life measurements are needed for assessment of new therapies, 
for audit purposes, and for medical plans to highlight the handicap caused by 
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skin disease when resources are being distributed. Quality of life 
measurement provides an understanding of the disease as seen by the 
patients, which may support the need for further research in atopic dermatitis, 
specifically, and dermatology generally. A valid and reliable measurement of 
quality of life may help in providing the justification needed for further 
research. It is clear from this finding that AD had affected the life of 92% of 
children in this study. Atopic dermatitis is a very common disease affecting 
not less than 10% of the UK population; therefore about 6 million sufferers 
with AD in the UK, and possibly more. In fact, 70% of AD cases are seen 
before the age of two. Given the previous two statements, 4,200,000 subjects 
would have had eczema during their childhood. Of these 4,200,000 cases, 
92% had an impaired quality of life and possibly abnormal behavioural 
development. Hence about 3,750,000 (6-25%) of the UK population have an 
impaired quality of life due to eczema alone. 
This may justify our claims as dermatologists for further research and 
redistribution of resources and may help in flagging the burden caused by the 
disease that not has a priority by the fund holders. 
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4.4 Section 4: Conclusion 
4.4.1 Course of AD 
Parents' assessment of AD severity has shown that there was a highly 
significant improvement of disease severity by age. Summer was the best 
season for children's eczema in 38% of children and most (90%) had applied 
topical steroids before joining the study. Increased frequency of topical 
steroids occurred with increased disease severity. The observer assessment 
of disease severity was higher in those receiving systemic antibiotics and oral 
prednisolone, while the scores were nearly the same in those using oral 
antihistamines. However, parents score of subjective symptom was higher in 
those taking orai antihistamines than those who did not take them. 
4.4.2 Disease severity 
This longitudinal study of children with atopic dermatitis showed that onset of 
eczema during the first year of life, asthma and/or hay fever (atopy) in the 
child and living in an urban area was associated with more severe disease. 
Black children also were at higher risk of severe disease than their white 
counterparts and reliance on erythema scores can mask this higher risk of 
severe disease. 
Certain types of food and reaction to wool were significantly associated with 
severe disease. However, the risk became insignificant after adjusting for 
potential confounders. Information bias also cannot totally be excluded. 
Therefore the association between these two factors and disease severity 
remains to be confirmed. 
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Family size, sex, birth weight, gestational age, child's age, any atopy (hay 
fever, asthma, or eczema) in the parents, social class, breastfeeding and any 
atopy in siblings were not significantly associated with disease severity. 
4.4.3 Quality of life 
The impact of atopic dermatitis on quality of life was documented by using 
the DFI and CDLQI. The study has showed that childhood atopic dermatitis 
had a remarkable effect on both families and children's and quality of life. 
Family's quality of life was affected in the household in 45% and 33% of 
children during the first and second visits respectively according to parents' 
assessments. Quality of life in 92% and 79% of children was affected during 
the first and second visits respectively when the children had assessed the 
impact. These figures document the impact of mostly mild atopic dermatitis 
on quality of life and highlight the difference in disease perception between 
parents and children. 
It was also shown that atopic dermatitis severity scores were positively 
correlated with the CDLQl and DFI scores. These showed that any 
deterioration in eczema would lead to a decline in both family and children's 
QOL. The finding demonstrated the construct validity of the two instruments 
used to assess the QOL, despite the fact that both questionnaires were 
constructed and tested on patients from out patients departments. It also 
implies that the DFI and CDLQl can be used in a community-based study 
where most of the cases are mild. The impact on the family highlights the 
importance of considering the parents' input in the management of AD as the 
disease affects the entire family. 
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This study has also shown that DFI and CDLQI can change predictably with 
changes in disease severity, despite the fact that changes in disease severity 
were not statistically significant. This suggests that these questionnaires 
were able to change and could be used as an extra measure of outcome in 
every day clinical practice as well as in research studies. 
4.4.4 Concluding remarks 
9 This is the first time that atopic dermatitis severity in the community has 
been studied prospectively and systematically using a valid and reliable 
scoring system by the same observer. It is also the first time that the 
impact of childhood atopic dermatitis documented in a structured way with 
the implementation of a longitudinal design in a community-based study. 
And also this is the first time that severity scores measured systematically 
have been correlated to quality of life scores that was measured by a 
published instrument at a single point and over a period of time. 
o The study design in this thesis has overcome two well-recognised 
difficulties in atopic dermatitis definitions and epidemiology. First, the UK 
diagnostic criteria for AD were used as a disease definition. Second, by 
implementing the longitudinal prospective study design, the disease 
severity was accessible to be assessed consistently by the same 
observer, which would have been impossible in a retrospective survey. 
The potential confounding variables were recorded by a piloted and 
structured questionnaire prior to starting the study. This cannot be done in 
a retrospective study. 
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* Another strength of this study was the systematic assessment of disease 
severity and quality of life. 
9 It must be realised that this was a selected group of children with AD, and 
these data may not be applicable to all patients with AD in the population. 
These results should be interpreted with the limitation of potential 
selection and observer biases. 
* This thesis has contributed to the body of knowledge regarding the 
principles and processes applied in the field of atopic dermatitis severity 
and it's impact on quality of life. It identifies significant factors that have an 
effect on disease severity and the significance of these factors in the 
perception of health status in this group of patients. This may improve 
health care and bring the attention of health agencies to the impact of this 
stressful disease on individuals, family and the community as whole. 
0 In conclusion, this study has provided findings that stress the need for 
further research to assess more factors that influence AD severity over a 
longer period of time. 
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4.4.5 Issues for the future 
The summary of other relevant findings not related to the aims of this study 
and lessons learnt from carrying out this study will be summarised in this 
section. 
9 The low response rate especially from the urban area (35%) highlights the 
difficulty in achieving enough subjects. It must be emphasised here that 
atopic dermatitis is a very common disease and affects about 15% of the 
UK population. Thus one should be cautious when carrying out research 
that involves the participation of large number of patients. Always think of 
a low response rate and ways of improving It. 
9 In any follow up study good relationships between the investigator and 
patients is necessary to achieve a low drop out rate. This can be simply 
accomplished by offering the patients enough time and by listening to 
them carefully. 
* General practitioners should be actively involved in any study that 
requires subjects from a primary care setting. This may improve the 
response and follow up rates. GPs must be chosen randomly to avoid any 
selection bias. It also strengthens working relationships between primary 
and secondary care. 
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9 Despite the fact that the UK diagnostic criteria ý%, ere validated in 
community based-studies, 14 (10%) cases had or had had atopic 
dermatitis but did not fulfil the criteria. This highlights a potential difficulty 
in identifying every single case of atopic dermatitis. 
* Severity assessment of atopic dermatitis is not an easy task despite using 
a potentially valid and reliable instrument. The various clinical 
presentations of the disease, extensor or flexural, localised or widespread 
expression and morphology of the lesions such as erythema that varies 
on a daily basis, and at the other end of the spectrum 11chenification that 
usually takes days before changing, could explain some of difficulties. 
This enhances the case for standard markers (genetic, serological, 
biochemical) that represent AD severity without clinical examination. 
4.4.6 Suggestion of further work 
o It would be interesting to examine the same cohort of patients 
participating in this study, in 5 or 10 years time. This would provide further 
information on the association between risk factors and disease severity, 
in the long term. It would also improve our understanding of the natural 
history of the disease. Re-examining this cohort of patients may explore 
the relationship between eczema severity and development of asthma 
and/or hay fever later as well as the clearance rate, and the impact on 
quality of life in a longer term, 
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* Using the same design implemented in this study to carry out a more 
national study to document atopic dermatitis severity distribution in a 
representative sample from the whole UK. This can be achieved by 
inviting a random sample of GlPs in the UK. From those GPs willing to 
participate, a random sample of patients with eczema should be taken. It 
should be emphasised that the ages should be clustered into 0-4,5-8,9- 
12,13-16,16-20,21-30,31-50 and more than 50. A representative 
sample of each age group would produce more detailed information about 
the impact of disease on each age group and the longitudinal design 
would explore the impact when the patients move from one age group 
into another. It could also explore and compare the association of risk 
factors with diseases severity from a longer-term study. 
* Given the difficulties in assessing atopic dermatifis severity, there is a 
need to develop a genetic, immunological or biochemical marker for 
disease severity. Such studies should be very strict in case definition and 
patients with the same morphological features must be chosen. Also other 
factors such as asthma, or early onset that may underestimate or 





Aberg N, Engstrom 1 (1990). Natural history of allergic diseases in children. 
Acta Paediatr Scand, 79,206-211. 
Altman DG, Gore SM, Gardner MJ, Pocock SJ (1995). Statistical guidelines 
for contributor to medical journals. In: Statistics with Confidence - Confidence intervals and statistical guidelines. Martin J Gardner and Douglas 
G Altman (eds). British Medical Association, The University Press (Belfast) 
Ltd. Pages 83-101. 
Amemiya T (1973). Regression analysis when the dependent variable is 
truncated normal. Econometrica, 41,997-1016 
Amemiya T (1984). Tobit models -A su rvey. J Econometrics, 24,3-6 1. 
Anderson JA (1984). Regression and ordered categorical variables. Royal 
Statistical Society, 1-30. 
Arikian SIR, Einarson TR, Doyle JJ (1998). Atopic dermatitis; Economic 
evaluation of treatments for eczema and atopic dermatitis. In: Care 
Management of Skin Diseases; life quality and economic impact. 
Rajagopalan R, Sherertz EF, Anderson RT (eds). ýNew York: Marcel Dekker, 
Inc; Chapter 23, page 317-340. 
Arshad SH, Matthews S, Gant C, Hide DW (1992). Effect of allergen 
avoidance on development of allergic disorders in infancy. Lancet, 339, 
1493-1497. 
Atherton DJ, Sewell M, Soothill JF, Wells RS (1978). A double-blind 
controlled crossover trial of an antigen-avoidance diet in atopic eczema. 
Lancet, ii, 401-403. 
Avenberg KM, Harper IDS (1980). Footnotes on Allergy. Uppsala, Sweden, 
Upplands Grafiska AB. 
Badia X, Mascaro JM, Lozano R (1999). Measuring health-related quality of 
life in patients with mild to moderate eczema and psoriasis: clinical validity, 
reliability and sensitivity to change of the DLQl. Br J Dermatol, 141,698-702. 
Bahmer FA, Schafer J, Schubert H-J (1991). Quantification of the extent and 
severity of atopic dermatitis: The ADASI Score. Arch Dermatol, 127,1239. 
Balarajan R, Raleigh (1992). The ethnic populations of England and Wales: 
the 1991 Census. Health Trends, 24,113-116. 
255 
Barker DJP, Rose G (1995). Epidemiology in Medical Practice, Fourth 
Edition. Churchill Livingstone, Edinburgh, London, pages 41-42.46-48,84- 
85. 
Bech P (1992). Measuring quality of life: The medical perspective. Nord J 
Psychiatry, 46,85-89. 
Beck H-1, Korsgaard J (1989). Atopic dermatitis and house dust mites. Br J 
Dermatol, 120,245-251. 
Bergner M, Bobbitt RA, Kressel S, et al (1976). The Sickness Impact Profile: 
Conceptual formulation and methodology for the development of a health 
status measure. Int J Health Services, 6,393-415. 
Bergner M, Bobbitt RA, Carter WB, Gilson BS (1981). The Sickness Impact 
Profile: Development and final revision of a health status measure. Medical 
Care, XIX, 787-805. 
Berth-Jones J (1996a). Six Area, Six Sign Atopic Dermatitis (SASSAD) 
severity score: a simple system for monitoring disease activity in atopic 
dermatitis. Br J Dermatol, 135 (suppl. 48), 25-30. 
Berth-Jones J, Finlay AY, Zaki 1, et al (1 996b). Cyclosporine in severe 
childhood atopic dermatitis: A multicenter study. J Am Acad Dermatol, 34, 
1016-1021. 
Berth-Jones J, George S, Graham-Brown RAC (1997). Predictors of atopic 
dermatitis in Leicester children. Br J Dermatol, 136,498-50 1. 
Besnier E (1892). Premiere note et observations preliminaries pour servir 
d'introduction a 1'etude des prurigos diathesques (dermatites multiformes 
prurigineuses chroniques exacerbantes et paroxystiques, du type du prurigo 
de Hebra). Ann Dermatol Syphilog, 93,634-648. 
Bjorksten B (1999). The intrauterine and postnatal environments. J Allergy 
Clin Immunol, 104,1119-1127. 
Bombardier C, Tugwell P (1982). A methodological framework to develop 
and select indices for clinical trials: statistical and judgmental approaches. J 
Rheumatol, 9,753-757. 
Bos JD, Van Leent EJM, Sillevis Smitt JH (1998). The millennium criteria for 
the diagnosis of atopic dermatitis. Exp Dermatol, 7,132-138. 
256 
Bowling A (1995). Measuring Disease. St Edmunclsbury Press Ltd, page 3. 
Brocq L, Jacquet L (1891). Notes pour servir a L'historie des 
ne u rode rmatitis. Du lichen circumscriptus des anciens auteurs, ou lichen 
simplex chronique de M. Le Dr E Vidal. Ann Dermatol Syphilog, 92,97-122. 
Buhrer C, Grimmer 1, Niggemann B, Obladen M (1999). Low 1-year 
prevalence of atopic eczema in very low birthweight infants. Lancet, 353, 
1674. 
Burke BM, Cunliffe WJ (1984). The assessment of acne vulgans - the Leeds technique. Br J Dermatol, 111,83-92. 
Calman KC (1984). Quality of life in cancer patients - an hypothesis. J Med 
Ethics, 10,124-127. 
Charman C, Venn AJ, Williams HC (1999). Measurement of body surface 
area involvement in atopic dermatitis: an impossible task? Br J Dermatol, 
140,109-111. 
Charman C, Morris AD, Williams HC (2000a). Topical corticosterold phobia in 
patients with atopic dermatitis Br J Dermatol, 142,931-936. 
Charman C, Williams HC (2000b). Outcome measures of disease severity in 
atopic eczema. Arch Dermatol, 136,763-769. 
Charman DP, Varigos G, Horne DJ de L, Oberklaid F (1 999a). The 
development of a practical and reliable assessment measure for atopic 
dermatitis (ADAM). J Outcome Meas, 3,21-34. 
Charman DIP, Varigos G (1 999b). Grades of severity and the validation of an 
atopic dermatitis severity measure. (ADAM). J Outcome Meas, 3,162-175. 
Coca AF, Cooke RA (1923). On the classification of the phenomena of 
hypersensitiveness. J Immunol, Vill, 163-182. 
Coleman R, Trembath R, Harper JI (1993). Chromosome 11 q 13 and atopy 
underlying atopic eczema. Lancet, 341,1121 -1122. 
Coleman R, Trembath R, Harper JI (1997). Genetic studies of atopy and 
atopic dermatitis. Br J Dermatol, 136,1-5. 
257 
Cookson WOCM, Sharp PA, Faux JA, Hopkin JM (1989). Linkage between 
immunoglobulin E responses underlying asthma and rhinitis and 
chromosome 11 q. Lancet, ii, 1292-1295. 
Cookson WOCM (2001). The genetics of atopic dermatitis: Strategies, 
candidate genes, and genorne screens. J Am Acad Dermatol, 45, S7-9. 
Costa C, Rilliet A, Nicolet M, Saurat J-H (1989). Scoring atopic dermatitis: 
the simpler the better? Acta Derm Venereol, 69,41-45. 
Cox HE, Moffatt MF, Faux JA, Walley AJ, Coleman R, Trembath RC, 
Cookson WOC, Harper Ji (1998). Association of atopic dermatitis to the beta 
subunit of the high affinity immunoglobulin E receptor. Br J Dermatol, 
138,182-1 ý87. 
Daly LE and Bourke GJ (2000). Interpretation and uses of medical statistics, 
Fifth edition. Daly LE and Bourke GJ (eds). Oxford: Blackwell Science Ltd, 
2000; pages 57,147,324. 
David TJ, Ewing CI (1988). Atopic eczema and preterm birth. Arch Dis Child, 
63,435-436. 
David TJ, Patel L, Ewing Cl, Stanton RHJ (2000). Dietary factors in 
established atopic dermatitis. In: Atopic dermatitis, The epidemiology, causes 
and prevention of atopic eczema. Williams HC (ed), Cambridge: Cambridge 
University Press; Chapter 15: pages 193-201. 
Daud LR, Garralda ME, David TJ (1993). Psychologicaý adjustment in 
preschool children with atopic eczema. Arch Dis Child, 69,670-676. 
Dean AG, Dean JA, Burton AH, Dicker RC (1997). Epi-Info, version 6.04b. 
Atlanta: Centers for Disease Control. 
Diepgen TL, Blettner M (1996). Analysis of familial aggregation of atopic 
eczema and other atopic diseases by using odds ratio regression models. J 
Invest Dermatol, 106,977-981. 
Dotterud LK, Kvammen B, Lund E, Falk ES (1995). Prevalence and some 
clinical aspects of atopic dermatitis in the community of Sor-Varanger. Acta 
Derm Venereol, 75,50-53. 
258 
Doward LC, McKenna SP. (1998): Evolution of quality-of-life assessment. In: 
Care Management of Skin Diseases: life quality and economic impact. 
Rajagopalan R, Sherertz EF, Anderson RT (eds). New York: Marcel Dekker, 
Inc; Chapter 2: page 9-33. 
Emerson RM, Williams HC, Allen BR, Mehta R, Finlay AY (1997). How much 
disability does atopic dermatitis cause compared with other common 
childhood health problems? Br J Dermatol, 137 (Suppl. 50), 19 (abstr. ). 
Emerson RM, Williams HC, Allen BR (1998). Severity distribution of atopic 
dermatitis in the community and its relationship to secondary referral. Br J 
Dermatol, 139,73-76. 
Emerson RM, Charman CR, Williams HC (2000). The Nottingham Eczema 
Severity Score: preliminary refinement of the Rajka and Langeland grading. 
Br J Dermatol, 142,288-297. 
Emerson RM, Williams HC, Allen BR (2001). What is the cost of atopic 
dermatitis in preschool children? Br J Dermatol, 143,514-522. 
Eun HC, Finlay AY (1990). Measurement of atopic dermatitis disability. Ann 
Dermatol, 2,9-12. 
European Task Force on Atopic Dermatitis (1993). Severity scoring of atopic 
dermatitis; the SCORAD Index. Dermatology, 186,23-31. 
Fallowfield L (1995). Questionnaire Design. Arch Dis Child, 72,76-79. 
Fartasch M, Bassukas ID, Diepgen TL (1992). Disturbed extruding 
mechanism of lamellar bodies in dry non-eczematous skin of atopics. Br J 
Dermatol, 127,221-227. 
Faust HB, Gonin R, Chuang T-Y, Lewis CW, Melfi CA, Farmer ER (1997). 
Reliability testing of the Dermatology Index of Disease Severity (DIDS). Arch 
Dermatol, 133,1443-1448. 
Feeny D, Juniper EF, Ferrie PJ, Griffith LE, Guyatt GH (1998). Why not just 
ask the kids? Health-related quality of life in children with asthma. In: 
Measuring Health-Related Quality of Life in Children and Adolescents; 
Implication for Research and Practice. Drotar D (ed). New Jersey: Lawrence 
Erlbaum Associates Publishers; Chapter 10, pages 171-185. 
259 
Fergusson DM, Horwood LJ, Shannon FT (1982). Risk factors in childhood 
eczema. J Epidemiol Community Health. 36,118-122. 
Finlay AY, Kelly SE (1987). Psoriasis-an index of disability. Clin Exp 
Dermatol, 12,8-11. 
Finlay AY, Khan GK (1994). Dermatology Life Quality Index (DLQI)-a 
simple practical measure for routine clinical use. Clin Exp Dermatol, 19,210- 
216. 
Finlay AY (1996). Measures of the effect of adult severe atopic eczema on 
quality of life. J EurAcad Dermatol Venereol, 7,149-154. 
Finlay AY (1997). Quality of life measurement in dermatology: a practical 
guide. Br J Dermatol, 136,305-314. 
Forrest S, Dunn K, Elliot K, Fitzpatrick E, Fullerton J, McCarthy M, Hill Dq 
Williamson R (1999). Identifying genes predisposing to atopic eczema. J 
Allergy Clin Immunol, 104,1066-1070. 
Fredriksson T, Pettersson U (1978). Severe psoriasis: oral therapy with a 
new retinoid. Dermatologica, 157,238-244. 
Gieler U, Hohmann M, Niemeier V, Kupfer J, Stangier U, Ehlers A (1999). 
Cost evaluation in atopic eczema. J Dermatol Treat, 10 (Suppl, 1), S1 5-S20. 
Gil KM, Keefe FJ, Sampson HA, McCaskill CC, Rodin J, Crisson JE (1987). 
The relation of stress and family environment to atopic dermatitis symptoms 
in children. J Psychosom Res, 31,673-684. 
Godfrey RC (1975). Asthma and IgE levels in rural and urban communities of 
the Gambia. Clin Allergy, 5,201-207. 
Golding DJ and Peters TJ (1987). The epidemiology of childhood eczema: 1. 
A population-based study of associations. Paediatr Perinatl Epidemiol, 1,67- 
79. 
Graham-Brown RAC (1998). Therapeutics in atopic dermatitis. Adv Dermatol, 
13,3-31. 
Guillet G, Guiflet M-H (1992). Natural history of sensitizations in atopic 
dermatitis. A 3-year follow-up in 250 children: food allergy and high risk of 
respiratory symptoms. Arch Dermatol, 128,187-192. 
260 
Gustafsson D, Sjoberg 0, Foucard T (2000). Development of allergies and 
asthma in infants and young children with atopic dermatitis -a prospective 
follow-up to 7 years of age. Allergy, 55,240-245. 
Hanifin JM, Rogge JL (1977a). Staphylococcus infections in patients with 
atopic dermatitis. Arch Dermatol, 113B, 1383-1386 
Hanifin JM, Lobitz WL (1977b). Newer concepts of atopic dermatitis. Arch 
Dermatol, 113,663-670. 
Hanifin JM, Rajka J (1980). Diagnostic features of atopic dermatifis. Acta 
Derm Venereol, (Suppl) 92,44-47. 
Hanifin JM (1989). Stanclarized grading of subjects for clinical research 
studies in atopic dermatitis: Workshop report. Acta Derm Venereol, (Suppl. ) 
144,28-30. 
Hanifin JM (1992). Atopic dermatitis. In: Dermatology, 3 rd Ed. Moschella SL, 
Hurley HJ (eds). W. B. Saunders, Philadelphia, Chapter 20, pages 441-464. 
Harper JI, Ahmed 1, Barclay G, et al (2000). Cyclosporin for severe childhood 
atopic dermatitis: short course versus continuous therapy. Br J Dermatol, 
142752-58. 
Harper Ji, Green A, Scott G, et al (2001). First experience of topical SDZ 
ASM 981 in children with atopic dermatitis. Br J Dermatol, 144,781-787. 
Helewa A, Goldsmith CH, Smythe HA (1982). Independent measurement of 
functional capacity in rheumatoid arthritis. J Reumatol, 9,794-797. 
Henderson AJW, Kennedy CTC, Thompson SJ, Carswell F (1990). Temporal 
association between Der pl exposure, immediate hypersensitivity and clinical 
severity of eczema. Allergy, 45,445-450. 
Herd RM, Tidman MJ, Prescott RJ, Hunter JAA (1996). The cost of atopic 
eczema. Br J Dermatol, 135,20-23. 
Herd RM, Tidman MJ, Ruta DA, Hunter JAA (1997). Measurements of quality 
of life in atopic dermatitis: correlation and validation of two different methods. 
Br J Dermatol, 136,502-507. 
261 
Hide DW, Matthews S, Matthews L et al (1994). Effect of allergen avoidance 
in infancy on allergic manifestation at age two years. J Allergy Clin Immunol, 
93,842-846 
Hill LW, Sulzberger MB (1935). Evolution of atopic dermatitis. Arch Dermatol, 
329451-63. 
Holden CA, Parish WE (1998). Atopic dermatitis. In: Textbook of 
Dermatology. Champion RH, Burton JL, Breathnach SM (eds), Oxford, 
Blackwell Science, Chapter 18, pages 681-708. 
Host A, Halken S (1990). A follow-up study of cow milk allergy in Danish 
infants during the first 3 years of life. Clinical course in relation to clinical and 
immunological type of hypersensitivity. Allergy, 45,587-596. 
Imokawa, G, Abe A, Jin K, et al (1991). Decreased level of ceramides in 
stratum corneum of atopic dermatitis: An etiologic factor in atopic dry skin? J 
Invest Dermatol, 96,523-526. 
Jarvis D, Chinn S, Luczynska C, Burney P (1997). The association of family 
size with atopy and atopic disease. Clin Exp Allergy, 27,240-245. 
Kulig M, Bergman R, Edenharter G, Whan U, and the Multicenter Allergy 
Study Group (2000). Does allergy in parents depend on allergy in their 
children? Recall bias in parental questioning of atopic disease. J Allergy Clin 
Immunol, 105,274-278. 
Kunz B, Oranje AP, Labreze L, et al (1997). Clinical validation and guidelines 
for the SCORAD Index: Consensus report of the European Task Force on 
Atopic Dermatitis. Dermatology, 195,10-19. 
Lammintausta K, Kalimo K, Raitala R, Forsten Y (1991). Prognosis of atopic 
dermatitis. A prospective study in early childhood. Int J Dermatol, 30,563- 
568. 
Laughter D, Istvan JA, Tofte SJ, Hanifin JIM (2000). The prevalence of atopic 
dermatitis in Oregon schoolchildren. J Am Acad Dermatol, 43,649-655. 
Lawson V, Lewis-Jones MS, Finlay AY, et al (1998). The family impact of 
childhood atopic dermatitis: the Dermatifis Family Impact questionnalre. Br J 
Dermatol, 138,107-113. 
Leete R, Fox J (1977). Registrar General's social classes: origin and uses. 
Population Trends, 9,1-7. 
262 
Leung DYM (1999). Pathogenesis of atopic dermatitis. J Allergy Clin 
Immunol, 1,04, S99-S108. 
Lever R (1996). Infection in atopic eczema. Dermatol Therapy, 1,32-37. 
Lever R (2001). The role of food in atopic eczema. J Am Acad Dermatol, 45, 
S57-60. 
Lewis-Jones MS, Finlay AY (1995). The Children's Dermatology Life Quality 
Index (CDLQI): initial validation and practical use. Br d Dermatol, 132,942- 
949. 
Lewis-Jones MS, Lawson V, Hill G, Reid P, Finlay AY (1996). Monitoring 
childhood skin disease handicap. BrJ Dermatol, 135 (Suppl. 47), 52. 
Lewis-Jones MS, Finlay AY, Hill G, Dykes PJ (1998). The impact of atopic 
dermatitis on children and their families. a community study. Ann Dermatol 
Venereol, 125, (Suppl 1: 8 th Int Cong Pediatric Dermatology, Paris May 
1998), 1 S62. 
Lewis-Jones MS, Finlay AY, Dykes PJ (2001). The Infants' Dermatitis Quality 
of Life Index. Br J Dermatol, 144,104-110. 
Leyden JJ, Marples RR, KlIgman AM (1974). Staphylococcus aureus in the 
lesions of atopic dermatitis. Br J Dermatol, 90,525-530. 
Lindstrom B, Eriksson B (1993). Quality of life among children in Nordic 
countries. Qual Life Res, 2,23-32. 
Linna 0, Kokkonen J, Lahtela P, Tammela 0 (1992). Ten-year prognosis for 
generalized infantile eczema. Acta Paediatr, 81,1013-1016. 
Linnet J, Jemec GBE (1999). An assessment of anxiety and dermatology life 
quality in patients with atopic dermatifis. Br J Dermatol, 140,268-272. 
Lobitz WC, Campbell CJ (1953). Physiological studies in atopic dermatifis 
(Disseminated ne u rode rmatitis). Arch Dermatol Syphilol, 67,575-585. 
Long CC, Funnell CM, Collard R, Finlay AY (1993). What do members of the 
National Eczema Society really want? Clin Exp Dermatol, 18,516-522. 
263 
Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M 
(1999). Quality of life, health-state utilities and willingness to pay in patients 
with psoriasis and atopic eczema. BrJ Dermatol, 141,1067-1075. 
Mali JWH (1975). Earliest description of atopic syndromes? Br J Dennatol, 
92,359. 
Marks GIB, Dunn S, Woolcock AJ (1993). An evaluation of an asthma quality 
of life questionnaire as a measure of change in adults with asthma. J Clin 
Epidemiol, 46,1103-1111. 
Matthews JNS, Altman DG, Campbell MJ, Royston P (1990). Analysis of 
serial measurements in medical research. BMJ, 300,230-235. 
McFadden JP, Noble WC, Camp RDR (1993). Superantigenic exotoxin- 
secreting potential of staphylococci isolated from atopic eczematous skin. Br 
J Dermatol, 128,631-632. 
McHenry PM, Williams HC (1995). Mangment of atopic eczema. BMJ, 310, 
843-47. 
McNally NJ, Williams HC, Smallman-Raynor M, Lewis S, Venn A, Britton J 
(1998). Atopic eczema and domestic water hardness. Lancet, 352,527-531. 
McNally NJ, Williams HC, Phillips DR, Strachan DID (2000). Is there a 
geographical variation in eczema prevalence in the U. K.? Evidence from the 
1958 British birth cohort study. Br J Dermatol, 142,712-720. 
Morgan M, McCreedy R, Simpson J, Hay RJ (1997). Dermatology quality of 
life scales -a measure of the impact of skin diseases. Br J Dermatol, 136, 
202-206. 
Morren M-A, Przybilla B, Bamelis M, Heykants B, Reynaers A, Degreef H 
(1994). Atopic Dermatitis: Triggering factors. J Am Acad Dermatol, 31,467- 
73. 
Motley RJ, Finlay AY (1989). How much disability is caused by acne? Clin 
Exp Dermatol, 14,194-198. 
Muldoon MF, Barger SID, Flory JD, Manuck SB (1998). What are quality of 
life measurements measuring? BMJ, 316,542-545. 
264 
Musgrove K, Morgan JK (1976). Infantile eczema, A long-term follow-up 
study. Br J Dermatol, 95,365-372. 
Nakamura Y, Oki 1, Tanihara S. et al (2000). Relationship between breast 
milk feeding and atopic dermatitis in children. J Epldemlol. 10.7/4-78. 
Neame RL, Berth-Jones J, Kurinczuk JJ, Graham-Brown RAC (1995). 
Prevalence of atopic dermatitis in Leicester: a study of methodology and 
examination of possible ethnic variation. BrJ Dermatol, 132,772-777. 
Neuber K, Konig W (1992). Effects of Staphylococcus aureus cell wall 
products (teichoic acid, peptidoglycan) and the enterotoxin B on 
immunoglobulin (IgE, IgA, IgG) synthesis and CD23 expression in patients 
with atopic dermatitis. Immunology, 75,23-28. 
O'Hare P and Krowchuk DP (1998). The impact of atopic dermatitis on the 
quality of life of children, adolescents, and adults. In: Care Management of 
Skin Diseases; life quality and economic impact. Rajagopalan R, Sherertz 
EF, Anderson RT (eds). New York: Marcel 'Dekker, Inc-, Chapter 14: pages 
185-198. 
Olesen AB, Ellingsen AR, Olesen H, Juul S, Thestrup-Pedersen K (1997). 
Atopic dermatitis and birth factors: historical follow up by record linkage. 
BMJ, 314,1003-1008. 
Oranje AP, Stalder JF, TaTeb A, Tasset C, de Longueville M (1997). Scoring 
of atopic dermatitis by SCORAD using a training atlas by investigators from 
different disciplines. Pediatr Allergy Immunol, 8,28-34. 
Queille-Roussel C, Raynaud F, Saurat J-H (1985). A prospective 
computerized study of 500 cases of atopic dermatitis in childhood. 1. Initial 
analysis of 250 parameters. Acta Derm Venereol, Suppl 114,87-92. 
Parmenter TR (1994). Quality of life as a concept and measurable entity. J 
Soc Indic Res, 33,9-46. 
Pearson RSB (1973). Asthma in Barbados. Clin Allergy, 3,289-297. 
Peters TJ, Golding J (1987). The epidemiology of childhood eczema: 11: 
Statistical analysis to identify independent early predictors. Paedlatr Perinatal 
Epidemiol, 1,80-94. 
265 
Platts-Mills TAE, Mitchell EB, Rowntree S. Chapman MID, Wilkins SIR (1983). 
The role of dust mite allergens in atopic dermatitis. Chn Exp Derm, 8,233- 
247. 
Poysa L, Korppi M, Pietikainen M, Remes K, Juntunen-Backman K (1991). 
Asthma, allergic rhinitis and atopic eczema in Finnish children and 
adolescents. Allergy, 46,161-165. 
Rajka G (1960). Prurigo Besnier (atopic dermatitis) with special reference to 
the role of allergic factors. 1. The influence of atopic hereditary. Acta Derm 
Venereol, 40,285-306. 
Rajka G (1961). Prurigo Besnier (atopic dermatitis) with special reference to 
the role of allergic factors. 11. The evaluation of the results of skin reactions. 
Acta Derm Venereol, 41,1-39. 
Rajka G (1989a). Essential aspects of atopic dermatitis. Berlin: Springer- 
Verlag. 
Rajka G, Langeland T (1989b). Grading of the severity of atopic dermatitis. 
Acta Derm Venereol, (Suppl. ) 144,13-14. 
Rasch C (1925). Die Besniersche Prungo. Arch Dermatol Syphil, 148,642. 
Reid P, Lewis-Jones MS (1995). Sleep difficulties and their management in 
preschoolers with atopic eczema. Clin Exp Dermatol, 20,38-41. 
Rona RJ, Duran-Tauleria E, Chinn S (1997). Family size, atopic disorders in 
parents, asthma in children, and ethnicity. J Allergy Clin Immunol, 99,454- 
460. 
Ruiz RGG, Kemeny DM, Price JF (1992). Higher risk of infantile atopic 
dermatitis from maternal atopy than from paternal atopy. Clin Exp Allergy, 22, 
762-766. 
Ruta DA, Garratt AM, Leng M, Russell IT, MacDonald LM (1994). A new 
approach to the measurement of quality of life. The patlent generated Index. 
Med Care, 32,1109-1126. 
Rystedt 1 (1985). Prognostic Factors in Atopic Dermatitis. Acta Derm 
Venereol, 65,206-213. 
266 
Salek MS, Finlay AY, Luscombe DK, et al (1993). Cyclosporin greatly 
improves the quality of life of adults with severe atopic dermatIt's. A 
randomized, double-blind, placebo-controlled trial. Br J Dermatol, 129,422- 
430. 
Sampson HA (1997). Food sensitivity and the pathogenesis of atopic 
dermatitis. JR Soc Med, 90 Suppl. 30.2-8. 
Saarinen LIM, Kajosaari M (1995). Breast-feeding as prophylaxis against 
atopic disease: prospective follow-up study until 17 years old. Lancet, 346, 
1065-1069. 
Schafer T, Dockery D, Kramer U, Behrenndt H, Ring J (1997). Experiences 
with the severity scoring of atopic dermatitis in a population of German pre- 
school children. Br J Dermatol, 137,558-562. 
Schafer T, Kramer U, Vieluf D, Behrendt H, Abeck D and Ring J (2000). The 
excess of atopic eczema in East Germany is related to the ýintrinsic type. Br J 
Dermatol, 143,992-998. 
Schmied C, Saurat J-H (1991). Epidemiology of atopic eczema. In: 
Handbook of atopic eczema. Ruzicka T, Ring J, Pryzbilla B (eds). Springer- 
Verlag: Berlin, pages 9-14. 
Schultz-Larsen F, Holm NV, Henningsen K (1986). Atopic dermatitis: A 
genetic-epiderniologic study in a population-based twin sample. J Am Acad 
Dermatol, 15,487-494. 
Schultz-Larsen IF (1993). Atopic dermatitis: A genetic-epidemiologic study in 
a population-based twin sample. J Am Acad Dermatol, 1993,28,719-723. 
Schultz-Larsen F, Diepgen T, Svensson A (1996). The occurrence of atopic 
dermatitis in North Europe: An international questionnaire study. J Am Acad 
Dermatol, 34,760-764. 
Sehgal VN, Jain S (1993). Atopic dermatitis: Nomenclature. Int J Dermatol, 
32,575-576. 
Sidbury R, Hanifin JM (2000). Systemic therapy of atopic dermatitis. ClIn Exp 
Dermatol, 25,559-566. 
Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM (1988). Who should 
measure quality of life, the doctor or the patient? Br J Cancer, 57,109-112. 
267 
Sly RM, O'Donnell R (1997). StablizýýJon of asthma se,. erity. Ann Allergy 
Asthma Immunol, 78,347-354. 
Smith CH (2000). New approaches to t--ýpical therapy. Clin Exp Dermatol, 25, 
567-574. 
Sprikkelman AB, Tupker RA, van Aalderen WMC, et al (1997). Severity 
scoring of atopic dermatitis: a comparison of three scoring systems. Allergy, 
52,944-949. 
Stalder JF (1995). Atopic dermatitis: From diagnosis to severity scoring. CID 
Rom Portfolio, Kodak. 
Stata Corp. (1999). Stata Statistical Software: Release 6.0. College Station, 
TX: Stata Corporation. 
Stein REK, Riessman CK (1980). The development of an impact-on-family 
scale: preliminary findings. Med Care, 18,465-472. 
Streiner DL, Norman GIR (1995). Health measurement scales: A practical 
guide to their development and use. 2 nd ed. New York, NY: Oxford University 
Press. 
Strachan DP (1989). Hay fever, hygiene, and household size. BMJ, 299: 
1259-1260. 
Su JC, Kemp AS, Varigos GA, Nolan TM (1997). Atopic eczema: its impact 
on the family and financial cost. Arch Dis Child, 76,159-162. 
Tan BB, Weald D, Strickland 1, Friedmann PS (1996). Double-blind controlled 
trial of effect of house dust-mite allergen avoidance on atopic dermatitis. 
Lancet, 347,15-18. 
Taylor B, Wadsworth J, Wadsworth M, Peckham C (1984). Changes in the 
reported prevalence of childhood eczema since the 1939-45 war. Lancet, ii, 
1255-1257. 
Thestrup-Pedersen K, Ring J (1999). Atopic Dermatitis: Summary of the 1'" 
Georg Rajka Symposium 1998 and a literature review. Acta Derm Venereol, 
79,257-264. 
268 
Tofte S, Graeber M, Cherill R, Omoto M, Thurston M. Hanifin J (1998). Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitis [abstract]. J Eur Acad Dermatol Venereol, 11 Suppl. 2, S1 97. 
Togias A, Horowitz E, Joyner D, Guydon L, Malveaux F (1997). Evaluating 
the factors that relate to asthma severity in adolescents. Int Arch Allergy Immunol, 113,87-95. 
Trinder PM, Croft PR, Lewis M (2000). Social class, smoking and the severity 
of respiratory symptoms in the general population. J Epidemiol Community 
Health, 54,340-343. 
Uehara M (1982). Reduced histamine reaction in atopic dermatitis. Arch 
Dermatol, 118,244-245. 
Uehara M, Sawai T (1989). A longitudinal study of contact sensitivity in 
patients with atopic dermatitis. Arch Dermatol, 125,366-368. 
Uehara M, Kimura C (1993). Descendant family history of atopic dermatitis. 
Acta Derm Venereol, 73,62-63. 
Van Hecke E, Leys G (1981). Evolution of atopic dermatitis. Dermatologica, 
163,370-375. 
Van Niekerk CH, Weinberg EG, Shore SC, et al (1979). Prevalence of 
asthma: a comparative study of urban and rural Xhosa children. Clin Allergy, 
91319-324. 
Vickers CHIF (1980). The natural history of atopic eczema. Acta Derrn 
Venereol, Suppl. 92,113-115. 
Von Mutius E, Weiland SK, Fritzsch C, Duhme H, Keil U (1998). Increasing 
prevalence of hay fever and atopy among children in Leipzig, East Germany. 
Lancet, 351,862-866. 
Walsh GA, Richards KL, Douglas SD, Blumenthal MN (1981). 
Immunoglobulin E anti-staphylococcus aureus antibodies in atopic patients. J 
Clin Microbiol, 13,1046-1048. 
Ware JE, Sherbourne CID (1992). The MOS 36-Item short-form health survey 
(SF-36). 1. Conceptual framework and item selection. Med Care, 30,473-483. 
269 
Watanabe M, Tagami H, Horii 1, Takahashi M. Kligman AM (1991). 
Functional analysis of the superficial stratum corneum in atopic xerosis. Arch Dermatol, 127,1689-1692. 
Williams HC (1992). Is the prevalence of atopic dermatitis increasing? Chn 
Exp Dermatol, 17: 385-391. 
Williams HC, Burney PG, Hay RJ, et al (1994a). The UK working party's 
diagnostic criteria for atopic dermatitis. 1: Derivation of a minimum set of 
discriminators for atopic dermatitis. Br J Dermatol, 131,383-396. 
Williams HC, Burney PG, Strachan D, Hay RJ on the behalf of the UK 
diagnostic criteria for atopic dermatifis working party (1994b). The UK 
working party's diagnostic criteria for atopic dermatitis. 11: Observer variation 
of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol, 131,397- 
405. 
Williams HC, Burney PG, Pembroke AC, Hay RJ, on the behalf of the UK 
diagnostic criteria for atopic dermatitis working party (1994c). The UK 
working party's diagnostic criteria for atopic dermatifis. III: Independent 
hospital validation. Br J Dermatol, 131,406-16. 
Williams HC, Strachan DP, Hay RJ (1 994d). Childhood eczema: disease of 
the advantaged? BMJ, 308,1132-1135. 
Williams HC, Pembroke AC, Forsdyke H, Boodoo G, Hay RJ, Bureny PGJ 
(1995a). London-born black Caribbean children are at increased risk of 
atopic dermatitis. J Am Acad Dermatol, 32,212-217. 
Williams HC, Forsdyke H, Boodoo G, Hay RJ, Burney PGJ (1 995b). A 
protocol for recording the sign of flexurJ dermatitis in children. BrJ Dermatol, 
133,941-949. 
Williams HC, Burney PGJ, Pembroke AC, Hay RJ on the behalf of the UK 
diagnostic criteria for atopic dermatitis working party (1996). Validation of the 
UK diagnostic criteria for atopic dermatitis in a population setting. Br J 
Dermatol, 135,12-17. 
Williams HC (1997). is a simple generic index of dermatologic disease 
severity an attainable goal? Arch Dermatol. 133,1451-1452. 
Williams HC, Strachan DP (1998). The natural history of childhood eczema: 
observations from the 1958 British birth cohort study. Br J Dermatol, 139, 
834-839. 
270 
Williams HC (2000a). What is atopic dermatitis and how should be defined in 
epidemiological studies? In: Atopic dermatitis, the epidemiology, causes and 
prevention of atopic eczema. Williams HC (ed), Cambridge: Cambridge 
University Press; Chapter 1: pages 16-21. 
Williams HC, Wuthrich B (2000b). The natural history of atopic dermatitis. In: 
Atopic dermatitis, the epidemiology, causes and prevention of atopic eczema. 
Williams HC (ed), Cambridge: Cambridge University Press; Chapter 3: pages 
41-59. 
Williams REA, Gibson AG, Aitchison TC, Lever R, MacKie RM (11990). 
Assessment of a contact-plate sampling technique and subsequent 
quantitative bacterial studies in atopic dermatitis. Br J Dermatol, 123,493- 
501. 
Wise F, Sulzberger MB (1933). Editorial remarks. In: Year book of 
Dermatology and Syphilology. Chicago: Year Book Medical Publishers, 
pages 30-48. 
Wutchirch B (1999). The atopy syndrome in the third millennium. Curr Probi 
Dermatol. Basel, Karger, vol 28, pages 1-8. 
Yamamoto A, Serizawa S, Ito M, Sato Y (1991). Stratum corneum lipid 
abnormalities in atopic dermatitis. Arch Dermatol Res, 283,219-223. 
Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC (2000). 
Dermatology Life Quality Index: Data from Danish inpatients and outpatients. 
Acta Derm Venereol, 80,272-276. 
Zeiger RS (1997). Prevention of food allergy and atopic disease. JR Soc 





6.1 One-page questionnaire for historical features of 
the UK diagnostic criteria 
Patient's Name: ........................................................... Date: .......................... 
Date of Birth: ...................................... Telephone Number: ........................... 
Could you please answer the following questions about ý-our child's 
skin? 
(The answers simply require a tick (-) in the appropriate box) 
1. 'Has your child had an itchy skin condition in the last 12 months --- 
by itchy we mean scratching or rubbing the skin a lot? YCS 0 No 0 
2. 'How old was your child when this skin condition began? 
t Tilder 2 years 
'I 3 -4 years 
ý -10 vciirs 
3. 'Has this skin condition ever affected the skin creases in the past--- 
by skin creases we mean fronts of elbows, behind the knees, 
fronts of ankles, around the neck, or around eyes"" Yes 0 N, 0 
4. (a) 'Has your child ever suffered from asthma-- by asthma 
we mean bouts of wheezing or whistling in the chest'. " YCS 0 No 
(b) 'Has your child ever suffered from hay fever-- 
by hay fever we mean bouts of sneezing, with 
a runny nose and/or itchy eyes in the summerT Yes 0 No 
5. 'In the last 12 months, has your child 
suffered from a generally dry skin" Yes 
0 
6. Has your child ever had eczema, bý, which, Nvc mean 
a scaly itchy rash mainly affects the skin creases? Ycs 
0 No 9 Doii*t know 0 
Appendix 6.2 
6.2 Recruitment questionnaire 
This questionnaire is completely confidential 
St John's Institute of Dermatology 
a, 
Questionnaire about Atopic Dermatitis (Childhood Eczema) 
Date: F 11 / 11 F1 / 1111 
Patient's Name: 
................................................................................................. 
Sex: MF (Please circle as appropriate) 
Date of Birth: F1 D/0 F1 /0 El A gy e: F1 El Years P" 
Body weight: 
1111. [= Kilograms OR llr]Stones[I Pounds 






n0 RO Il] 0 
Telephone: [I OUP 111111 n 11111111 
ID Number: QAD El 11 El (To be filled in by the doctor) 
NHS Number: D 11 El 11 F1 El 11 El 11 
Hoirv, to complete this questionnaire? 
Most questions simply require a tick (v) in the appropriate box. 
I 
-74 
Appendix 6.2 continue 
BACKGROUND INFORMATION ABOUT THE CHILD: 
1. Birth weight: in Kilograms EI-1111 or in Pounds L-ý' 
2. During which week in pregnancy did you give birth? 
3. How many sister(s) and brother(s) does your child have? 
4. Country of birth: .............................................................................. If not the UK, for how long has your child has been living in the UK? 
Less than I year 
1-2 years 
3-4 years 
5 years or more 
5. Which of the following categories do you feel 











6. BACKGROUND INFORMATION ABOUT CHILD'S MOTHER: 
Name: ........................................................................ Address (if different from above): ................................ 
................................................................................... 












Country of Birth: ........................................................ 
Are you employed at present? Yes 0 No 
If yes, please specify ....................................................................... 
7. BACKGROUND INFORMATION ABOUT CHILD'S FATHER: 
Name: .......................................................................... 
Address (if different from above): ................................. 
...................................................................................... 
.................................................................................... 
Date of Birth: El El / El El / El 11 OR Age: El [I Years 
Country of Birth: .......................................................... 
Are you employed at present? Yes 0 No 
If yes, please specify ........................................................................... 






5 or more, 0 
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Appendix 6.2 continue 
BACKGROUND INFORMATION ABOUT THE CHILD'S HOUSE/ FLAT: 




9. How far is your house/flat from a main road (busy road)? 
On a main road 0 
Approximately 100 metres (yards) or less 0 
Approximately more than 100 metres (yards) 0 
Don't know 0 
10. Do you keep any pets at home (house or garden)? No Pets 0 
(Tick all that apply) Dogs 0 
Cats 0 
Birds (e. g. Canary, Parrot) 0 
Other 0 
11. Do you have trees outside the house or 
on the road in front of the house? Yes 0 No 0 
12. Do you have fitted carpets in your home? Yes 0 No 0 
13. What is the type of heating used in your home9 No heating 0 
(Tick all that apply) Central heating 0 
Electrical fire 0 
Gas fire 0 
Wood burning stove 0 
Open fire 0 
14. How often do you vacuum clean/ hoover the house/flat? 
Every day 0 
Once or twice per week 0 
Once a month 0 
Less often 0 
Never 0 
15. How many times was the child's mattress 
vacuumed during the last 12 months? Once a week 0 
Twice a month 0 
Less often 0 
Never 0 
INFORMATION RELATED TO THE WEATHER: 





No difference 0 
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Appendix 6.2 continue ,. *e go DETAILED INFORMATION A-BOUT YOUR CHILD: 
17. Was this child breast fed? No 1: 1 
3 months or less 0 
More than 3 months 0 
18. At what age did she/he develop eczema? Less than 6 months 0 
7 to 12 months 0 
13 to 24 months 0 
3 to 6 years 0 
7 years or more 0 
19. Do any of the following suffer from or has she/he ever suffered 
from eczema, asthma, or hay fever? (Tick all that apply) 
The child Asthma 11 Hay fever 0 N/A 
Brother(s)/sister(s) Eczema 0 Asthma 0 Hay fever 0 N/A 0 
Father Eczema 0 Asthma 0 Hay fever 0 N/A 0 
Mother Eczema 0 Asthma 0 Hay fever 0 N/A 0 
Any of mother's family Eczema 0 Asthma 0 Hay fever 0 N/A 0 
Any of father's family Eczema 0 Asthma 0 Hay fever 0 N/A 0 
20. When your child first had eczema, how do you grade or rate his/her eczema on 
a scale of 0 to 10? Please circle as appropriate between 0 (no eczema) and 10 (the 
worst eczema your child has ever had). 
10 
21. If your child's eczema flares up or gets worse does this affect her/his school 
achievement? 
No change 0 
She/he does not like to go to school 0 
She/he cannot concentrate 0 
She/he can not play games or sport 0 
She/he is quiet in class 0 
Other reactions, please specify .......................................................... 
22. Does your child's eczema flare up or get worse 
while she/he is under stress such as around exam time? 
Yes 11 No 0 Don't Know 0 
23. Does your child's eczema get worse while 
she/he is feeling hot (playing, sweating)? Yes 11 No 0 Don't Know 0 
24. Does your child's eczema improve 
in the school holidays? Yes 0 No 0 Don't Know 0 
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DETAILED INFORMATION ABOUT YOUR CHILD Cont.... 
25. At which age(s) has your child been free of eczema? (Tick all that apply) 
Under 10 10 20 30 40 50 60 70 80 90 100 
Never free of eczema 0 
26. During the last year, how many days has your child missed/stayed away from 





4 weeks or more 
27. How frequently has your child's eczema 





Every 2-3 months 
I to 2 times per year 
28. In the past 12 months, how many times have you had to 
















29. At the moment, how would you grade or rate your child's eczema on a scale of 0 
to 10? Please circle as appropriate between 0 (no eczema) and 10 (the worst 
eczema your child has ever had). 
0 ------- I ------- 2 -------- 3 ------- 4 ------- 5 ------- 6 ------- 7 ------- 8 ------- 9 -------- 10 
30. During the last 12 months, how many 
times has your child had a sore throat? 
3 1. In the last 12 months, has your child been able to sleep 




Three times 0 
Four or more times 0 
Sleep well 0 
Wakes up occasionally at night 0 
Often awake at night 0 
Seldom has a peaceful night 0 
INFORMATION ABOUT FOOD: 
32. Are you aware of any kind of food which 
makes your child's eczema worse? Yes 11 No 0 
Don't know 0 
If yes, please specify .................................................................................................... 
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Appendix 6.2 continue 
INFORMATIONABOUT SKIN CONTACT: 
33. Do you apply or have you ever applied 
steroid cream/ointment to your child's skin? Y e, --, j If no, please go to question number 35 
34. Do you apply steroids.. 
No Lj Don't kno%,. - El 
.. twice a dav? 
.. once a day? 
.. e%-cr,, - other day? 
-. Icsý frequently" 
Nc% cr 
35. Who usually applies the cream/ointment to your child's skiii" 
36. Does your child's skin react to wool? 
INFORMATION ABOUT SYSTEMIC DRt'GS: 
37. Has your child received any of the following 
















INFORMATION ABOUT HOSPITAL ADMISSION(S): 
38. Has your child been admitted to hospital 
because of her/his eczema'? Yes 0 No 0 
If no, please go to the last question. 
39. On your child's most recent admission, how would ý'oti grade or rate ý'oijl- 
child's eczema on a scale of 0 to 10? Circle as appropriate between 0 (no cc/cma) 
and 10 (the worst eczema your child has ever had). 
- Before the admission 40 --- I --- 2 --- 3---4---5 --- 6 --- 7 --- 8---9 --- 10 
- After discharge from hospital -+ 0 --- I --- 2 --- 3 --- 4 --- 5---6---7---8 --- 9 --- 10 
40. On the most recent admission, how long did your child staý, in hospital because 
of her/his eczema9 I dav 0 
2-4 days 0 
- 'days 0 
-3 %\ ecks 0 
4 weeks or more 0 
111111111100111111HIIIH11 
41. Are you aware of any-thing not mentioned above wluch niakes or has made your 
child's eczema worse" Yes 0 No Don't Know U 
If yes, please describe 




6.3 Follow-up questionnaire 
This questionnaire is completely confidential 
St. John's Institute of Dermatology 
a. 
FOLLOW-UP QUESTIONNAIRE 
ABOUT ATOPIC DERMATITIS (CHILDHOOD ECZEMA) 
Date: [][] 
/ 1111 / 1111 
Patient's Name: ................................................................................. 
Age: 11 Fý Years 
Address (only if you have moved house): .......................................................... 
City: ................................ 
Post code: 
1ý D 1ý F] RFIFI 
Telephone: Ell] 0 011 [][][]FIEIEIEI 
ID Number: QAD [11](To bc filled in h%, the doctor) 
NHS number: DOEIDDE] noE; 
How to complete this questionnaire? 
Most questions simply require a tick (-) in the appropriate box. 
Appendix 6.3 continue .... 
1. BACKGROUND I NNFORM AT ION' ABOUT CHILD'SNIOTHER: 
Address (if different from above) ........................................ 
........ I ................................................................................. 
Are you employed at present? Yes E No 0 
If yes, please specify .................................................................. 
2. BACKGROUND INFORMATION ABOUT CHILD'S FATHER: 
Address (if different from above) ........................................ 
.......................................................................................... 
Are you employed at present? Yes "ýO 0 
If yes, please specify .................................................................... 
BACKGROUND INFORMATION ABOUTTHE CHILD'S HOUSE/ Fl, k-l': 
3. In the last 6 months, have you moved liouse" YcS No 
If no, please go to question nuinher 8 




5. How far is your new house/flat from 
a main road (busy road)? On a main road 0 
Approximately 100 metres (yards) or Icss 0 
Approximately more than 100 metres (vat-ds) 0 
Don't know 0 
6. Do you have trees outside the new house 
or on the road in front of the new house? 
7. Do you have fitted carpets in the new home? 
8. In the last 6 months, havc you kept any pets 
at home (house or garden)? (Tick all that apply) 









(c. g. CanarN-, par-rot) i 
Ll 
9. In the last 6 months, what was the type of 





Wood burning stove 
Open firc 
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BACKGROUND INFORMATION ABOUT THE CHII-D*S HOUSE/ FLAT 
cont.: 
10. In the last 6 months, how often did vnn - ---- --- j -- 
vacuum clean/ hoover the house flat? 
1. How many times was the child's mattress 
vacuumed during the last 6 months? 
DETAILED INFORMATION ABOUT YOUR CHI1, D: 
12. In the last 6 months, has your child 
suffered from attacks of \ollc 
Once a %% eck- 
Twice a nionth 
Less often 
Ný2% ci- 
asthma onl,. ". ' 
hay fevcr only? 
both asthma and liav IcN, cr'. ) 
13. In the last 6 months, for how long has your 
child been free of eczema? Not at all 
Otic wcek 
2-4 \-,, cck-s 
2-3 months 
All the time 
14. How frequently has your child's eczema 
got worse during the last 6 months? 
15. In the past 6 months , how many times 
have you had to 



























t - -ý Imes 
11 
4-5 times 0 
0 times or more, ] 
16. During the last 6 months, how many days has voLir child 
missed/stayed away from school because of her, Ns eczema? 
Noiie 
I -') days 
4-1 days 
2-. ) weeks 
4 weeks or more 
Everv dav 
Once or ice per week 






Appendix 6.3 continue .... 
DETAILED INFORMATION ABOUT YOUR CHILD cont.... 
17. At the moment, how would you grade or rate your child's cczcnia on a scale of 0 Zý - to 10? Please circle as appropriate hetNveen 0 (no cc/cnia) and I () (the X% or, ýI 
eczema your child has ever had). 
0-1-2-3-4-5-6-7-8-9-10 
18. In the last 6 months, has your child been able to slecp 
well or has the eczema disturbed lier Ns sleep? 
Sleep well 
Wakes up occasionally at night 
Often awake at im0it 
g ScIdorn lias a peaceful night 
19. During the last 6 months, how maný, 
times has your child had a sore throat? 





Four or morc tinics 
20. In the last 6 months, how frequently have you applicd 
steroid cream/ointment to your child's AM? NN (-) IIe 
Less frequently 
Fvcry other day 
Oncc a day 
kvice a dav 
INFORMATION ABOUT SYSTEINII('DRUGS: 
21. Has your child received any of the following None 






INFORMATION ABOUT HOSPITAL ADMISSION: 
1-2. In the last 6 months, has your child been admitted 
to hospital because of her/his eczema" 
YCS 
If yes, for how long? 
. 
I dav 
" -4 davs 
5-- davs 
%veeks 








6.4 Guidefines and definitions on how to use the 
SCORAD Index 
Most of the following definitions and instructions copied from original article 
(European Task Force on Atopic Dermatitis, 1993). 
A. Grading of Extent 
The rule of nine is detailed in the front-back drawing on the evaluation sheet (Figure 
3). Lesions taken into account must include only inflammatory lesions such as 
erythema, oozing/crusting and not dryness. In practice it is recommended to draw 
directly the extent of individual lesions on the printed figure of the evaluation sheet. 
B. Intensity 
1. Erythem . There is no problem to define this 
item on light-coloured skin. If 
grading is impossible, just mention it in the evaluation sheet (Figure 3) under remark. 
2. Oedema/ppulation. Oedema/papulation stands for palpable infiltration of the skin 
that may occur both in acute erythematous, excoriated lesions as well as in chronic 
lesions during flares. This item is difficult to define with clinical photographs. Thus 
palpation of the lesion should be taken into account in assessing this item. 
3. Oozing/Crust. This item applies to exudative lesions resulting from epidermal 
edema and vesiculation. 
4. Excoriation. This item is per se an objective marker for pruritus, more visible in 
nonlichenified lesions. 
5. Lichenification. This item is synonymous with epidermal thickening in chronic 
lesions. Grossly accentuated skin ftuTows separate shiny rhomboid areas, and the 
colour is greyish or brownish. 
6. Dryness. Whenever possible, this item should be appreciated at best at a distance 
from inflammatory lesions and without prior application of emollients/-moisturisers. 
Palpation is also important to assess the roughness of the skin (European Task 
Force 
on Atopic Dermatitis., 1993). 
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6.5 Hanifin and Rajka criteria for atopic dermatitis 
Must have 3 or more basic features: 
1. Pruritus. In which the diagnosis cannot be made in the absence of this critcr-la 
2. Typical morphology and distribution: 
Flexural lichenification or linearity in adults 
Facial and extensor involvement in infants and children 
3. Chronic or chronically-relap sing dermatitis 
4. Personal or family history of atopy (asthma, allergic rhinitis, atopic dcrinatitis) D 
Plus 3 or more minor features: 
1. Xerosis 
2. Ichthyosis/palmer hyperlinearity/keratosis pilaris 
3. Immediate (type 1) skin test reactivitv 
4. Elevated serum IgE 
5. Early age of onset 
6. Tendency toward cutaneous infections (esp. Staph. aureus and Hcrpcssi . Inph, 
impaired cell-mediated immunity 
7. Tendency toward non-specific hand or foot dennatitis 
8. Nipple eczema 
9. Chellitis 
10. Recurrent conjunctivitis 
11. Dennie-Morgan infraorbital fold 
12. Keratoconus 
13. Anterior subcapsular cataracts 
14. Orbital darkening 
15. Facial pallor/facial erythema 
16. Pityriasis Alba 
17. Anterior neck folds 
18. Itch when sweating 
19. Intolerance to wool and lipid solvents 
20. Perifollicular accentuation 
2 1. Food intolerance 
22. Course influenced by environmentaUemotional factors 
23. White dermographisn-i/delayed blanch 
The Hanifin and Rajka criteria mentionc(I above are copied xvord 
for word as cited in 
the original article (Hanifin and Rajka., 1980). 
